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Abstract 
The cJUN NH2-terminal kinase (JNK) pathway responds to environmental 
stresses and participates in many cellular processes, including cell death, 
survival, proliferation, migration, and genome maintenance.  Importantly, genes 
that encode components of the JNK signaling pathway are frequently mutated in 
human breast cancer, but the functional consequence of these mutations in 
mammary carcinogenesis is unclear. 
Anoikis – suspension-induced apoptosis – has been implicated in 
oncogenic transformation and tumor cell metastasis.  Anoikis also contributes to 
lumen formation during mammary gland development and epithelial cell 
clearance during post-lactational involution.  JNK is known to contribute to certain 
forms of cell death, but the role of JNK during anoikis was unclear.  I examined 
the requirement of JNK in anoikis and discovered that JNK promotes cell death 
by transcriptional and post-translational regulation of pro-apoptotic BH3-only 
proteins.  This conclusion suggested that JNK signaling may contribute to 
mammary gland remodeling during involution.  Indeed, JNK deficiency in 
mammary epithelial cells disrupted the remodeling program of gene expression 
and delayed involution.  Finally, I sought to understand the importance of JNK in 
mammary carcinogenesis. I found that JNK loss in the mammary epithelium was 
sufficient for genomic instability and tumor formation.  Moreover, JNK loss in a 
model of breast cancer resulted in significantly accelerated tumor development.  
Collectively, these studies advance our understanding of the JNK pathway and 
vii 
 
breast biology, and provide insight that informs the design of therapeutic 
approaches that target the JNK signal transduction pathway. 
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CHAPTER I 
INTRODUCTION 
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The cJUN NH2-terminal Kinase (JNK) Signaling Pathway 
The mitogen activated protein kinases (MAPK) allow cells to integrate signals 
from their environment and respond appropriately.   These pathways are 
organized as three-tiered phosphorylation cascades with the MAPK kinase 
kinases (MAP3K) phosphorylating and activating the MAPK kinases (MAP2K), 
which then phosphorylate and activate the MAPK (Figure I.1A).  
Dephosphorylation mediated by dual-specificity phosphatases enables pathway 
inactivation as well as crosstalk between the MAPK pathways (Farooq and Zhou 
2004; Huang and Tan 2012).  The MAPK are divided into 4 subgroups: 
extracellular-signal regulated kinase 1/2 (ERK1/2), extracellular-signal regulated 
kinase 5 (ERK5), p38 MAPK, and cJUN NH2-terminal kinase (JNK).  The ERK1/2 
and ERK5 groups respond primarily to mitogens, though ERK5 can also be 
activated by stress (Nishimoto and Nishida 2006; Hoang et al. 2017).  The p38 
MAPK and JNK groups are primarily activated by stress stimuli (Davis 2000; 
Wagner and Nebreda 2009).   
Recent sequencing studies have demonstrated that members of the JNK 
pathway are frequently mutated in human cancer.   However, the role of this 
pathway in tumorigenesis is still not understood. 
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Figure I.1.   The JNK signaling pathway. 
A)  MAPK kinase kinases (MAP3K) phosphorylate the MAPK kinases (MAP2K) that in 
turn phosphorylate the MAPK.  Once activated, MAPK phosphorylate their targets, 
including transcription factors and non-transcription factors. 
B)  Signaling through the cJUN NH2-terminal Kinase (JNK) pathway may be initiated by 
many MAP3K, including tumor promoting locus 2 (TPL2), apoptosis signal-regulating 
kinases (ASK), TGFβ activated kinases (TAK), mixed-lineage kinases (MLK), and 
MAPK/extracellular signal-regulated kinase kinases (MEKK).  These MAP3K can 
phosphorylate and activate MAP2K4 and MAP2K7 that in turn phosphorylate and 
activate JNK.  Once activated, JNK phosphorylates its targets, including effector proteins 
(E; e.g., BIM) as well as transcription factors (TF; e.g., cJUN).   
 
  
4 
 
 
The JNK Signaling Cascade 
JNK pathway activation occurs in response to stress stimuli, including the 
inflammatory cytokines TNF and IL-1, radiation, and osmotic and redox stress 
(Davis 2000).  Studies using over-expression of proteins or dominant-negative 
mutants have implicated many MAP3K in the JNK pathway (Figure I.1B), 
including MEKK1-4 (encoded by MAP3K1-4); ASK1-3 (encoded by MAP3K5-6, 
MAP3K15); TAK1 (encoded by MAP3K7); TPL2 (encoded by MAP3K8); and the 
mixed lineage kinases MLK1-4 (encoded by MAP3K9-11, MAP3K21), DLK 
(encoded by MAP3K12), ZAK (encoded by MAP3K20), and LZK (encoded by 
MAP3K13) (Davis 2000; Gallo and Johnson 2002; Kaji et al. 2010).  However, 
considering that these transfection-based assays result in the activation of other 
MAPK pathways, the physiological relevance of these MAP3K is unclear.  
Studies using animals genetically ablated for the individual MAP3K will be 
necessary to untangle their functions, both regarding which MAP3K are in which 
MAPK pathway and which stimuli activate which MAP3K.  For example, genetic 
ablation of MAP3K1 impairs JNK activation, demonstrating that MEKK1 is indeed 
a component of the JNK pathway (Yujiri et al. 1998).  ASK1 has also been 
identified as a member of the JNK pathway, as it is required for sustained JNK 
activation in the presence of TNFα or hydrogen peroxide (Tobiume et al. 2001).  
Similarly, loss of TAK1 markedly decreases JNK phosphorylation in response to 
LPS, TNFα, or IL1 (Shim et al. 2005) and compound loss of Map3k10 and 
Map3k11 causes impaired JNK phosphorylation in response to TNFα and 
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saturated fatty acids (Jaeschke and Davis 2007; Kant et al. 2011; Kant et al. 
2017).  Exposure of MAP3K-deficient cells to various stimuli has revealed the 
specialization of these proteins.  Whereas MEKK2 is required for JNK activation 
in response to FGF2, it is dispensable for UV-mediated JNK activation (Kesavan 
et al. 2004). 
MEKK1 was shown to activate JNK through MAP2K4 (Yang et al. 1997a), 
one of the two MAP2K responsible for JNK activation (Davis 2000).  
Phosphorylation by both MAP2K4 (on Tyr185) and MAP2K7 (on Thr183) (Figure 
I.1B) in the activation loop of JNK (Derijard et al. 1994; Davis 2000) is required 
for JNK activation (Tournier et al. 2001).  Once fully activated, JNK 
phosphorylates Ser/Thr-Pro motifs on its targets, notably the AP1 proteins JUNB, 
cJUN, JUND, and ATF2, as well as other proteins (Figure I.1B) (Davis 2000).   
The JNK-mediated phosphorylation of cJUN on serines 63 and 73 in its activation 
domain increases the transcriptional activity of cJUN (Pulverer et al. 1991; Smeal 
et al. 1991; Adler et al. 1992).  Additionally, JNK promotes the expression of 
cJUN and JUND (Lamb et al. 2003; Ventura et al. 2003).  These findings show 
that regulation of cJUN and AP1 proteins by the JNK pathway enables the cell to 
initiate appropriate changes in gene expression in response to environmental 
cues. 
There are three JNK genes (MAPK8, MAPK9 and MAPK10, encoding 
JNK1, JNK2, and JNK3 proteins respectively) that are alternatively spliced to 
produce 10 different JNK isoforms with distinct substrate specificities (Gupta et 
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al. 1996).   The JNK1 and JNK2 proteins are ubiquitously and constitutively 
expressed after embryonic day 7, while JNK3 is restricted to heart, testes, and 
brain, and is expressed after embryonic day 10 (Kuan et al. 1999).  Mapk8-/- and 
Mapk9-/- mice as well as Mapk8-/- Mapk10-/- and Mapk9-/- Mapk10-/- mice are 
viable and fertile (Dong et al. 1998; Yang et al. 1998; Weston et al. 2004).  In 
contrast, Mapk8-/- Mapk9-/- compound mutant mice die in mid-gestation (Kuan et 
al. 1999; Sabapathy et al. 1999).  These observations together with additional 
genetic experiments (Tournier et al. 2000) have demonstrated that there is 
extensive redundancy between JNK1 and JNK2, necessitating the use of 
compound mutants to fully dissect the function of this pathway.  The embryonic 
lethality of Mapk8-/- Mapk9-/- compound mutant mice also indicates that this 
pathway is essential for mammalian development. 
 
The JNK pathway in Cell Life and Death 
In times of stress, a cell must make life or death decisions.  Thus, it is not 
surprising that JNK, a stress-activated protein, mediates a cell’s decision to 
proliferate, senesce or die (Davis 2000; Whitmarsh and Davis 2007).   
Understanding how the JNK pathway regulates these processes would provide 
insight into its importance during development and disease, and may inform 
therapeutic approaches and predict consequences of targeting the JNK pathway 
in the clinic.   It has become clear that the JNK-regulated response to stimuli is 
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influenced by the cell type, genetic context, time course of activation, and 
environmental factors. 
 
JNK and cell death  
The JNK pathway can promote cell death in response to different stimuli.  
Neuronal death following growth factor deprivation or excitotoxicity proceeds 
through JNK-mediated cell death pathways (Xia et al. 1995; Yang et al. 1997b).  
In response to ultraviolet light (UV), anisomycin, or methyl methanesulfonate , 
JNK initiates mitochondrial membrane depolarization and cytochrome c release 
to engage the apoptotic machinery (Tournier et al. 2000).  However, JNK 
deficiency does not protect cells from FAS ligand-induced cell death, indicating 
that JNK is not required for the FAS/CASP8 apoptotic pathway (Tournier et al. 
2000).  Similarly, TNFα-induced death does not depend on the JNK pathway 
(Lamb et al. 2003; Das et al. 2009).  Collectively, these data demonstrate that 
JNK selectively promotes cell death. 
Cell detachment from the extracellular matrix can trigger a specialized 
form of apoptosis, anoikis (Frisch and Francis 1994).  The role of JNK in anoikis 
has been controversial.  Loss of JNK pathway activity, using either a JNK 
dominant-negative mutant (Frisch et al. 1996) or an MEKK1 dominant-negative 
mutant (Cardone et al. 1997), delays suspension-induced cell death.  However, 
another study showed that a JNK dominant-negative mutant and a MAP2K4 
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dominant-negative mutant failed to improve cell survival, implying that JNK is not 
necessary for efficient cell death (Khwaja and Downward 1997).  More recently, 
work has shown that JNK is needed for acinus lumen formation in vitro (Murtagh 
et al. 2004) and demonstrated its necessity for luminal clearance in vivo 
(Cellurale et al. 2012), suggesting that JNK is indeed needed for anoikis.   
Genetic models will be required to resolve this controversy. 
How does JNK promote cell death?  One mechanism involves JNK 
regulation of gene expression through its AP1 targets.  Indeed, mutation of the 
JNK phosphorylation sites on cJUN (JUNAA) renders mice more resistant to 
neuronal apoptosis during excitotoxicity (Behrens et al. 1999). Furthermore, 
cJUN induces expression of the pro-apoptotic Hrk (Ma et al. 2007) and Bcl2l11 
(Whitfield et al. 2001) genes that encode the BH3-only proteins HRK and BIM, 
respectively.  However, treatment of mouse embryonic fibroblasts (MEFs) with 
inhibitors of mRNA and protein synthesis demonstrated that gene expression and 
protein synthesis were not required for the observed cell death after UV exposure 
(Tournier et al. 2000).  Thus, JNK could promote cell death independently of 
gene expression. 
Among the targets of JNK are the BCL2 family of proteins (Davis 2000).  
The anti-apoptotic BCL2-like proteins (BCL2, BCLXL, MCL1, A1, and BCLW) 
prevent mitochondrial membrane depolarization while the pro-apoptotic 
BAK/BAX-like (BAK, BAX, and BOK) and BH3-only (BAD, BID, BIK, BIM, BMF, 
HRK, NOXA, and PUMA) proteins induce it (Huang and Strasser 2000; Pinon et 
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al. 2008; Czabotar et al. 2014).   Therefore, JNK could promote apoptosis by 
inhibiting BCL2-like proteins.   Indeed, JNK phosphorylates BCL2 and BCLXL, 
although it has been reported that this JNK-mediated phosphorylation regulates 
autophagy instead of apoptosis (Wei et al. 2008).  JNK also phosphorylates and 
inhibits the anti-apoptotic BCL2-like protein MCL1, which serves as a point of 
integration of pro-apoptotic signaling from JNK and pro-survival signaling from 
AKT (Morel et al. 2009).   
JNK may also promote cell death by activating pro-apoptotic BH3-only 
members of the BCL2 family.   JNK is reported to phosphorylate the BH3-only 
protein BAD to promote cell death (Donovan et al. 2002), though how this 
phosphorylation activates BAD is unknown.  In contrast, the JNK-mediated 
activation of two other BH3-only proteins, BIM and BMF, is better understood.  
JNK phosphorylates the dynein light chain binding motif present on BIM, 
releasing it from sequestration and allowing it to promote BAX-mediated 
apoptosis (Lei et al. 2002; Lei and Davis 2003; Hubner et al. 2008; Hubner et al. 
2010).   The presence of a similar site on the BH3-only protein BMF, another 
target of JNK, suggests a similar mechanism may regulate BMF activation (Lei 
and Davis 2003).     These phosphorylation events on anti- and pro-apoptotic 
BCL2 family members may account for transcription-independent JNK-mediated 
cell death (Tournier et al. 2000).   
JNK-mediated cell death relies on inactivation of survival pathways, 
including AKT and ERK.  The inhibitory phosphorylation of JNK on MCL1 will 
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only promote cell death if the AKT pathway is inactivated (Morel et al. 2009).  
BIM is another point of JNK and survival signal integration.  Whereas JNK 
phosphorylation allows BIM to translocate to mitochondria and activate 
BAK/BAX, ERK phosphorylation induces proteasomal degradation of BIM (Ley et 
al. 2003; Hubner et al. 2008).  Thus, the examples of BIM and MCL1 
demonstrate that the pro-apoptotic signals from JNK are balanced by the pro-
survival signals from AKT and ERK to decide the fate of the cell. 
Clearly, JNK promotes cell elimination in response to certain stimuli.   
However, the absence of JNK in the developing forebrain results in increased 
apoptosis (Kuan et al. 1999; Sabapathy et al. 1999).  Similarly, in transformed 
lymphoblasts (Hess et al. 2002) and in carcinogen-treated livers (Das et al. 2011) 
loss of JNK signaling increases cell death, indicating that JNK signaling can also 
contribute to cell survival.  Studies of JNK-deficient MEFs demonstrated that they 
are more sensitive to TNF treatment than control cells (Lamb et al. 2003; Ventura 
et al. 2004a; Jaeschke et al. 2006; Ventura et al. 2006).   A missing survival 
signal was Jund, a pro-survival protein whose expression is JNK-dependent 
(Lamb et al. 2003).  Through JUND, the JNK pathway cooperates with the NF-κB 
pathway to promote expression of cIAP2 thereby enabling cell survival following 
TNF exposure (Lamb et al. 2003; Ventura et al. 2006).   Moreover, the dynamics 
of JNK signaling determines cell survival.  That is, acute JNK activation in 
response to TNFα treatment is important for survival signaling, while chronic JNK 
activation mediates cell death (Ventura et al. 2006).   
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JNK and cell proliferation 
In addition to its role in cell death and survival, JNK regulates proliferation.   
Genetic studies in Drosophila have demonstrated that JNK pathway activation 
can promote cell autonomous (Igaki et al. 2006; Biteau et al. 2008) and non-
autonomous (Ryoo et al. 2004; Uhlirova et al. 2005) proliferation.   In mice, p38α 
deficiency results in increased JNK pathway activity and increased proliferation in 
various cell types (Hui et al. 2007).   Similarly, loss of NF-κB activity leads to JNK 
activation and proliferation in the epidermis (Zhang et al. 2004).   The 
observation that JNK-deficient MEFs undergo Trp53-dependent senescence 
further supports a positive role for JNK in proliferation (Das et al. 2007). 
One means by which JNK could promote proliferation is through its major 
target cJUN.   Loss of cJUN results in increased Trp53 expression, delayed G1-
to-S phase progression, and decreased proliferation rates (Schreiber et al. 1999).  
Furthermore, cJUN phosphorylation by JNK is required for cell proliferation 
(Behrens et al. 1999).  In both the p38α- and RelA-deficient mice that exhibit 
increased proliferation and JNK activity there is also increased cJUN activity, 
suggesting that JNK-cJUN pathway drives proliferation in these models (Zhang 
et al. 2004; Hui et al. 2007).   Supporting this conclusion is the observation that 
JNK inhibition can reverse cJUN activation and hyperplasia in the epidermis of 
Rela-/- animals (Zhang et al. 2004).  Finally, loss of JNK in MEFs leads to 
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decreased levels of cJUN, which increase Trp53 mRNA and TRP53 protein, 
resulting in cellular senescence (Das et al. 2007).    
These findings suggest that tissues relying on proliferation to cope with 
high turnover or damage would require JNK signaling.  However, mice lacking 
JNK in the intestine and colon exhibit no changes in TRP53 levels, and no 
decrease in proliferation or disruption to the tissue architecture (Cellurale et al. 
2012).   Similarly, JNK is dispensable in mammary gland transplantation assays 
and its loss increases proliferation of mammary epithelial cells in vitro (Cellurale 
et al. 2012).  In the context of tissue injury, hepatocytes lacking JNK regenerate 
damaged livers comparably to controls (Das et al. 2011).  This model also 
demonstrated that JNK deficiency in hepatocytes causes increased pro-
inflammatory cytokine expression and subsequent compensatory proliferation, 
leading to increased tumor burden- (Das et al. 2011).  This observation suggests 
that in the presence of liver damage, JNK deficiency causes changes in gene 
expression that result in an environment that supports growth.  Thus, the role of 
JNK in proliferation is context-dependent, relying on cell type, other signaling 
pathways, and environmental factors. 
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JNK and Development 
It is clear that the JNK pathway regulates cell death, survival, and proliferation.  
This pathway has also been shown to influence cell migration (Huang et al. 
2004).  It is therefore not surprising that genetic studies of the JNK pathway in 
flies and mice have demonstrated that it is essential during developmental 
morphogenesis.   
 
The JNK Pathway in Drosophila Development 
During embryonic development in Drosophila, two sheets of ectodermal cells 
migrate toward the dorsal midline and subsequently fuse to form a strong 
connection in a process termed dorsal closure (Ring and Martinez Arias 1993).  
This process requires the MAP2K7/JNK/JUN pathway (Riesgo-Escovar et al. 
1996; Sluss et al. 1996).  In particular, in the absence of JNK or JUN the TGFβ 
homolog DPP is not expressed, resulting in defects in cell shape changes 
(Riesgo-Escovar and Hafen 1997; Sluss and Davis 1997).  Re-expression of 
DPP partially rescues the dorsal closure defect in JNK-mutant embryos, 
indicating that JNK-mediated expression of DPP represents a mechanism for 
JNK regulation of cell migration and spreading (Riesgo-Escovar and Hafen 
1997).  In addition to the expression of DPP, JNK may play a role in actin 
polymerization and stabilization during dorsal closure (Xia and Karin 2004).  
Similarly, thoracic closure requires a JNK/FOS pathway for proper execution 
(Zeitlinger and Bohmann 1999).  Furthermore, in later stages of development, 
14 
 
 
loss of JNK activity causes decreased size and malformation of imaginal discs, 
and delayed larval development (Agnes et al. 1999).   
The JNK pathway is also required to maintain healthy epithelial cell sheets 
in Drosophila during development as well as in the adult fly.  JNK-dependent cell 
death eliminates cells as a result of limiting amounts of morphogen, such as 
TGFβ (Moreno et al. 2002), or as a result of oncogene expression, such as 
cMYC (Moreno and Basler 2004).   Additionally, extrusion of epithelial cells from 
the epithelium results in JNK activation in these cells, leading to apoptosis 
(Adachi-Yamada et al. 1999; Adachi-Yamada and O'Connor 2002; Gibson and 
Perrimon 2005; Shen and Dahmann 2005).  Collectively, these results 
demonstrate that the JNK pathway is important throughout development and in 
various tissues of the fly.   
 
The JNK Pathway in Mammalian Development 
Unlike Drosophila, mammals have 3 JNK genes, necessitating the study of 
compound knock-out mutants to establish the importance of these genes.  
Mapk8-/- Mapk9-/- animals die during gestation (Kuan et al. 1999).  However, 
Mapk8-/- Mapk10-/- and Mapk9-/- Mapk10-/- mice are healthy and fertile (Weston et 
al. 2004).  Thus, for mammalian development, Mapk10 is dispensable, while the 
ubiquitously expressed Mapk8 and Mapk9 are essential. 
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A major defect observed in Mapk8-/- Mapk9-/- animals is a failure of neural 
tube closure (Kuan et al. 1999; Sabapathy et al. 1999).  This morphogenic 
process in mammals shares characteristics with dorsal and thoracic closure in 
Drosophila.  JNK is also needed for expression of BMP4 during optic fissure 
closure through a process analogous to the DDP-driven dorsal closure 
mechanism in Drosophila (Weston et al. 2003).  These results demonstrate an 
evolutionarily conserved role for JNK in these developmental programs, and they 
suggest that this role for JNK applies across different species. 
The presence of a single copy of Mapk9 does not greatly improve animal 
health.  Studies using Mapk8-/- Mapk9+/- mice revealed that 80% die within 48 
hours of birth and those surviving to adulthood are sterile (Weston et al. 2003; 
Weston et al. 2004).  As a result of decreased EGF expression and subsequent 
decreased signaling through EGFR, these mice exhibit epidermal defects, 
including open eyes at birth.  In contrast, Mapk8+/- Mapk9-/- animals were healthy 
and fertile, indicating some differences between JNK1 and JNK2 expression or 
function (Weston et al. 2004).   
The eye lid closure defect in Mapk8-/- Mapk9+/- (Weston et al. 2004) was 
also observed in Map3k1-/- (Yujiri et al. 2000; Zhang et al. 2003) and in 
epidermis-specific cJUN-knockout mice (Zenz et al. 2003).  Together with the 
neural tube and optic fissure closure defects, these data strongly implicate JNK 
in the promotion of cell migration.  Indeed, in addition to regulating the 
expression of factors that drive cell migration, JNK can phosphorylate paxillin, a 
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protein involved in focal adhesion turnover (Huang et al. 2003).  However, JNK is 
dispensable in the gut and mammary gland (Cellurale et al. 2012). Also, loss of 
JNK in endothelial cells has no impact on their motility (Ramo et al. 2016).  Thus, 
contrary to the widely accepted essential role of JNK in cell migration (Huang et 
al. 2004), its contribution to migration is likely to be more nuanced than 
previously thought, depending on cell type, developmental stage, and stimulus. 
The development of conditional alleles for Mapk8 and Mapk9 has allowed 
dissection of JNK function in specific cell types during organismal development 
and in adulthood.  For example, loss of the MLK2/3-JNK signaling pathway in 
endothelial cells impairs collateral artery formation due to decreased Dll4-Notch 
signaling in the JNK-deficient mice (Ramo et al. 2016).  In contrast, JNK is 
dispensable in the gut epithelium (Cellurale et al. 2012). Similarly, T cells develop 
normally in the absence of JNK signaling, though their differentiation to the Th1 
lineage is compromised, indicating an important role for the pathway in adulthood 
(Dong et al. 1998).  Studies using these conditional alleles crossed to additional 
tissue-specific Cre strains will undoubtedly yield new insight into additional 
developmental programs regulated by this pathway. 
 
Mammary gland biology 
On the 12th day of development in the mouse, 5 pairs of placodes can be found 
along the milk line (Watson and Khaled 2008).  These structures will become 
epithelial cell buds that invade into the fat pad at embryonic day 13.5, and by  
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embryonic day 18.5 they will become quiescent, having formed rudimentary 
glands (Watson and Khaled 2008).  During puberty, ovarian and pituitary 
hormones (in particular estrogen and growth hormone) re-initiate mammary 
gland development, stimulating branching morphogenesis to produce a ductal 
tree (Sternlicht et al. 2006).  Cyclic ovarian stimulation throughout adulthood 
leads to increased proliferation and apoptosis, resulting in the formation of 
tertiary branches (Fata et al. 2001).  The adult ducts are composed of an 
epithelial bilayer, with contractile myoepithelial cells able to propel milk toward 
the nipple lining the outside of the duct and luminal cells capable of differentiating 
to milk-producing cells on the inside of the duct (Inman et al. 2015).  The adult 
gland is now prepared for the cycle of expansion and contraction in response to 
pregnancy, lactation, and involution (Figure I.2). 
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Figure I.2.   The mammary gland is a dynamic organ capable of multiple cycles of 
expansion and contraction in adulthood. 
Branching morphogenesis during puberty results in a network of ducts prepared for 
expansion in response to pregnancy.   As pregnancy progresses to lactation, the luminal 
epithelial cells differentiate to alveolar cells in preparation for lactation.   Upon weaning, 
the epithelial compartment collapses and the gland returns to a virgin-like state through 
the process of involution.  This cycle continues throughout the life of the animal. 
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The fact that this cycle relies on several processes involved in 
tumorigenesis (proliferation, angiogenesis, matrix remodeling, and inhibition of 
apoptosis) indicates that tight regulation by many signaling pathways at different 
stages is necessary to prevent disease (Figure I.3).  Among the identified 
regulators of branching morphogenesis is the JNK pathway (Cellurale et al. 
2012).  Its role in other stages of breast development has yet to be elucidated.  
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Figure I.3.  Processes occurring during the normal stages of mammary gland 
development are also involved in carcinogenesis. 
The cyclic expansion and regression of the mammary gland that occurs in response to 
pregnancy, parturition, and weaning involves many of the programs co-opted by 
transformed cells for their expansion, including proliferation, angiogenesis, suppression 
of apoptosis, and matrix remodeling.  Thus, the epithelial cells must retain tight control of 
these processes to prevent the development of ductal carcinoma in situ (DCIS). 
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Mammary gland development: Puberty to Adulthood 
The active sites of branching morphogenesis during puberty are the tips of the 
invading branches that contain the mammary stem cells (Scheele et al. 2017), 
bulbous structures called terminal end buds (TEB, Figure I. 4A).  These 
structures are organized into the tip-lining cap cells and the interior body cells 
(Figure I.4B) (Williams and Daniel 1983).  Proliferation to expand the mammary 
epithelium occurs in the cap cells of the TEB (Humphreys et al. 1996), while the 
body cells are the site of extensive apoptosis due to lack of cell attachment 
(anoikis) (Humphreys et al. 1996).  Three-dimensional cultures of mammary 
epithelial cells has provided additional support for this model of lumen formation 
(Mailleux et al. 2008).  The removal of these occluding cells leaves the luminal-
myoepithelial cell bilayer (Figure I.4C & D).   
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Figure I.4.  Mammary gland structure during pubertal development into adulthood.  
A, B)  In the pubertal mammary gland (A), the tips of the ducts have bulbous, multi-
layered structures called terminal end buds (circle in A).  These structures are organized 
into the interior body cells and the tip-lining cap cells (B).  While the highly proliferative 
cap cells expand and invade into the mammary fat pad, the body cells are cleared by 
apoptosis to form a single layer of luminal epithelial cells.   
C, D)  Terminal end buds are absent in the adult mammary gland (circle in C); the 
clearance of the excess cells during puberty leaves a cell bilayer with myoepithelial cells 
lining the outside of the duct and luminal epithelial cells lining the inside (D). 
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The BCL2 family of proteins are key players in luminal clearance.  Over-
expression of the pro-survival protein BCL2 in the mammary epithelium leads to 
decreased apoptosis in the TEBs (Humphreys et al. 1996) and loss of the pro-
apoptotic BH3-only protein BIM causes delayed luminal clearance (Mailleux et al. 
2007).  Similarly, the BH3-only protein BMF is upregulated during acinar 
morphogenesis and promotes lumen formation (Schmelzle et al. 2007).  Because 
there are several BH3-only proteins with partial redundancies (Huang and 
Strasser 2000; Pinon et al. 2008; Czabotar et al. 2014), it is likely that other 
members of this family are involved in luminal clearance during pubertal 
development. 
As a regulator of BH3-only proteins, both at the level of mRNA through 
cJUN activation and the level of protein by phosphorylation, JNK is an appealing 
candidate for regulating mammary gland development.  Indeed, JNK is required 
for proper acinus formation in vitro (Murtagh et al. 2004; Zhan et al. 2008; 
McNally et al. 2011).  During this process, JNK is activated by a 
Scribble/bPIX/GIT1-RAC pathway and subsequently activates cJUN to induce 
Bcl2l11 expression (Zhan et al. 2008).  Regardless of when JNK is inhibited 
during acinar morphogenesis, luminal clearance is impaired, but early inhibition 
of JNK also disrupts cell polarization (McNally et al. 2011).  This finding indicates 
that the JNK pathway influences different stages of acinar morphogenesis.   
In vivo studies have confirmed the importance of JNK in mammary gland 
development.  Mice with whole-body deletion of Mapk9 exhibit increased 
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branching morphogenesis and an expanded luminal cell population (Cantrell et 
al. 2015).  These perturbations resolve in adulthood; mammary glands of adult 
Mapk8-/- and Mapk9-/- mice do not have architectural or functional defects 
(Cellurale et al. 2010).  Because MAPK8 and MAPK9 proteins serve redundant 
functions, it was important to examine compound mutant glands.  A 
transplantation model in which mammary fat pads of wildtype mice were cleared 
and reconstituted with Mapk8Loxp/Loxp Mapk9-/- Rosa-CreERT tissue revealed that 
loss of JNK proteins results in increased ductal branching, a phenotype also 
observed in in vitro organoid cultures (Cellurale et al. 2012).  The TEBs of these 
glands also exhibited filled lumens without increased proliferation, suggesting 
that loss of JNK compromises anoikis (Cellurale et al. 2012).  Surprisingly, JNK 
deficiency did not prevent epithelial cell migration into the fat pad as would have 
been predicted based on the observed requirement for JNK in cell migration 
(Huang et al. 2003). 
It remains unclear how JNK regulates luminal clearance.  Inhibition of the 
related p38 MAPK pathway during pubertal mammary gland development results 
in a similar phenotype to the JNK-deleted gland: occluded lumens and increased 
branching (Wen et al. 2011).  In MEC, the p38 MAPK pathway activates ATF2 
resulting in ATF2-cJUN heterodimers that increase the expression of cJUN and 
BIMEL (Wen et al. 2011).  As an activator of AP1 proteins, JNK may employ a 
similar mechanism.  An alternative mechanism of JNK-mediated luminal 
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clearance could involve BH3-only protein phosphorylation to promote cell death 
(Hubner et al. 2008). 
 
Mammary gland development: Involution 
During pregnancy, the hormones progesterone and prolactin are critical for 
additional expansion of the epithelial compartment and lobuloalveolar 
differentiation in preparation for lactation (Humphreys et al. 1997; Ormandy et al. 
1997) (Figure I.5).  Through STAT5, prolactin induces mammary epithelial cell 
proliferation and differentiation (Liu et al. 1997; Cui et al. 2004).  However, 
prolactin levels drop during weaning, resulting in decreased STAT5 activity (Philp 
et al. 1996).  Epithelial cell death, adipocyte repopulation, and extracellular matrix 
remodeling all occur to return the gland to a virgin-like state through the process 
of involution. 
 
26 
 
 
 
 
 
Figure I.5.  Mammary gland structure during pregnancy and lactation. 
A) In response to pregnancy, the mammary epithelial cells expand and differentiate in 
preparation for lactation. 
B, C)  The expanded epithelial comparment begins lactating following parturition (B).  
Within it, the luminal epithelial cells have differentiated to alveolar cells, forming 
lobuloalveolar units that are responsible for milk production (C).   
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Involution has distinct phases that are characterized by their reversibility 
and differential gene expression (Lund et al. 1996; Li et al. 1997; Stein et al. 
2007).  As demonstrated in sealed teat models that maintain lactogenic hormone 
circulation with continual nursing, milk accumulation is sufficient to induce Bax 
expression, STAT3 activation, and cell death during the first phase of involution 
(Li et al. 1997).  The second, irreversible phase of involution is induced by 
decreased lactogenic hormones and is characterized by alveolar collapse and 
extensive remodeling of the gland (Li et al. 1997).  Among the upregulated genes 
are proteinases, such as Mmp3, which promotes adipogenesis in the gland (Lund 
et al. 1996; Alexander et al. 2001). 
Just as STAT5 maintains lactation, STAT3 is required for efficient 
involution (Chapman et al. 1999; Humphreys et al. 2002).  In fact, loss of STAT3 
not only delays involution, it also prolongs lactation even in the absence of 
lactogenic stimuli (Humphreys et al. 2002).  During involution, there is increased 
expression of STAT3-activating cytokines LIF, IL6, and oncostatin M (Zhao et al. 
2002; Kritikou et al. 2003; Tiffen et al. 2008).  The activation of STAT3 through 
JAK1 induces the expression of STAT3 target genes, including the pro-apoptotic 
BH3-only proteins BIM and BMF (Sakamoto et al. 2016).  This induction of BIM 
and BMF is likely functional, as loss of either delays mammary gland involution 
(Sakamoto et al. 2016; Schuler et al. 2016).  STAT3 can also promote 
expression of cathepsin b and cathepsin l to induce a lysosome-mediated death 
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pathway in mammary epithelial cells (Kreuzaler et al. 2011; Sargeant et al. 
2014). 
The TGFβ pathway also contributes to the involution program.  Several 
TGFβ isoforms are induced during involution, suggesting they may regulate this 
process (Faure et al. 2000).  Indeed, loss of TGFβ or SMAD3 causes decreased 
cell death during involution (Nguyen and Pollard 2000; Yang et al. 2002).  
Conversely, overexpression of TGFβ3 results in increased cell death during 
lactation (Nguyen and Pollard 2000). 
The ability of the JNK pathway to respond to cytokines and induce cell 
death suggests it may participate in the involution program.  Furthermore, BIM 
and BMF, two mediators of cell death during involution that promote the collapse 
of the epithelium, are targets of JNK phosphorylation (Lei et al. 2002; Lei and 
Davis 2003; Hubner et al. 2008; Hubner et al. 2010).  Thus, JNK may promote 
involution by phosphorylating BIM and BMF.  Alternatively, JNK may regulate the 
expression of genes implicated in involution, such as Bcl2l11 (Whitfield et al. 
2001) or matrix metalloproteases (Chakraborti et al. 2003), through AP1 
members.  Indeed, AP1 DNA binding activity is dynamically regulated by 
suckling: within 24 hours of removing pups AP1 DNA binding increases, and the 
resumption of nursing reverses this binding (Jaggi et al. 1996).  Activated cJUN 
is still present after 3 days of involution, suggesting that it may contribute to both 
stages of mammary gland involution (Marti et al. 1999).  Because studies of 
Mapk8-/- and Mapk9-/- mice did not reveal any defects during involution (Cellurale 
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et al. 2010), it will be necessary to examine compound loss of JNK in the 
mammary epithelium to determine the importance of this pathway in involution. 
 
Stromal cells in mammary gland involution 
The return to a quiescent mammary gland after lactation does not rely solely on 
epithelial cells.  As the epithelial cells are removed, adipocytes must differentiate 
and repopulate the gland, otherwise involution is disrupted (Lund et al. 2000; 
Selvarajan et al. 2001).  Fibroblast-like cells produce proteases to aid in gland 
remodeling during the second phase of involution (Lund et al. 1996).  Also, 
immune cells, such as neutrophils and B cells, mount a response in the involuting 
gland that is similar to the wound healing response (Stein et al. 2004; Martinson 
et al. 2015).   
Perhaps the most studied stromal cells in involution are macrophages.  
Macrophage depletion during lactation delays epithelial cell death and adipocyte 
repopulation during involution (O'Brien et al. 2012).  The infiltrating macrophages 
of involuting glands express M2 markers, arginase 1 and mannose receptor 
(O'Brien et al. 2010).  These macrophages along with the other infiltrating 
immune cells produce an environment that resembles the wound healing 
response, both in the type of infiltrating cell and the timing of the cells’ arrival 
(Martinson et al. 2015).  Macrophage infiltration of involuting breast tissue has 
been observed in humans as well (O'Brien et al. 2010).  Even after regression of 
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the epithelial compartment, macrophages are present at elevated levels (Jindal 
et al. 2014).   
Inflammation characterized by M2 macrophages promotes cancer by 
providing beneficial cytokines and aiding tissue remodeling (Melief and Finn 
2011).  Also, collagen deposition that occurs during remodeling can promote 
tumor cell growth and invasion (Lyons et al. 2011).  Thus, involution creates an 
environment conducive to tumorigenesis in which human tumor cells thrive 
(Lyons et al. 2011).  Indeed, women diagnosed with breast cancer within 5 years 
of pregnancy have a poorer prognosis than nulliparous women (Schedin 2006).  
Additional work is needed to understand involution in order to develop 
therapeutic approaches for women who develop post-partum breast cancer. 
 
JNK and Cancer 
Cellular transformation involves co-opting normal processes to promote cell 
survival and expansion (Hanahan and Weinberg 2011).  The PI3K/AKT (Yuan 
and Cantley 2008), RAS (Downward 2003), and p53 (Halazonetis et al. 2008; 
Vousden and Prives 2009) pathways are frequently used by cells to escape the 
regulatory mechanisms checking their growth.   
Sequencing of human tumors and tumor-derived cell lines has implicated 
the JNK pathway in cancer.   Deletions or loss of heterozygosity of MAP2K4, one 
of the upstream activators of JNK, were found in a subset of human tumor cell 
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lines, suggesting that this gene is a tumor suppressor (Teng et al. 1997).  With 
increased sequencing of human tumors, more evidence has been found for the 
JNK pathway’s involvement in this disease.  A study focused on serine/threonine 
kinase mutations in colorectal cancers also identified MAP2K4 mutations 
(Parsons et al. 2005).  Yet another study found mutations in MAPK8 and MAPK9 
as well as MAP2K7 in different human tumors (Greenman et al. 2007).  While 
these sequencing studies implicate the JNK pathway in human cancer, the 
functional relevance of these mutations in tumorigenesis is unknown. 
 
JNK pathway: tumor promoting or suppressing? 
The examination of JNK in Drosophila models revealed different roles for the 
JNK pathway.   The JNK pathway was able to suppress tumorigenesis by 
eliminating cells that had lost polarity due to mutations in genes like scribble 
(Brumby and Richardson 2003; Uhlirova et al. 2005; Igaki et al. 2006; Igaki et al. 
2009).   However, in the context of activated RAS, JNK took on oncogenic roles 
and was required for the invasive and metastatic behavior of cells (Igaki et al. 
2006; Uhlirova and Bohmann 2006).  These experiments supported a role for the 
JNK pathway in cancer. 
The major target of JNK is the proto-oncogene cJUN.  Since the JNK 
pathway activates cJUN, it would be predicted that JNK promotes cancer.  
Indeed, the oncogene RAS causes increased JNK activity and phosphorylation of 
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cJUN on Ser63 and Ser73, the JNK target sites (Pulverer et al. 1991; Smeal et 
al. 1991; Derijard et al. 1994).  Furthermore, these phosphorylation sites on 
cJUN contribute to RAS- or FOS-driven transformation (Behrens et al. 2000).  
Similarly, ERBB2-driven transformation of mammary epithelial cells was reported 
to rely on the JNK/cJUN pathway (Guo et al. 2006).  These observations suggest 
that JNK activity drives cancer. 
In contrast to the reported tumor-promoting function of JNK, aging studies 
of Trp53+/- Mapk8-/- and Trp53+/- Mapk9-/- mice showed enhanced tumor 
formation compared to Trp53+/- controls (Cellurale et al. 2010).  Furthermore, an 
in vivo KRASG12D-driven model of lung cancer (Cellurale et al. 2011) as well as a 
transplantation model of breast cancer (Cellurale et al. 2012) demonstrated that 
JNK was dispensable during oncogenesis if Trp53 was deleted.  In fact, JNK loss 
together with Trp53 deletion accelerated tumor formation (Cellurale et al. 2011; 
Cellurale et al. 2012).  These data contrast with the observed requirement for 
JNK in transformation and demonstrate that the JNK pathway plays context-
specific roles during tumorigenesis. 
 
Cancer stem cells and the JNK Pathway  
As a regulator of transcription factors, it is likely that JNK signaling may impinge 
on genes that modulate cell differentiation.  Inactivation of the JNK pathway 
together with Pten loss in prostate epithelial cells results in large tumors that form 
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more rapidly than in mice only deficient for Pten (Hubner et al. 2012).  
Characterization of the tumor cells revealed that the prostate cancer cells without 
a functional JNK pathway had an expanded stem cell-like population relative to 
controls, indicating that JNK pathway inhibition in prostate epithelial cells may 
promote cancer by expanding the stem cell compartment (Hubner et al. 2012).  
This observation contrasts with the reported requirement for JNK signaling to 
maintain cancer stem cell activity in triple negative breast cancer cell lines (Xie et 
al. 2017).  This discrepancy may be due to the means of pathway inactivation 
(i.e. genetic inactivation of JNK versus small molecule or siRNA targeting of JNK) 
or the tissue being studied.  Nevertheless, both studies indicate that the JNK 
pathway can influence the stem cell compartment. 
More generally, these observations indicate that the JNK pathway may 
regulate terminal cell differentiation and in doing so may impact tumorigenesis.  
Indeed, JNK is known to be required for proper embryonic stem cell 
differentiation (Xu and Davis 2010).  In both the mammary gland and in 
mammary tumors, loss of JNK2 expands ER-positive cells and results in 
increased ER-associated proliferation (Cantrell et al. 2015).  Similarly, mice with 
activated KRAS and no functional JNK pathway showed accelerated acinar-to-
ductal metaplasia in the pancreas (Davies et al. 2014).  This result suggests that 
the JNK pathway prevents cells from differentiating to a cell type more 
susceptible to transformation.  Thus, JNK enables cells to retain acinar 
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differentiation, making them refractory to KRAS-driven transformation and 
pancreatic ductal adenocarcinoma (Davies et al. 2014).   
 
JNK and DNA damage 
The acquisition of advantageous mutations marches cells down the path of 
transformation; therefore sensing and repairing lesions in the DNA are key tumor 
suppressive processes (Hanahan and Weinberg 2011).  These mutations can 
occur after exposure to environmental sources of DNA damage, such as ionizing 
radiation, ultraviolet light, and chemotherapeutic drugs, or from cell-intrinsic 
sources.  For example, insults to DNA occur as a result of metabolic processes 
that generate reactive oxygen species (ROS) (Kryston et al. 2011).  In settings of 
chronic inflammation, increased cell proliferation in the presence of ROS results 
in increased mutagenesis (Grivennikov et al. 2010).  Oncogene activation can 
also increase DNA double strand breaks due to increased replication stress 
(Halazonetis et al. 2008).    
In the presence of DNA damage, sensing proteins activate the PI3K family 
members ATM/ATR to engage the appropriate repair pathway (Ciccia and 
Elledge 2010).  DNA damage also causes phosphorylation of the histone H2AX 
protein at serine 139 to promote the assembly of factors that mediate repair 
(Ciccia and Elledge 2010).  JNK has been implicated in the phosphorylation of 
H2AX at this site (Lu et al. 2006; Boege et al. 2017) and JNK inhibition resulted 
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in decreased DNA damage repair signaling (Boege et al. 2017).    In the 
presence of oxidative stress, JNK is activated and it phosphorylates SIRT6,  
resulting in SIRT6 binding to DNA and recruiting PARP for double strand break 
(DSB) repair (Van Meter et al. 2016).  JNK can also phosphorylate DGCR8 to 
promote transcriptional-coupled nucleotide exchange repair (Calses et al. 2017).  
The involvement of JNK in the DNA damage response suggests that JNK-
deficient tumors will exhibit increased genomic instability.  Indeed, Mapk9-/- tumor 
cells experience replicative stress and have increased aneuploidy relative to 
controls (Chen et al. 2010). 
JNK activity in response to various genotoxic agents has also been 
examined.  For example, the DNA alkylating agent MMS strongly activates JNK 
(Wilhelm et al. 1997).  In Mapk8-/- Mapk9-/- MEFs, MMS treatment results in 
growth arrest rather than cell death (Tournier et al. 2000).  Cisplatin treatment 
also results in JNK activation (Sanchez-Perez et al. 1998; Hayakawa et al. 2004; 
Helbig et al. 2011), with prolonged JNK activation leading to increased cell death 
(Chen et al. 1996; Sanchez-Perez et al. 1998).  However, cisplatin treatment of 
breast carcinoma cells also causes a JNK-dependent induction of a substantial 
number of genes involved in DNA repair (Hayakawa et al. 2004).  Thus, JNK 
activation during cisplatin treatment may enable cells to repair damaged DNA 
and survive, suggesting that pathway inhibition may sensitize cells to cisplatin. 
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JNK in breast cancer 
In the breast, transformation goes through different stages with hyperplasia 
leading to ductal carcinoma in situ, or DCIS (Bombonati and Sgroi 2011).  Two 
models exist for the subsequent filling of the ductal lumen observed in DCIS: 
(1) Transformed cells translocate to the luminal space and, having overcome 
anoikis, proliferate there.  The increased cell number causes the observed 
ductal occlusion (Taraseviciute et al. 2010; Leung and Brugge 2012; 
Pradeep et al. 2012). 
(2) Cell proliferation results in chords of polarized and unpolarized cells 
spanning the lumen, creating secondary lumina.  These structures 
eventually collapse, resulting in a filled duct (Halaoui et al. 2017).   
The resulting breast tumors are classified according to the expression of 
estrogen receptor (ER) and progesterone receptor (PR), and HER2 amplification, 
which informs therapeutic approaches (American Cancer Society 2013).    Triple 
negative breast cancers are characterized by lack of ER/PR expression or HER2 
amplification and as a result must be treated using chemotherapy which, while 
beneficial, is less specific (Perou 2011).  Gene expression studies have been 
performed on breast cancer samples to more thoroughly classify these tumors to 
better understand the disease and its subtypes, to predict clinical outcomes, and 
to uncover potential therapeutic targets (van 't Veer et al. 2002; Sorlie et al. 
2003). 
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Studies focusing on human breast cancer have found that MAP2K4 and 
MAP3K1 are mutated in human breast cancer (Cancer Genome Atlas 2012; 
Stephens et al. 2012).  In fact, MAP2K4 and MAP3K1 are among the most 
frequently mutated genes in this disease (Nik-Zainal et al. 2016a).  A mutation in 
MAP2K7, the gene encoding the other upstream activator of JNK, was also found 
in a triple negative breast cancer (Wang et al. 2014).  The types of mutations 
identified in these proteins suggest that they result in a loss of protein function 
(Kan et al. 2010; Banerji et al. 2012; Ellis et al. 2012).  A comparison of invasive 
lobular carcinoma with invasive ductal carcinoma revealed that MAP3K1 and 
MAP2K4 mutations are more frequent in the latter disease, indicating that 
different breast cancers show a preference for JNK pathway mutations (Ciriello et 
al. 2015).  Collectively, these data implicate the JNK pathway in human breast 
cancer, but they do not provide insight into how JNK influences cellular 
transformation. 
To address this gap in knowledge, mouse models have been used to 
examine the role of JNK in breast cancer.  Whole-body Mapk9 deletion in the 
presence of MMTV-driven polyoma middle T antigen resulted in earlier tumor 
formation and increased tumors per mouse relative to control animals (Chen et 
al. 2010).  In the context of Trp53 deficiency, whole-body loss of either Mapk8 or 
Mapk9 resulted in similar tumor spectrums forming with the same kinetics in 
Trp53-/-, Trp53-/- Mapk8-/-, and Trp53-/- Mapk9-/- mice (Cellurale et al. 2010).  
However, a comparison of Trp53+/-, Trp53+/- Mapk8-/- and Trp53+/- Mapk9-/- mice 
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revealed that loss of either JNK isoform reduced tumor-free survival (Cellurale et 
al. 2010).  Additionally, loss of either JNK1 or JNK2 increased the percentage of 
breast tumors relative to Trp53-/- controls (Cellurale et al. 2010). 
Because the JNK1 and JNK2 proteins are largely redundant (Tournier et 
al. 2000), both genes must be deleted to understand the role of this pathway in 
breast cancer.  Considering that compound loss of JNK results in embryonic 
lethality (Kuan et al. 1999; Sabapathy et al. 1999), a conditional deletion 
approach is necessary.  In a mammary gland transplantation model in which 
tumors were driven by KRAS activation and Trp53 deletion, compound JNK loss 
significantly increased mammary tumor formation (Cellurale et al. 2012).  These 
findings agree with the whole body knock-out studies of JNK in breast cancer 
(Cellurale et al. 2010; Chen et al. 2010).  Additional studies of more human 
relevant breast cancer models are warranted to better appreciate the role of the 
JNK pathway in cancer. 
 
Cell-specific Functions of JNK in Cancer 
The immune system actively participates in cancer development by both 
suppressing and promoting the disease (Hanahan and Weinberg 2011; Schreiber 
et al. 2011).   Immune cells prevent tumorigenesis by removing mutant cells and 
suppressing inflammation; however tumors eventually break through this barrier 
(Schreiber et al. 2011).   Through the recruitment of M2 macrophages, Th2 and 
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Treg cells, and the exclusion of Th1 cells and M1 macrophages, tumor cells 
establish an environment that promotes growth and tissue remodeling (Melief 
and Finn 2011).   In addition to influencing cellular transformation in the epithelial 
cells of a particular tissue, JNK signaling may influence tumorigenesis through 
immune cells.  Indeed, the JNK pathway is important for immune cell 
differentiation and function (Dong et al. 1998; Yang et al. 1998; Conze et al. 
2002; Han et al. 2013).  
A role for the JNK pathway in macrophages during carcinogenesis has 
been identified in hepatocellular carcinoma (HCC), a tumor that relies on an 
inflammatory environment for its development.  While whole-body Mapk8-/- mice 
develop fewer chemically induced HCC lesions than controls (Sakurai et al. 
2006; Hui et al. 2008), Mapk8 deletion in hepatocytes results in increased tumor 
burden (Das et al. 2011).  Simultaneous loss of JNK in parenchymal and non-
parenchymal cells of the liver recapitulated the observations made in the whole-
body knock-out, indicating that loss of JNK in stromal cells is key for the 
development of HCC (Das et al. 2011).  Furthermore,  JNK expression in 
hematopoietic cells, not hepatocytes, is needed for hepatitis (Das et al. 2009).  
The observations that JNK is needed for M1 macrophage cytokine expression 
and is involved in macrophage polarization, led to the hypothesis that HCC 
development relies on macrophage JNK (Han et al. 2013).   Indeed, JNK 
expression in macrophages is required for the expression of pro-inflammatory 
cytokines and tumor formation in a model of HCC (Han et al. 2016).   These 
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observations may apply to other tumor types, like breast cancer, that also recruit 
macrophages to enable disease progression (Lin et al. 2002; Qian and Pollard 
2010).  
In addition to illustrating a tumor-promoting role for JNK signaling in 
macrophages, these findings highlight the importance of targeted JNK deletion to 
study its role in cancer.  Studies of whole-body deletion of Mapk8 or Mapk9 that 
have examined the importance of JNK in breast cancer (Cellurale et al. 2010; 
Chen et al. 2010; Cantrell et al. 2015) may have come to erroneous conclusions 
because of JNK deficiency in other cell types.  Genetically engineered mouse 
models that target JNK deletion to the mammary epithelium will be necessary to 
elucidate the role of this pathway in breast cancer.    
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Rationale and Objectives 
The frequent mutation of JNK pathway components in breast cancer 
necessitates an understanding of its involvement in normal and diseased states 
of the mammary gland.   Overcoming anoikis and surviving in luminal spaces is 
an early step in transformation (Taraseviciute et al. 2010; Leung and Brugge 
2012; Pradeep et al. 2012).  Initial studies found evidence supporting (Frisch et 
al. 1996) and refuting (Khwaja and Downward 1997) a role for JNK during this 
form of cell death.  However, studies of acinar morphogenesis and mammary 
gland development indicate that JNK is required for luminal clearance (McNally 
et al. 2011; Cellurale et al. 2012).  In Chapter II, I resolve the controversy 
regarding the requirement for JNK in epithelial cell anoikis and show that JNK 
promotes this cell death through transcriptional and post-translational regulation. 
I next examined the role of the JNK pathway in mammary gland involution 
following lactation (Chapter III).   While the STAT3 (Chapman et al. 1999; 
Humphreys et al. 2002) and TGFβ (Nguyen and Pollard 2000) pathways are 
known to regulate the return to a virgin-like state, it is likely that other pathways 
also contribute to this process.  The stress-activated MAP kinases are known to 
participate in mammary gland biology, making them prime candidates (Avivar-
Valderas et al. 2014).  For example, JNK regulates branching morphogenesis 
and luminal clearance during pubertal development, demonstrating its 
importance in mammary gland biology (Cellurale et al. 2012).  Furthermore, JNK 
and its AP1 targets are activated during involution (Jaggi et al. 1996; Marti et al. 
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1999).  These observations suggested that JNK signaling to AP1 members may 
be involved in the involution program.  I found that JNK was required for efficient 
mammary gland involution and for the expression of a large number of genes 
involved in this process.  Furthermore, this promotion of involution was 
independent of STAT3 or TGFβ signaling. 
Finally, I addressed the question of JNK pathway involvement in breast 
cancer (Chapter IV).  Sequencing studies of human tumors have demonstrated 
that the pathway is frequently mutated in breast cancer (Nik-Zainal et al. 2016a), 
but the importance of these mutations has not been tested.  In vivo studies of 
JNK in breast cancer had used whole-body loss of either Mapk8 or Mapk9 
(Cellurale et al. 2010; Chen et al. 2010) leaving open the question of how 
complete JNK pathway inactivation restricted to mammary epithelial cells 
influences disease progression.  While the mammary gland transplantation 
assays partially addressed this question, these tumors developed in the 
presence of a compromised immune system and were driven by an oncogene 
not frequently observed in human breast cancer (Cellurale et al. 2012).  Thus, I 
used conditional gene ablation to delete JNK in the mammary epithelium.   I 
found that JNK loss was sufficient for genomic instability and carcinogenesis.   
Additional studies in a murine model of breast cancer confirmed that JNK plays a 
tumor suppressive role in breast cancer, and suggested its main function is to 
prevent tumor initiation rather than to produce a more aggressive tumor 
phenotype. 
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CHAPTER II 
JNK PROMOTES EPITHELIAL CELL ANOIKIS BY TRANSCRIPTIONAL AND 
POST-TRANSPLATIONAL REGULATION OF BH3-ONLY PROTEINS 
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Abstract 
Developmental morphogenesis, tissue injury, and oncogenic transformation can 
cause the detachment of epithelial cells.  These cells are eliminated by a 
specialized form of apoptosis (anoikis).  While the processes that contribute to 
this form of cell death have been studied, the underlying mechanisms remain 
unclear.  Here I tested the role of the cJUN NH2-terminal kinase (JNK) signaling 
pathway using murine models with compound JNK-deficiency in mammary and 
kidney epithelial cells.  These studies demonstrated that JNK is required for 
efficient anoikis in vitro and in vivo.  Moreover, JNK-promoted anoikis required 
pro-apoptotic members of the BCL2 family of proteins.  I show that JNK acts 
through a BAK/BAX-dependent apoptotic pathway by increasing BIM expression 
and phosphorylating BMF leading to death of detached epithelial cells. 
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Introduction 
Multicellular organisms rely on apoptosis to remove excess cells, mediate cell 
turnover, and clear damaged cells in order to prevent disease (Fuchs and Steller 
2011).  Improper regulation of cell death is implicated in pathogenic processes, 
including cancer (Hanahan and Weinberg 2011).  Gaining an understanding of 
the pathways that mediate these forms of cell death is therefore critically 
important.   
Pro-apoptotic BCL2-family proteins, including BAK/BAX-like proteins and 
BH3-only proteins, can initiate cell death, while anti-apoptotic BCL2-family 
proteins can suppress cell death (Huang and Strasser 2000; Pinon et al. 2008; 
Czabotar et al. 2014).  BAK and BAX can release cytochrome c from 
mitochondria, thereby committing cells to apoptosis (Jurgensmeier et al. 1998; 
Narita et al. 1998).  Anti-apoptotic BCL2-like proteins can prevent BAK and BAX 
activation, while pro-apoptotic BH3-only members of the BCL2 family can initiate 
BAK/BAX-mediated cell death.  Multiple signaling pathways target the BCL2-
family proteins, and the balance of these signals determines whether a cell 
initiates apoptosis (Puthalakath and Strasser 2002).  The stress-activated c-JUN 
NH2-terminal kinase (JNK) pathway (Davis 2000) is one of these signaling 
mechanisms (Tournier et al. 2000).  Pro-apoptotic targets of JNK signaling 
include the BH3-only proteins BIM and BMF that can initiate BAK/BAX-
dependent apoptotic cell death (Lei et al. 2002; Lei and Davis 2003; Hubner et al. 
2008; Hubner et al. 2010).   
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Anoikis – apoptosis induced by epithelial cell detachment – is implicated in 
the luminal clearance of developing mammary glands (Humphreys et al. 1996), 
involution of lactating mammary glands (Boudreau et al. 1995), and cancer 
metastasis (Douma et al. 2004).  The initiation of anoikis is induced by the 
disruption of epithelial cell interactions with the cell matrix (Frisch and Francis 
1994; Frisch and Screaton 2001; Reginato et al. 2003).  The role of JNK in 
anoikis is controversial because it has been reported that JNK is essential (Frisch 
et al. 1996) and also that JNK is dispensable (Khwaja and Downward 1997) for 
epithelial cell apoptosis in response to detachment.  This controversy has yet to 
be resolved.  More recent studies suggest that JNK may promote epithelial cell 
anoikis in vitro (Zhan et al. 2008; McNally et al. 2011) and in vivo (Cellurale et al. 
2012).   
The purpose of this study was to rigorously test the role of JNK in anoikis 
using compound ablation of the Mapk8 and Mapk9 genes that encode the JNK1 
and JNK2 protein kinases (Han et al. 2013) and pharmacological inhibition using 
a highly specific small molecule (Zhang et al. 2012).  These loss-of-function 
studies demonstrated that JNK signaling is required for epithelial cell anoikis.  
Conversely, gain-of-function studies using constitutively activated JNK 
demonstrated that JNK signaling promotes anoikis.  Mechanistic analysis 
demonstrated that JNK-promoted anoikis requires the pro-apoptotic BCL2-family 
proteins BAK/BAX and the BH3-only proteins BIM and BMF.  I show that JNK-
induced BIM expression and JNK-mediated phosphorylation of BMF lead to 
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engagement of the BAK/BAX apoptosis pathway that causes death of detached 
epithelial cells.   
 
 
  
48 
 
 
Results 
JNK promotes epithelial cell anoikis 
To test the role of the JNK pathway during epithelial cell anoikis, I examined the 
effect of JNK inhibition using a small molecule (JNK-IN-8) that selectively and 
potently blocks JNK activity (Zhang et al. 2012).  Normal human mammary 
epithelial cells were treated with JNK-IN-8 or solvent (DMSO) and then cultured 
in suspension (1 h or 48 h).  The number of apoptotic (Annexin V+ 7-AAD-) cells 
was measured by flow cytometry.  Suspension culture (48 h) caused a large 
increase in apoptosis (anoikis) that was strongly suppressed following treatment 
with the JNK inhibitor (Figure II.1A-D).  Gene expression analysis performed on 
attached and suspended cells demonstrated JNK-dependent expression of pro-
apoptotic genes that encode BH3-only members of the BCL2 family, including 
BBC3, BIK, BCL2L11, HRK, and PMAIP1 (Figure II.1E). 
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Figure II.1.  JNK promotes anoikis of human mammary epithelial cells.   
A - C)  Human mammary epithelial cells (HMEC) were cultured in suspension for 1 h (A) 
or 48 h (B,C).  The effect of JNK inhibition was examined by incubating the cells with 
solvent (DMSO) (B) or 2 µM JNK-IN-8 (C).  The cells were stained with Annexin V-PE 
and 7AAD and examined by flow cytometry.  The 7AAD- cell population was gated and 
examined for Annexin V staining intensity.  Representative flow cytometry data are 
presented. 
D) Apoptotic cells (Annexin V+  (AnxV+) and 7AAD-) were quantitated (mean ± SEM of 5 
independent experiments; * p<0.05).  
E)  HMEC were cultured in suspension for 24 h in the absence or presence of JNK-IN-8.  
BH3-only gene expression was quantitated using RT-PCR.  Mean values are 
represented as a heatmap (n=3). 
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 To obtain genetic evidence for a role of JNK in epithelial cell anoikis, I 
examined the effect of Mapk8 (encodes JNK1) and Mapk9 (encodes JNK2) gene 
ablation in primary murine kidney epithelial cells.  Immunoblot analysis of Control 
(Mapk8+/+ Mapk9+/+) and JNKKO (Mapk8-/- Mapk9-/-) cells confirmed that JNK was 
expressed in Control, but not JNKKO, epithelial cells (Figure II.2A).  I examined 
anoikis of Control and JNKKO epithelial cells caused by suspension culture (1 h or 
24 h).  Colony formation assays demonstrated that JNK deficiency promoted 
epithelial cell survival (Figure II.2B).  Quantitation of apoptotic (Annexin V+ 7-
AAD-) cells using flow cytometry (Figure II.2C) and activation of the apoptosis 
effector caspase 3 by cleavage (Figure II.2D) confirmed that JNK is required for 
efficient epithelial cell anoikis.   
To test whether JNK promotes anoikis, I examined the effect of conditional 
expression of constitutively activated JNK using epithelial cells transduced with a 
doxycycline-inducible lentiviral vector that expresses Flag-Mkk72-Jnk11 
(JNK1CA).  Immunoblot analysis confirmed that treatment with doxycycline 
induced the expression of JNK1CA (Figure II.2E).  When cultured in suspension (1 
h or 24 h), JNK1CA expression in epithelial cells caused an increase in the 
number of apoptotic (Annexin V+ 7-AAD-) cells detected by flow cytometry 
(Figure II.2F).  These data demonstrate that JNK functions to promote anoikis.   
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Figure II.2.  JNK promotes anoikis of murine epithelial cells.   
A)  Mapk8LoxP/LoxP Mapk9-/- RosaCreERT mouse kidney epithelial cells were treated with 4-
hydroxytamoxifen to generate Mapk8Δ/Δ Mapk9-/- cells (JNKKO).  JNK expression by 
Control (RosaCreERT) and JNKKO cells was examined by immunoblot analysis.   
B)  Control and JNKKO mouse kidney epithelial cells were replated after suspension (1 h 
or 24 h) and stained with crystal violet.  Representative images of cultures are 
presented.  The fraction of surviving cells was quantitated by staining with crystal violet 
(mean ± SEM; n=3; * p<0.05).  
52 
 
 
C)  Control (red) and JNKKO (blue) mouse kidney epithelial cells were cultured in 
suspension (1 h or 24 h).  Representative flow cytometry data are presented.  Apoptotic 
Control and JNKKO cells (Annexin V+ (AnxV+) and 7AAD-) were quantitated by flow 
cytometry (mean ± SEM; n=4; ** p<0.001).  
D)  Extracts prepared from Control and JNKKO mouse kidney epithelial cells (attached, 
attached and starved 24 h, and anoikis 24 h) were examined by immunoblot analysis of 
caspase 3 (C3), cleaved caspase 3 (c-C3), and αTubulin.  The data were quantitated 
(mean and SEM; n=3; ** p<0.01).  
E, F)  Control mouse kidney epithelial cells were transduced with an empty vector or a 
vector that expresses constitutively activated JNK1 (Flag-Mkk7β2-Jnk1α1 (JNK1CA)), 
treated with doxycycline, and examined by immunoblot analysis using antibodies to 
FLAG and GAPDH (E). The epithelial cells were cultured in suspension (1 h or 24 h) and 
apoptotic cells (Annexin V+ (AnxV+) and 7AAD-) were quantitated by flow cytometry (F) 
(mean ± SEM; n=4; *** p<0.001).  Representative flow cytometry data are also 
presented. 
  
53 
 
 
MLK2/3 are dispensable for epithelial cell anoikis 
JNK activation requires phosphorylation by both MAP2K4 and MAP2K7 (Tournier 
et al. 2001).  Upstream of these MAP kinase kinases are the MAP kinase kinase 
kinases (MAP3K), including the mitogen-activated protein/ERK kinase kinases 
(MEKK), apoptosis signal-regulating kinase (ASK), TGFβ-activated kinase 1 
(TAK), tumor-progression locus 2 (TPL2), and mixed lineage kinases (MLK) 
(Davis 2000).  These kinases respond to different stimuli and can activate 
different subsets of MAPK pathways.  Knock-out studies have demonstrated that 
ASK1 (Tobiume et al. 2001), TAK1 (Shim et al. 2005), MEKK1 (Yujiri et al. 1998), 
MEKK2 (Kesavan et al. 2004), and MLK2 and MLK3 (Jaeschke and Davis 2007; 
Kant et al. 2011; Kant et al. 2017) are members of the JNK pathway.   
To test the involvement of the mixed lineage kinases in anoikis, I placed 
Control and Map3k10-/- Map3k11-/- (encoding MLK2 and MLK3; MLK2/3KO) cells 
into suspension culture (1 h and 24 h).  Both genotypes experienced a similar 
increase in cell death following 24 h of suspension (Figure II.3), indicating that 
these MAP3K are not involved in the JNK-mediated response to cell suspension. 
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Figure II.3. MLK2 and 3 proteins are not essential for epithelial cell anoikis. 
A, B)  Control and Map3k10-/- Map3k11-/- (MLK2/3KO) cells were cultured in suspension 
(1 h or 24 h).  Apoptotic cells (Annexin V+ (AnxV) 7AAD-) were quantitated using flow 
cytometry.  Graph shows mean ±SEM (Control n=4, MLK2/3KO n=8) (A).  A 
representative flow cytometry plot is presented (B). 
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JNK-promoted anoikis is mediated by the BAK/BAX pathway 
I next sought to understand how JNK promotes anoikis.  Cell detachment 
activates autophagy, leading to enhanced survival (Fung et al. 2008).  
Furthermore, the JNK pathway can regulate autophagy, though this regulation 
may be cell-type specific (Wei et al. 2008; Xu et al. 2011; Barutcu et al. In press).  
Thus, I examined autophagy in attached and suspended (4 h) Control and JNKKO 
kidney epithelial cells.  Suspension culture resulted in increased levels of LC3B II 
in Control cells, indicating that anoikis induced autophagy (Figure II.4).  However, 
no JNK-dependent changes in LC3B II accumulation were detected (Figure II.4).  
This observation suggests that alterations in the regulation of autophagy is 
unlikely to account for the increased survival of JNKKO kidney epithelial cells. 
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Figure II.4.  Autophagy induction is comparable in Control and JNKKO cells. 
A, B) Control and JNKKO cells were cultured in growth media without (GM) or with 
(GM+CQ) 25 µM chloroquine, or were placed in suspension culture without (S) or with 
(S+CQ) 25 µM chloroquine.  Cell lysates were subjected to immunoblot analysis with 
antibodies for LC3B and αTubulin.  A representative blot is presented (A).  Two 
independent experiments were quantified and the mean±SEM was plotted with 
conditions normalized to the Control cells in growth media (B). 
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It is established that the pro-apoptotic BCL2 family proteins BAK and BAX 
play a central role in apoptotic cell death (Lindsten et al. 2000; Wei et al. 2001).  
To test whether this pathway contributes to anoikis, I examined the effect of 
suspension culture (1 h and 24 h) on Control and Bak1-/- Bax-/- (BAK/BAXKO) 
epithelial cells.  I found that BAK/BAX-deficiency greatly decreased the number 
of apoptotic (Annexin V+ 7-AAD-) cells detected by flow cytometry following 
epithelial cell detachment (Figure II.5A).  BAK and BAX are therefore key players 
in anoikis.   
To test whether BAK/BAX contribute to JNK-promoted anoikis, I examined 
BAK/BAXKO epithelial cells transduced with a lentiviral vector that conditionally 
expresses JNK1CA.  Expression of JNK1CA in doxycycline-treated BAK/BAXKO 
epithelial cells was confirmed by immunoblot analysis (Figure II.5B).  
Examination of BAK/BAXKO epithelial cell suspension cultures demonstrated that 
JNK1CA expression did not cause increased anoikis (Figure II.5C).  Together, 
these data demonstrate that JNK-promoted anoikis is mediated by the BAK/BAX 
pathway.   
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Figure II.5.  BAK and BAX are required for JNK-promoted anoikis. 
 A)  Control and Bak1-/- Bax-/- (BAK/BAXKO) mouse kidney epithelial cells were cultured in 
suspension (1 h or 24 h) and apoptotic cells (Annexin V+ (AnxV+) and 7AAD-) were 
quantitated by flow cytometry (mean ± SEM; n=3; *** p<0.001).  Representative flow 
cytometry data are also presented.   
B, C)  BAK/BAXKO kidney epithelial cells were transduced with an empty vector or a 
vector that expresses constitutively activated Flag-tagged JNK1 (JNK1CA), treated with 
doxycycline, and examined by immunoblot analysis using antibodies to FLAG and 
GAPDH (B).  The cells were cultured in suspension (1 h or 24 h) and apoptotic cells 
(Annexin V+ (AnxV+) and 7AAD-) were quantitated by flow cytometry (C).  The data 
shown are the mean ± SEM; n=3).  Representative flow cytometry data are also 
presented. 
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BH3-only proteins promote epithelial cell anoikis in vitro 
The BAK/BAX pathway of cell death can be engaged by BH3-only members of 
the BCL2 protein family by interacting with pro-survival BCL2-family proteins 
(Zong et al. 2001; O'Neill et al. 2016).  I found that anoikis was not associated 
with increased BAK or BAX expression (Figure II.6A).  Consequently, BAK/BAX-
mediated cell death may be initiated by either increased pro-apoptotic BH3-only 
protein function and/or decreased pro-survival BCL2 family protein function.   
 I examined the potential role of pro-survival members of the BCL2 family.  
Gene expression studies demonstrated decreased expression of Bcl2 and Bcl2l1 
during anoikis of primary murine epithelial cells (Figure II.6B).  Increased 
expression of pro-survival BCL2 family genes was not detected in JNKKO 
epithelial cells (Figure II.6B) and therefore cannot account for the resistance of 
JNKKO epithelial cells to anoikis (Figure II.2).   
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Figure II.6.  BCL2 family gene expression in suspended epithelial cells.  
A, B) RNA-seq analysis of attached and suspended (4 h) Control and JNKKO cells was 
performed. Expression of pro-apoptotic (A) and pro-survival (B) BCL2 family genes is 
presented as a heat map with samples normalized to the attached Control. Bar graphs 
show the mean fragments per kilobase of exon model per million mapped fragments 
(FPKM) ± SEM (n=3 replicates per condition). 
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Expression of the anti-apoptotic BCL2 family member MCL1 is regulated 
by ubiquitin-mediated degradation promoted by the AKT-regulated GSK3 
signaling pathway (Maurer et al. 2006).  I therefore performed immunoblot 
analysis to examine survival signaling pathways and MCL1 expression during 
anoikis.  I found that suspension culture caused decreased activation of the ERK 
and AKT signaling pathways and decreased expression of MCL1 protein (Figure 
II.7).  However, JNK-deficiency caused no change in MCL1 protein abundance 
(Figure II.7).  Together, these data demonstrate that decreased expression of 
pro-survival BCL2 family member MCL1 protein likely contributes to anoikis, but 
this mechanism is not targeted by JNK to promote anoikis.   
I also examined the role of pro-apoptotic BH3-only members of the BCL2 
family in JNK-promoted apoptotic cell death during anoikis.  Gene expression 
analysis demonstrated that the expression of Bcl2l11 (encoding BIM), Bmf, and 
Hrk were increased during epithelial cell anoikis (Figure II.8A).  However, only 
very low levels of Hrk gene expression were detected (Figure II.9A).  This 
analysis indicates that BIM and BMF may mediate the effects of JNK on anoikis.  
However, studies of gene expression by JNKKO epithelial cells demonstrated that 
only the Bcl2l11 gene (not the Bmf gene) exhibited JNK-dependent expression 
during anoikis (Figure II.7, II.8A & II.9B).  Thus, JNK promotes BIM expression 
during anoikis. 
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Figure II.7.  Anoikis causes JNK-independent decreased expression of MCL-1.   
Attached, attached and starved (24 h), and suspended (24 h) Control and JNKKO 
epithelial cells were examined by immunoblot analysis by probing with antibodies to 
phospho-ERK (p-ERK), ERK2, phospho-Ser473 AKT (p-AKT), AKT, MCL1, GAPDH, 
BAX, BCLXL, BCL2, BIM, BMF, and αTubulin.  A representative blot of 3 independent 
experiments is presented.  The subtle change in BIM protein levels observed between 
Control and JNKKO cells after 24 h of suspension contrasts with the dramatic changes 
observed in Bcl2l11 mRNA expression after 4 h of suspension (Figures II.8 & II.9).  This 
discrepancy likely reflects additional expression of BIM in the intervening time in 
suspension culture and accounts for the ability of JNK-deficient cells to die at a later time 
point. 
  
63 
 
 
  To test the role of BIM and BMF in anoikis, I prepared primary epithelial 
cells from Control mice (Bcl2l11+/+ Bmf+/+), BIMKO mice (Bcl2l11-/- Bmf+/+), and 
BMFKO mice (Bcl2l11+/+ Bmf-/-).  I also prepared primary epithelial cells from 
BIM/BMFKO mice (Bcl2l11-/- Bmf-/-) because it has previously been established 
that BIM and BMF have partially redundant functions (Hubner et al. 2010; Labi et 
al. 2014).  These cells were cultured in suspension (1 h and 24 h) to test the 
effect of BIM and BMF-deficiency on anoikis.  Colony formation assays 
demonstrated that BIM-deficiency, but not BMF-deficiency, significantly 
increased survival following suspension culture (Figure II.8B).  Similarly, BIM-
deficiency, but not BMF-deficiency, suppressed cleavage and subsequent 
activation of the apoptosis effector caspase 3 during anoikis (Figure II.8C).  
However, both BIM-deficiency and BMF-deficiency significantly decreased the 
number of apoptotic (Annexin V+ 7-AAD-) cells detected by flow cytometry during 
anoikis (Figure II.8D).  These data indicate that while BIM and BMF can both 
contribute to anoikis, BIM (which exhibits JNK-dependent expression) plays a 
key role during anoikis, while BMF (which is expressed by a JNK-independent 
mechanism) most likely plays a partially redundant role.   
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Figure II.8.  Anoikis causes JNK-dependent increased expression of BH3-only 
genes.   
A)  Attached and suspended (4 h) Control and JNKKO mouse kidney epithelial cells were 
examined by RNA-seq analysis.  The expression of BH3-only genes is presented using 
a heat map with samples normalized to the attached Control epithelial cells (mean, n=3).   
B)  Control (n=9), Bmf-/- (BMFKO, n=9), Bcl2l11-/- (BIMKO, n=12), and compound mutant 
Bmf-/- Bcl2l11-/- (BIM/BMFKO, n=10) kidney epithelial cells were cultured in suspension (1 
h or 24 h).  Epithelial cell viability was tested by colony formation assays and quantitated 
by staining with crystal violet (mean ± SEM; ** p<0.01, *** p<0.001).  Representative 
images of cultures are also presented 
C)  Kidney epithelial cells were cultured in suspension (1 h or 24 h) and extracts were 
examined by immunoblot analysis of caspase 3 (C3), cleaved caspase 3 (c-C3), and 
GAPDH.  The data were quantitated (mean and SEM; n=2; *** p<0.001).   
D)  Kidney epithelial cells were cultured in suspension (1 h or 48 h) and apoptotic cells 
(Annexin V+ (AnxV+) and 7AAD-) were quantitated by flow cytometry (mean and SEM; 
Control n=6, BMFKO n=4, BIMKO n=4, BIM/BMFKO n=6; ** p<0.01, *** p<0.001).  
Representative flow cytometry data are also presented. 
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Figure II.9.  BH3-only gene expression by suspended epithelial cells.   
A)  RNA-seq analysis of Control (WT) mouse epithelial cells cultured in suspension (4 h) 
was performed.  BH3-only gene expression is presented as FPKM values of BH3-only 
mRNA (mean ± SEM of 3 independent experiments; ** p<0.01, ***p<0.001). 
B)  The expression of Bcl2l11 and Bmf mRNA by Control and JNKKO epithelial cells is 
presented as FPKM values (mean ± SEM of 3 independent experiments; n. s., p>0.05; 
***, p<0.001).   
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BIM and BMF-deficiency in epithelial cells causes resistance to JNK-
promoted anoikis 
To confirm that BIM and BMF mediate the effects of JNK to promote anoikis, I 
examined the effect of compound BIM and BMF-deficiency in epithelial cells that 
conditionally express JNK1CA.  Activated JNK was expressed using a 
doxycycline-inducible lentiviral vector (Figure II.10A).  JNK-promoted anoikis in 
control (Bcl2l11+/+ Bmf+/+) epithelial cells was detected by flow cytometry of 
Annexin V staining (Figure II.10B, C).  However, this JNK-promoted anoikis was 
suppressed in Bcl2l11-/- Bmf-/- (BIM/BMFKO) epithelial cells (Figure II.10B, C).   
The low level of JNK-promoted anoikis detected in BIM/BMFKO epithelial 
cells may be caused by the increased expression of other BH3-only proteins.  
Indeed, I found that constitutively activated JNK caused increased expression of 
Hrk (Figure II.11A) and Pmaip1 (encodes NOXA, Figure II.11B) mRNA by 
epithelial cells in suspension culture.  It is therefore possible that HRK and NOXA 
may also contribute to anoikis caused by constitutively activated JNK.  However, 
studies of wild-type epithelial cells demonstrated that anoikis was associated with 
very low levels of Hrk mRNA expression (Figure II.9A) and only modest changes 
in Pmaip1 mRNA expression (Figure II.8A).  These data suggest that BIM and 
BMF are the major physiological targets of JNK signaling and that very high 
levels of activated JNK may also engage additional pathways, such as the NOXA 
pathway.   
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Figure II.10.  BIM and BMF contribute to JNK-promoted anoikis.   
A)  Control and BIM/BMFKO mouse kidney epithelial cells expressing doxycycline (Dox)-
inducible FLAG-tagged constitutively active JNK (JNK1CA) were cultured in suspension 
(1 h or 24 h) in medium supplemented without or with doxycycline.  The expression of 
FLAG-JNK1CA and GAPDH was examined by immunoblot analysis.   
B, C)  The epithelial cells were cultured in suspension (1 h or 24 h) and apoptotic cells 
(Annexin V+ (AnxV+) and 7AAD-) were examined by flow cytometry (mean ± SEM; n=6; * 
p<0.05, ** p<0.01, *** p<0.001) (B).  Representative flow cytometry data are presented 
(C). 
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Figure II.11.  Constitutively activated JNK1 causes increased expression of the 
BH3-only genes Hrk and Pmaip1.   
A,B)  Control and BIM/BMFKO mouse epithelial cels expressing doxycycline (Dox)-
inducible FLAG-tagged constitutively active JNK (JNK1CA) were cultured in suspension 
(1 h or 4 h) in medium supplemented with doxycycline.  RNA was isolated from attached 
cells and suspended cells (4 h) and used to measure Hrk mRNA (A) and Pmaip1 mRNA 
(B) expression (mean ± SEM of 3 independent experiments; ** p<0.01, *** p<0.001).   
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BIM and BMF are required for epithelial cell anoikis in vivo 
It is established that lumen formation in terminal end buds (TEBs) and ducts is 
mediated by apoptosis (Humphreys et al. 1996) and that defective anoikis 
causes TEB/ductal occlusion (Mailleux et al. 2007).  Interestingly, JNK-deficiency 
is associated with TEB/ductal occlusion (Cellurale et al. 2012), suggesting that 
JNK signaling in the breast epithelium may be required for developmental 
anoikis.  Previous studies have established roles for BIM and BMF in mammary 
acinar formation (Mailleux et al. 2007; Schmelzle et al. 2007).  To elucidate the 
relative roles of BIM and BMF in this form of anoikis in vivo, I examined murine 
mammary gland development.  I found that BMF-deficiency caused no major 
defects in mammary gland development of young (5-6 week-old) or mature (6 
month old) mice (Figure II.12A,B & II.13A), although BMF-deficiency was found 
to cause increased duct extension in young mice compared with Control mice 
(Figure II.13B).  In contrast, young BIM-deficient mice exhibited a marked defect 
in duct extension (Figure II.13B) and occlusion of TEB and ducts (Figure II.12A 
and II.13A) compared with Control mice.  Duct occlusion in mature BIMKO mice 
was not observed (Figure II.12B).  Interestingly, the developmental defects 
detected in compound mutant BIM/BMFKO mice were more severe than those 
detected in either BIMKO mice or BMFKO mice.  Compared with BIMKO mice, 
young BIM/BMFKO mice exhibited a larger duct extension defect and significantly 
greater occlusion of TEB and ducts (Figure II.12A & II.13).  Moreover, the duct 
occlusion phenotype persisted in mature BIM/BMFKO mice (Figure II.12B) and 
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was not associated with increased proliferation, as monitored by PCNA staining 
(Figure II.12C & II.13C).  These data demonstrate that BIM plays a key role 
during mammary gland development, and confirm the conclusion that the anoikis 
functions of BIM are partially redundant with BMF.   
 The mammary epithelium is composed of keratin 5+ myoepithelial cells 
that form the exterior surface of ducts and keratin 8+ luminal epithelial cells that 
form the interior surface of ducts (Deugnier et al. 2002).  To determine which of 
these cell types occluded the ducts of BIM/BMFKO mice, I stained tissue sections 
with antibodies to keratin 5 and keratin 8.  Both myoepithelial and luminal cells 
contributed to luminal occlusion in young mice (Figure II.14A), but I primarily 
found luminal cells in the occluded lumens of mature mice (Figure II.14B).  Thus, 
while myoepithelial and luminal epithelial cells are initially retained within the 
ducts of the developing mammary glands of BIM/BMFKO mice, it is the luminal 
epithelial cells that persist in mature mice (Figure II.14). 
  
71 
 
 
 
 
 
72 
 
 
Figure II.12.  BIM and BMF contribute to normal mammary gland development.   
A,B)  Representative carmine alum-stained whole-mount mammary glands (upper 
panels, scale bar = 2 mm) and hematoxylin and eosin stained sections (middle and 
lower panels, scale bar = 100 µm) from 6 week-old (A) and 6 month-old (B) mice are 
presented.   
C)  Representative sections of mammary glands from 6 week-old mice were stained with 
DAPI (blue) and an antibody to PCNA (red).  5 Control mice and 7 BIM/BMFKO mice 
were examined.  Sections showing ducts and terminal end buds (TEB) are presented. 
Scale bar = 75µm. 
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Figure II.13.   BIM/BMFKO compound mutant mice exhibit impaired mammary gland 
development.   
A)  Terminal end buds (TEBs) in whole-mounts of mammary glands from 6 week-old 
animals were examined. Abnormal TEBs with filled lumens were counted.  Ten to thirty 
TEBs were examined per animal (mean ± SEM; n = 4~7 mice; * p<0.05, ** p<0.01, *** 
p<0.001). 
 B)  The distance from the lymph node to terminal end buds was measured in mammary 
glands from 6 week-old mice (mean ± SEM; n = 4~11 mice; * p<0.05, *** p<0.001).   
C) Glands from 6 week-old animals were stained with PCNA to measure cell 
proliferation.  PCNA-positive cells in terminal end buds were counted (mean ± SEM; n = 
5 Control mice, n=6 BIM/BMFKO mice).  No significant (p>0.05) differences were 
detected. 
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Figure II.14.  Basal and luminal cells occlude ducts of BIM/BMFKO mammary 
glands.   
A, B)  Representative sections of mammary glands from Control (upper panels) and 
BIM/BMFKO (lower panels) mice were stained with antibodies against keratin 5 (red) and 
keratin 8 (green), and counterstained with DAPI.  Scale bars = 75µm.  Six week-old (A) 
and 6 month-old (B) mice are presented. 
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Role of BIM and BMF phosphorylation during anoikis 
The anoikis phenotypes of Mapk8-/- Mapk9-/- (JNKKO) epithelial cells (Figure II.2) 
and Bcl2l11-/- Bmf-/- (BIM/BMFKO) epithelial cells (Figure II.8) are similar.  It is 
possible that this observation reflects the finding that both BIM and BMF are 
phosphorylated by JNK (Lei and Davis 2003; Hubner et al. 2008; Hubner et al. 
2010).  To test whether JNK-mediated phosphorylation of BIM and BMF 
contributes to JNK-dependent anoikis, I isolated primary epithelial cells from mice 
harboring point mutations in the Bcl2l11 and Bmf genes at the JNK 
phosphorylation sites Thr112 on BIM and Ser74 on BMF (Hubner et al. 2008; 
Hubner et al. 2010).  I also examined a Bcl2l11 mutant that is resistant to ERK-
promoted proteasomal degradation due to mutations at the ERK phosphorylation 
sites Ser55, Ser65, and Ser73 (BIM3SA) (Hubner et al. 2008).  I found that mutation 
of the ERK phosphorylation sites on BIM caused no change in epithelial cell 
anoikis monitored by flow cytometry analysis of 7-AAD/Annexin V staining 
(Figure II.15A).  Similarly, mutation of the JNK phosphorylation site Thr112 
(replacement with Ala) caused no change in anoikis, including studies using 
epithelial cells on a sensitized genetic background (Bmf-/-) (Figure II.15A, B).  In 
contrast, mutation of the BMF phosphorylation site Ser74 (replacement with Ala) 
caused decreased anoikis in vitro (Figure II.15C), but caused only limited ductal 
occlusion in vivo (Figure II.16). 
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Figure II.15.  Phosphorylation of BMF, but not BIM, contributes to JNK-promoted 
anoikis.   
A)  Control, Bcl2l11-/- (BIMKO), Bcl2l11Ser55,65,73A/Ser55,65,73A (BIM3SA), and Bcl2l11T112A/T112A 
(BIMT112A) kidney epithelial cells were cultured in suspension (1 h or 48 h).  Apoptotic 
cells (Annexin V+ (AnxV+) and 7AAD-) were quantitated by flow cytometry (mean ± SEM; 
n=6; ** p<0.01, *** p<0.001).  Representative flow cytometry plots are presented.   
B)  Control, Bmf-/- (BMFKO), Bcl2l11T112A/T112A (BIMT112A), and Bmf-/- Bcl2l11T112A/T112A 
(BMFKO BIMT112A) kidney epithelial cells were cultured in suspension (1 h or 48 h).  
Apoptotic cells (Annexin V+ (AnxV+) and 7AAD-) were quantitated by flow cytometry 
(mean ± SEM; n=6; ** p<0.01, *** p<0.001).  Representative flow cytometry plots are 
presented. 
C)  Control, Bmf-/- (BMFKO), and Bmf S74A/S74A (BMFS74A) mouse kidney epithelial cells 
were cultured in suspension (1 h or 48 h).  Apoptotic cells (Annexin V+ (AnxV+) and 
7AAD-) were quantitated by flow cytometry (mean ± SEM; n=6; ** p<0.01, *** p<0.001).  
Representative flow cytometry plots are presented. 
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Figure II.16.  Mammary gland development in mice with defects in JNK-mediated 
BIM and BMF phosphorylation.   
A,B)  Representative carmine alum-stained whole mounts (A) and hematoxylin & eosin-
stained sections (B) of mammary glands from 6-week-old Control (WT), BMFS74A, 
BIM3SA, BIMT112A, and BIMT112A BMFKO mice are presented.  Scale bars = 2 mm (A) and 
100 µm (B).   
C)  The distance from the terminal end buds (TEBs) to the lymph node (LN) was 
measured (mean ± SEM; n = 7~10 mice).  No statistically significant differences were 
detected (p>0.05).   
D)  The number of abnormal TEBs with filled lumens were counted.  Ten to thirty TEBs 
were examined per animal (mean ± SEM; n = 7~10 mice).  No statistically significant 
differences were detected (p>0.05).   
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Collectively, these data indicate that BIM and BMF phosphorylation is not 
essential for anoikis.  Indeed, BIM phosphorylation at these sites appears to play 
no role in anoikis.   However, phosphorylation of BMF on Ser74, a site targeted by 
JNK, partially contributes to anoikis.  I conclude that BMF phosphorylation (but 
not BIM phosphorylation) may contribute to cell death following epithelial cell 
detachment.   
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Discussion 
Genetic studies of epithelial cell sheet development in Drosophila demonstrate a 
role for extrusion and death of compromised cells.  This extrusion mechanism 
causes the removal of cells from the epithelial cell sheet and JNK activation in 
the detached epithelial cells subsequently causes apoptosis (Adachi-Yamada et 
al. 1999; Adachi-Yamada and O'Connor 2002; Gibson and Perrimon 2005; Shen 
and Dahmann 2005).  Similarly, competition between cells in epithelial cell 
sheets for limiting amounts of morphogen (e.g. a TGF ligand) (Moreno et al. 
2002) or cell-intrinsic fitness (e.g. cMYC expression) (Moreno and Basler 2004) 
can cause JNK-dependent elimination of compromised cells.  These 
mechanisms not only ensure normal development of epithelial cell sheets, but 
also act to suppress tumor formation (Brumby and Richardson 2003; Uhlirova et 
al. 2005; Igaki 2009).  JNK therefore plays a key role in epithelial cell sheet 
development.  Nevertheless, the mechanism of pro-apoptotic signaling by JNK in 
Drosophila is unclear.   
 Mammalian studies of the role of JNK in epithelial cell detachment and 
death (anoikis) are controversial because early studies using dominant-negative 
over-expression approaches in MDCK epithelial cells were interpreted both to 
support a required role for JNK in anoikis (Frisch et al. 1996) and to refute a role 
of JNK in anoikis (Khwaja and Downward 1997).  More recently, studies using 
the drug SP600125, that inhibits JNK and many other protein kinases (Bain et al. 
2003), indicated that JNK may be required for acinar formation and luminal 
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clearance by human MCF10A mammary epithelial cells (McNally et al. 2011).  
This observation suggested that JNK may play a role in anoikis.  This was later 
supported by studies of murine mammary gland development using mice with 
wild-type or compound mutant Mapk8-/- Mapk9-/- mammary epithelial cells that 
demonstrated a requirement of JNK for the luminal clearance of mammary ducts 
and terminal end buds by apoptosis (anoikis) (Cellurale et al. 2012).  The present 
study extends these findings to demonstrate a requirement for JNK in anoikis of 
human and murine primary epithelial cells (Figures II.1 & II.2). 
This requirement for JNK in anoikis contrasts with the observation that 
JNK does not contribute to other forms of apoptosis, including cell death 
mediated by the cell surface receptors FAS and TNFR1 (Tournier et al. 2000; 
Lamb et al. 2003; Das et al. 2009).  These observations indicate that JNK plays a 
selective role in apoptosis.  This is illustrated by the finding that constitutively 
activated JNK does not cause apoptosis of attached epithelial cells, but 
constitutively activated JNK promotes apoptosis of detached epithelial cells 
(Figures II.2 & II.10).   
 I demonstrate that the mechanism of JNK signaling to cause anoikis 
requires the pro-apoptotic BCL2 family proteins BAK and BAX (Figure II.5) and 
the pro-apopotic BH3-only proteins BIM and BMF (Figure II.8).  Gain-of-function 
studies using conditional expression of constitutively activated JNK demonstrated 
that the JNK-promoted anoikis detected in wild-type epithelial cells was 
suppressed in BAK/BAXKO epithelial cells (Figure II.5) or BIM/BMFKO epithelial 
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cells (Figure II.10).  The residual cell death detected in BAK/BAXKO and 
BIM/BMFKO cells may reflect partial compensation by the related pro-apoptotic 
proteins BOK (Figure II.6) and NOXA (Figures II.8 & II.9), respectively.  Together, 
these data establish the BH3-only proteins BIM and BMF as mediators of JNK-
promoted anoikis caused by activation of the cell intrinsic BAK/BAX mitochondrial 
apoptosis pathway.   
Whereas BIM and BMF co-operate to cause anoikis, BIM plays a key role 
while the pro-apoptotic functions of BMF are partially redundant with BIM (Figure 
II.8).  This co-operation is illustrated by the finding that compound mutant 
BIM/BMFKO mice exhibited a larger duct extension defect and significantly 
greater occlusion of TEB and ducts compared with BIMKO mice or BMFKO mice 
(Figure II.12A & II.13).  Moreover, unlike BIMKO mice or BMFKO mice, the duct 
occlusion phenotype persisted in mature BIM/BMFKO mice (Figure II.12B).  These 
functions of BIM and BMF are consistent with previous observations 
demonstrating co-operative roles of BIM and BMF during cell death (Hubner et 
al. 2010; Labi et al. 2014; Sakamoto et al. 2016).  Moreover, these roles are 
consistent with the established functions of BIM and BMF during mammary 
acinar development (Mailleux et al. 2007; Schmelzle et al. 2007).   
Two mechanisms may account for the activation of BIM and BMF by JNK 
signaling:   
1)  Anoikis is associated with markedly increased expression of both BIM and 
BMF (Figure II.8A).  The increased expression of BIM, but not BMF, was JNK-
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dependent (Figure II.9B).  Indeed, it is established that the JNK target cJUN 
strongly promotes the expression of BIM (Whitfield et al. 2001).  This JNK-
dependent increase in BIM expression may account for the requirement of both 
JNK and BIM for anoikis.   
2)  BIM and BMF are substrates that are phosphorylated by activated JNK (Lei 
and Davis 2003; Hubner et al. 2008; Hubner et al. 2010).  Studies of mice with 
germ-line point mutations in BIM phosphorylation sites (Ser55, Ser65, Ser73 or 
Thr112) demonstrated that BIM phosphorylation was not required for anoikis 
(Figure II.15A, B).  In contrast, studies of mice with a germ-line point mutation in 
BMF at the JNK phosphorylation site Ser74 demonstrated that BMF 
phosphorylation was required for efficient anoikis (Figure 11.15C).   
Collectively, these data establish that JNK promotes anoikis by increasing 
BIM expression and by phosphorylating BMF.  It is possible that these roles of 
BIM and BMF are augmented by effects of JNK on other BH3-only proteins, 
including HRK and NOXA (Figure II.8A).  HRK is expressed at extremely low 
levels in primary epithelial cells, but does exhibit increased JNK-dependent 
expression during anoikis (Figures II.8A & II.9A).  This JNK-dependent HRK 
expression may reflect the targeting of the Hrk gene by the cJUN transcription 
factor (Ma et al. 2007).  Nevertheless, the very low level of HRK expression in 
epithelial cells indicates that HRK may only contribute to anoikis under 
specialized circumstances.  NOXA is expressed by epithelial cells and this 
expression is modestly increased during anoikis (Figure II.8).  NOXA may 
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therefore contribute to anoikis under some conditions, particularly when a 
threshold amount of BH3-only protein is required to promote anoikis.  
Interestingly, the expression of HRK and NOXA are increased when epithelial 
cells expressing constitutively activated JNK are cultured in suspension (Figure 
II.11).  It is therefore possible that BIM and BMF mediate the pro-anoikis effects 
of moderate levels of JNK activation in detached epithelial cells and that very 
high levels of JNK activity may additionally recruit JNK-dependent expression of 
NOXA to promote efficient anoikis.   
Genetic analysis of Drosophila indicates that JNK plays a role in tumor 
suppression by promoting the elimination of compromised epithelial cells 
(Brumby and Richardson 2003; Uhlirova et al. 2005; Igaki 2009; Igaki et al. 2009; 
Ohsawa et al. 2011).  This observation suggests that JNK may play a similar role 
in mammalian epithelial cells.  Thus, loss of JNK function by epithelial cells may 
lead to survival in luminal spaces and the subsequent acquisition of additional 
mutations that may cause cancer.  Indeed, JNK-deficiency enhances tumor 
formation in a transplantation model of breast cancer (Cellurale et al. 2012).  
Moreover, sequencing of human tumors has revealed that two upstream 
components of the JNK pathway (MAP2K4 and MAP3K1) are frequently mutated 
in human cancer (Stephens et al. 2012; Nik-Zainal et al. 2016a).  Whether these 
human mutations contribute to cancer development is unclear.  Studies to test 
this hypothesis are therefore warranted.   
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In conclusion, I have demonstrated that JNK is required for efficient 
anoikis of detached human and mouse epithelial cells.  I show that JNK causes 
increased BIM expression and phosphorylation of BMF following epithelial cell 
detachment.  These BH3-only proteins act as mediators of JNK-promoted anoikis 
that engage the cell intrinsic BAK/BAX mitochondrial apoptosis pathway.  
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Materials and Methods 
Mice 
Bmf-/- mice (RRID:IMSR_JAX:011024), BmfS74A/S74A mice 
(RRID:IMSR_JAX:011022), Bcl2l11T112A/T112A mice (RRID:IMSR_JAX:011026), 
Bcl2l11S55,65,73A/S55,65,73A mice (RRID:IMSR_JAX:011025), (Hubner et al. 2008; 
Hubner et al. 2010), Map3k10-/- Map3k11-/- mice (Kant et al. 2011), and 
Mapk8LoxP/LoxP Mapk9-/- RosaCreERT mice (Das et al. 2007) have been previously 
described.  C57BL/6J mice (Stock # 000664; RRID:IMSR_JAX:000664), B6;129-
Gt(ROSA)26Sortm1(cre/ERT)Nat/J mice (Stock # 004847; RRID:IMSR_JAX:004847) 
(Badea et al. 2003), and B6.129S1-Bcl2l111tm1.1Ast/J mice (Stock # 004525; 
RRID:IMSR_JAX:004525) (Bouillet et al. 1999)) were obtained from The Jackson 
Laboratories.  Virgin females (age 6 weeks and 6 months) were used for 
mammary gland studies.  Both male and female mice (age 8 weeks) were used 
to establish kidney epithelial cells.  The mice were housed in a specific pathogen-
free facility accredited by the American Association of Laboratory Animal Care.  
All animal studies were approved (A-1032) by the Institutional Animal Care and 
Use Committee of the University of Massachusetts Medical School.   
 
Cell culture  
Tertiary human mammary epithelial cells were purchased and maintained in 
MammaryLife Media (Lifeline Cell Technology).  Primary murine kidney epithelial 
cells were prepared (Follit et al. 2008) using kidneys from mice (8 week-old) 
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digested at 37°C (<2 h) with 0.1% collagenase, 0.1% trypsin, and 150 mM NaCl 
in Dulbecco’s modified Eagle’s medium (DMEM) (Life Technologies).  These 
cells were maintained in DMEM/F12 media containing 10% fetal bovine serum 
and supplemented with 150 mM urea plus 150 mM NaCl.  Wild-type and Bak1-/- 
Bax-/- (BAK/BAXKO) epithelial cells were obtained from Applied Biological 
Materials (ABM Inc) and maintained in DMEM media containing 10% fetal bovine 
serum.  Rosa-CreERT kidney epithelial cells were treated with 1 µM 4-
hydroxytamoxifen (24 h) to ablate floxed alleles.  
 
Immunoblot Analysis 
Cell lysates were prepared using Triton lysis buffer (20 mM Tris [pH 7.4], 1% 
Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM β-
glycerophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl 
fluoride, and 10 μg/mL of aprotinin plus leupeptin).  Extracts (30 µg) were 
subjected to immunoblot analysis with antibodies to Caspase 3 (Cell Signaling 
Technology Cat# 9662 RRID:AB_331439; dilution 1:500), LC3B (Cell Signaling 
Technology, Cat#2775), ERK2 (Santa Cruz Biotechnology Cat# sc-1647; 
RRID:AB_627547; dilution 1:1000), Flag (Sigma-Aldrich Cat# F3165 
RRID:AB_259529; dilution 1:5000), GAPDH (Santa Cruz Biotechnology Cat# sc-
25778; RRID:AB_10167668; dilution 1:1000), JNK (R & D Systems Cat# AF1387 
RRID:AB_2140743R&D; dilution 1:1000), p-ERK (Cell Signaling Technology 
Cat# 9101 RRID:AB_2315114; dilution 1:1000), AKT (Cell Signaling Technology 
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Cat# 9272 RRID:AB_329827; dilution 1:1000), p-Ser473 AKT (Cell Signaling 
Technology Cat# 9271 RRID:AB_329825; dilution 1:1000), MCL1 (Rockland 
Cat# 600-401-394S RRID:AB_11179937; dilution 1:2000), BAX (Abcam Cat# 
ab32503 RRID:AB_725631; dilution 1:5000), BCLXL (Abcam Cat# ab32370 
RRID:AB_725655; dilution 1:2000), BCL2 (Abcam Cat# ab182858 
RRID:AB_2715467; dilution 1:2000), BMF (Abcam Cat# ab181148 
RRID:AB_2715466; dilution 1:1000), BIM (Abcam Cat# ab32158 
RRID:AB_725697), and αTubulin (Sigma-Aldrich Cat# T5168; 
RRID:AB_477579).  Immune complexes were detected with IRDye 680LT 
conjugated-donkey anti-mouse IgG antibody (LI-COR Biosciences Cat# 926-
68022 RRID:AB_10715072) and IRDye 800CW conjugated-goat anti-rabbit IgG 
(LI-COR Biosciences Cat# 926-32211 RRID:AB_621843), and quantitated using 
the Odyssey infrared imaging system (LI-COR Biosciences).   
 
Analysis of mRNA 
RNA was isolated using the RNeasy kit (Qiagen).  RNA quality (RIN > 9) was 
verified using a Bioanalyzer 2100 System (Agilent Technologies).  Total RNA (10 
µg) was used to prepare each RNA-seq library by following the manufacturer’s 
instructions (Illumina).  Three independent libraries were examined for each 
condition.  The cDNA libraries were sequenced by Illumina Hi-Seq with a paired-
end 40-bp format.  These RNA-seq data have been deposited in the Gene 
Expression Omnibus (GEO) database with accession number GSE88856.  
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Reads from each sample were aligned to the mouse genome (UCSC genome 
browser mm10 build) using TopHat2 (Kim et al. 2013).  The average number of 
aligned reads per library was > 30,000,000.  Gene expression was quantitated as 
fragments per kilobase of exon model per million mapped fragments (FPKM) 
using Cufflinks (Trapnell et al. 2010).  Differentially expressed genes were 
identified using the Cufflinks tools Cuffmerge and Cuffdiff.   
 The expression of mRNA was also examined by quantitative RT-PCR 
analysis using a Quantstudio 12K Flex machine (Life Technologies).  TaqMan® 
assays were used to quantify BAD (Hs00188930_m1), BBC3 (Hs00248075_m1), 
BID (Hs01026792_m1), BIK (Hs00154189_m1), BCL2L11 (Hs00708019_s1), 
BMF (Hs00372937_m1), HRK (Hs02621354_s1), and PMAIP1 
(Hs00560402_m1), Bad (Mm00432042_m1), Bbc3 (Mm00519268_m1), Bcl2l11 
(Mm00437797_m1), Bid (Mm00432073_m1), Bik (Mm00476123_m1), Bmf 
(Mm00506773_m1), Hrk (Mm01208086_m1), and Pmaip1 (Mm00451763_m1) 
mRNA (Life Technologies).  The relative mRNA expression was normalized by 
measurement of the amount of 18S RNA in each sample using Taqman© assays 
(catalog number 4308329; Life Technologies).   
 
Anoikis Assay 
Tertiary human mammary epithelial cells were suspended (4x105 cells/ml) in 
MammaryLife media (Lifeline Cell Technology) containing 0.5% methylcellulose 
(Sigma) in poly-HEMA (Sigma) coated plates.  Murine kidney epithelial cells were 
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suspended (1.2x105 cells/ml) in serum-free DMEM/F12 media supplemented with 
0.5% methylcellulose in poly-HEMA coated plates.  To study autophagic flux 
during suspension, cells were treated with 25 µM chloroquine diphosphate (Fluka 
Biochemika).  Where indicated, cells were treated with 2 µM JNK-in-8 (Millipore) 
at 24 h prior to the anoikis assay.  Cell death was measured using colony 
formation assays and by measurement of Annexin V-staining.   
 
Colony Formation Assay 
Cells were washed with PBS, replated in 24-well plates, and cultured (24 h) prior 
to fixation (100% methanol, -20°C) and staining with 0.1% crystal violet dissolved 
in 20% methanol / 80% PBS.  The cells were imaged using a Zeiss SteREO 
Discovery.V12 microscope and quantitated by extracting the crystal violet dye 
with 10% acetic acid and measurement of the absorbance at 590 nm (Tecan 
Instruments).   
 
Flow Cytometry 
The flow cytometry data were deposited in Flow Repository with accession 
number FR-FCM-ZYCR.  Cells were washed twice with PBS and stained with 
phycoerythrin-conjugated Annexin V and 7-aminoactinomycin D (7-AAD) using 
the PE Annexin apoptosis detection kit I (BD Pharmingen #559763) and 
examined by flow cytometry using a FACSCalibur (BD Biosciences) to quantitate 
the apoptotic (Annexin V+ 7-AAD-) population.  7-AAD+ cells were gated using 
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single-stained controls. The Annexin V+ and Annexin V- populations were defined 
using cells suspended for 1 hr.  The data obtained were analyzed using FlowJo 
version 9.7.6 (Tree Star). 
 
Mammary Gland Analysis 
The 4th inguinal mammary glands were harvested from 6-week old and 6-month 
old virgin female mice.  Whole mount preparations were fixed with formalin, 
stained with carmine alum, and imaged using a Zeiss SteREO Discovery.V12 
microscope.  Sections (5 µm) were prepared using tissue fixed in 10% formalin 
that was dehydrated and embedded in paraffin.  A board-certified pathologist 
examined sections stained with hematoxylin & eosin and imaged using a Zeiss 
AxioVert 200M.  Sections were also stained with antibodies against keratin 5 
(BioLegend Cat# 905501 RRID:AB_2565050; 1:50 dilution) and keratin 8 
(Developmental Studies Hybridoma Bank Cat# TROMA-I RRID:AB_531826; 
1:100 dilution), and immune complexes were detected using AlexaFluor 546 
conjugated-goat anti-rabbit IgG (H+L) antibody (Molecular Probes Cat# A11035 
RRID:AB_143051) and AlexaFluor 488 conjugated-goat anti-rat IgG (H+L) 
antibody (Molecular Probes Cat# A11006 RRID:AB_141373) and counterstained 
with 2-(4-amidinophenyl)-1 h -indole-6-carboxamidine (DAPI).  Proliferating cells 
were stained using the endogenous biotin blocking kit (Thermo Fisher Scientific 
E21390), biotin-conjugated PCNA antibody (Thermo Fisher Scientific Cat# 13-
3940 RRID:AB_2533; dilution 1:50), and AlexaFluor 633-conjugated streptavidin 
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(Thermo Fisher Scientific Cat# S-21375 RRID:AB_2313500).  
Immunofluorescence was examined using a Leica SP2 confocal microscope.   
 
Plasmids 
The plasmid pCDNA3-Flag-MKK72-Jnk11 (Lei et al. 2002) has been 
previously described.  The Flag-MKK72-Jnk11 cDNA fragment was excised by 
PCR using the primers 5’-
AAACCGCGGGCCGCCACCATGGACTATAAGGACGATGA-3’ and 5’-
AAATCTAGATCACTGCTGCACCTGTGCTAAAGGAG-3’, restricted using SacII 
and XbaI, and cloned into the SacII and XbaI sites of the entry vector 
pEN_Tmirc3 (Addgene plasmid # 25748 (Shin et al. 2006)) before insertion, 
using Gateway Technology, into the lentiviral vector pSLIK-Hygro (Addgene 
plasmid # 25737 (Shin et al. 2006)) to create the vector pSLIK- Flag-MKK72-
Jnk11-Hygro.   
 
Transduction assays 
HEK293T cells (American Type Culture Collection Cat # CRL-3216) were 
transfected with 7.5 μg each of the packaging plasmids pMD2.G (Addgene 
plasmid #12259 (Naldini et al. 1996)) and psPAX2 (Addgene plasmid # 12260 
(Naldini et al. 1996)) plus 10 μg of pSLIK-Hygro or pSLIK- Flag-MKK72-Jnk11-
Hygro using Lipofectamine 2000 (Life Technologies).  The culture supernatant 
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was collected at 24 h post-transfection and filtered (0.45 µm).  Primary epithelial 
cells were transduced (x2) with the lentivirus plus polybrene (8 µg/ml).  The 
transduced epithelial cells were selected at 48 h post-infection using medium 
supplemented with 8 µg/ml hygromicin (Life Technologies).  The cells were 
maintained in selection medium with tetracycline-free fetal bovine serum 
(Clontech).  To induce expression of the MKK7-JNK1 fusion protein, the cells 
were treated with 1 µg/ml doxycycline (24 h).   
 
Statistical Analysis 
Data are presented as the mean and standard error.  The n values provided in 
the figure legends correspond to the number of independent experiments for 
studies using cultured cells or the number of animals examined.  Statistical 
analysis was performed using GraphPad Prism version 6 (GraphPad Software).  
Pair-wise comparisons of data with similar variance were performed using a t-test 
to determine significance (p<0.05).  Pair-wise comparisons of data with unequal 
variance were performed using Welch’s unpaired t-test to determine significance 
(p<0.05).  When more than two populations were compared ANOVA with 
Bonferroni’s test was used to determine significance with an assumed confidence 
interval of 95%.   
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CHAPTER III 
THE JNK PATHWAY CONTRIBUTES TO MOUSE MAMMARY GLAND 
REMODELING DURING INVOLUTION 
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Abstract 
Involution returns the lactating mammary gland to a quiescent state after 
weaning.  The mechanism of involution involves collapse of the mammary 
epithelial cell compartment.  To test whether the cJUN NH2-terminal kinase (JNK) 
signal transduction pathway contributes to involution, I established mice with JNK 
deficiency in the mammary epithelium.  I found that JNK is required for efficient 
involution.  JNK deficiency did not alter the STAT3/5 or SMAD2/3 signaling 
pathways that have been previously implicated in this process.  Nevertheless, 
JNK promotes the expression of genes that drive involution, including matrix 
metalloproteases, cathepsins, and BH3-only proteins.  These data demonstrate 
that JNK plays a key role in mammary gland involution post-lactation.   
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Introduction 
The mammary gland is dynamically regulated by circulating hormones and 
paracrine/autocrine cytokines during post-natal development.  Estrogen 
promotes ductal development by epithelial cells in the mammary gland after 
puberty (Mallepell et al. 2006; Feng et al. 2007).  In contrast, progesterone and 
prolactin are critically required for the epithelial development of alveoli and 
subsequent milk production by the mammary gland in response to pregnancy 
(Horseman et al. 1997; Humphreys et al. 1997; Ormandy et al. 1997).  Weaning 
causes milk stasis, decreased circulating concentrations of prolactin, and 
increased expression of cytokines that activate the JAK1/STAT3 signaling 
pathway, including leukemia inhibitory factor (LIF) (Kritikou et al. 2003), 
interleukin 6 (IL6) (Zhao et al. 2002), and oncostatin M (OSM) (Tiffen et al. 2008).  
LIF may serve to initiate STAT3 activation that engages an autocrine pathway 
sustained by STAT3-induced OSM expression (Tiffen et al. 2008).  The switch 
from prolactin-stimulated STAT5 activation to LIF/IL6/OSM-stimulated STAT3 
activation drives remodeling (involution) of the mammary gland, including 
collapse of the epithelial cell compartment and replacement by adipose tissue, to 
enable return to a quiescent state (Chapman et al. 1999; Cui et al. 2004).   
 The requirement of the LIF/JAK1/STAT3 pathway for mammary gland 
involution is strongly supported by studies of knockout mice.  Deficiency of LIF 
(Kritikou et al. 2003), JAK1 (Sakamoto et al. 2016), or STAT3 (Li et al. 1997) 
causes a similar delay in mammary gland involution.  Targets of STAT3 signaling 
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include pathways of lysosome-mediated cell death involving cathepsins 
(Kreuzaler et al. 2011) and mitochondrion-mediated apoptotic pathways 
mediated by members of the BCL2 family (Schmelzle et al. 2007; Sakamoto et 
al. 2016; Schuler et al. 2016).  Indeed, it is established that the Bcl2l11 and Bmf 
genes that encode the pro-apoptotic BH3-only proteins BIM and BMF are direct 
targets of STAT signaling (Sakamoto et al. 2016; Schuler et al. 2016).  Increased 
Bcl2l11 and Bmf gene expression during involution may result from loss of 
transcriptional repression by STAT5 and increased transcriptional activity 
mediated by STAT3 (Sakamoto et al. 2016; Schuler et al. 2016).  The importance 
of Bcl2l11 and Bmf gene induction is confirmed by analysis of knockout mice that 
show delayed involution (Sakamoto et al. 2016; Schuler et al. 2016).  The BH3-
only proteins BAD and NOXA are also implicated in involution, but studies of 
BAD-deficient (Bad-/-) mice and NOXA-deficient (Pmaip1-/-) mice demonstrate 
that these BH3-only proteins are not essential for involution (Schuler et al. 2016).   
Although the LIF/IL6/OSM – JAK1 – STAT3 signaling pathway plays a key 
role in involution, this pathway appears to function in collaboration with other 
signaling pathways that contribute to involution, including TGF (Nguyen and 
Pollard 2000).  Several TGFβ isoforms are expressed at low levels during 
lactation, but are greatly induced during involution (Faure et al. 2000).  It is 
therefore likely that TGF signaling during involution may contribute to 
remodeling of the extracellular matrix during involution and TGF may also 
contribute to mammary epithelial cell death.  Indeed, deficiency of TGFβ3 
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(Nguyen and Pollard 2000) or Smad3 (Yang et al. 2002) causes decreased cell 
death during involution, while the forced expression of TGFβ3 causes increased 
cell death during lactation (Nguyen and Pollard 2000).   
 Other signaling pathways might also contribute to the involution response.  
For example, loss of survival signaling (e.g. AKT and ERK) caused by cell 
detachment and loss of signaling by integrins and receptor tyrosine kinases may 
promote cell death (Frisch and Francis 1994; Frisch and Screaton 2001; 
Reginato et al. 2003).  Similarly, increased signaling by stress-activated MAP 
kinases (Davis 2000; Cuadrado and Nebreda 2010; Avivar-Valderas et al. 2014) 
may promote cell death during involution.  Indeed, it is established that the 
stress-activated protein kinases p38 MAP kinase (Wen et al. 2011) and cJUN 
NH2-terminal kinase (JNK) (Cellurale et al. 2012; Girnius and Davis 2017b) can 
promote anoikis of mammary epithelial cells.  However, it is not known whether 
these stress-activated MAP kinases contribute to the involution response.   
The purpose of this study was to test whether JNK contributes to 
mammary gland remodeling during the involution response.  JNK is activated 
during involution and has been mechanistically implicated in the involution 
response (Marti et al. 1999).  Interestingly, JNK can promote cell death mediated 
by BH3-only proteins (BMF and BIM) (Tournier et al. 2000; Lei et al. 2002; Lei 
and Davis 2003; Hubner et al. 2008; Hubner et al. 2010) that are known to 
contribute to cell death during involution (Schmelzle et al. 2007; Sakamoto et al. 
2016; Schuler et al. 2016).  Two JNK isoforms (JNK1 and JNK2) with partially 
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redundant functions are expressed in the mammary epithelium.  Developmental 
studies demonstrate that these JNK isoforms are required for anoikis and the 
clearance of cells from mammary ducts and terminal end buds (Cellurale et al. 
2012; Girnius and Davis 2017b).  Indeed, deficiency of JNK1 plus JNK2 in the 
mammary epithelium (but not deficiency of JNK1 or JNK2 alone (Cellurale et al. 
2010)) causes ductal occlusion by suppressing anoikis (Cellurale et al. 2012; 
Girnius and Davis 2017b).  Thus, JNK is required for normal mammary gland 
development and could contribute to involution.   
Previous studies have established that involution defects were not 
observed in mice lacking JNK1 or JNK2 (Cellurale et al. 2010).  I therefore 
examined mice with compound deficiency of JNK1 plus JNK2 in the mammary 
epithelium.  These JNK-deficient mice exhibited delayed involution.  Moreover, 
JNK deficiency caused major disruption of the gene expression program that 
mediates involution.  Together, these data demonstrate that JNK contributes to 
the normal mammary gland involution response.    
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Results 
JNK is required for efficient mammary gland involution 
To study mice with compound disruption of the Mapk8 gene (encodes JNK1) plus 
the Mapk9 gene (encodes JNK2) in the mammary epithelium, I established 
Control (JNKWT) mice (Wap-Cre-/+) and JNK-deficient (JNKKO) mice (Wap-Cre-/+ 
Mapk8LoxP/LoxP Mapk9 LoxP/LoxP).  Wap-Cre expression is induced in the mammary 
epithelium during lactation (Wagner et al. 1997) and I found Cre-mediated 
recombination in mammary epithelial cells (Figure III.1.A).  Analysis of genomic 
DNA demonstrated efficient ablation of the Mapk8 and Mapk9 genes in the 
mammary glands of lactating JNKKO mice (Figure III.1.B, C).   
To test the role of JNK in involution, I examined JNKWT and JNKKO dams 
that nursed litters for 9 days.  Involution was initiated by removal of the pups 
(involution day 0).  Microscopic analysis of tissue sections at this stage 
demonstrated no differences between the mammary glands of JNKWT and JNKKO 
mice (Figure III.2 & III.3).  After 3 days of involution, the JNKWT glands exhibited 
collapse of alveolar structures and the reappearance of adipocytes.  In contrast, 
analysis of the JNKKO glands demonstrated the presence of distended alveoli and 
no reappearance of adipocytes (Figure III.2 & III.3).  After 7 days of involution, 
the JNKWT glands had returned to a virgin-like state, while JNKKO glands still had 
an expanded epithelial compartment with many collapsed alveoli (Figure III.2 & 
III.3).  However, on day 14 after the initiation of involution, no differences were 
detected between the tissue architecture (Figure III.2 & III.3) or epithelial cell   
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Figure III1.  Mapk8 and Mapk9 gene disruption in luminal mammary epithelial cells.   
(A)  Sections of mammary glands prepared from single parous female Wap-Cre-/+ 
RosamT/mG reporter mice were stained with antibodies to GFP, keratin 5 (K5), or keratin 8 
(K8), and then counter-stained with DAPI.  The GFP antibody stains Cre+ cells in the 
reporter mice.  The images presented are representative of sections prepared from 
mammary glands of 7 mice.  Scale bar = 50 µm.  
(B, C)  Cre-mediated recombination of Mapk8LoxP (B) and Mapk9 LoxP (C) alleles was 
confirmed by PCR analysis of genomic DNA isolated from mammary epithelial cells 
isolated from mice after 10 days of lactation.   
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Figure III.2.  JNK is required for efficient mammary gland involution.   
Sections of #4 mammary glands from JNKWT and JNKKO mice on involution day 0, 3, 7 
and 14 were stained with H&E.  The images presented are representative of sections 
prepared from the mammary glands of 5 JNKWT mice and 5 JNKKO mice for each 
condition.  Scale bar = 100 µm.  
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Figure III.3.  JNK is required for mammary gland involution.   
Sections of mammary glands from JNKWT and JNKKO female mice on day 0, 3, 7, and 14 
of involution were stained with H&E.  The images are representative of sections taken 
from 5 JNKWT mice and 5 JNKKO mice for each condition.  Scale bar = 50 µm. 
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Figure III.4.  Epithelial cell populations in mammary glands after involution.  
(A, B)  Mammary gland sections were stained with antibodies to smooth muscle actin 
(SMA, a) or with antibodies to keratin 5 and 8 (K5 and K8, b), and counterstained with 
DAPI.  Representative images are presented.  Scale bars = 50 µm (A) and 30 µm (B). 
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populations (Figure III.4) of mammary glands from JNKWT and JNKKO mice.  
These findings demonstrate that JNK-deficiency delays involution, indicating that 
JNK is required for the proper execution of this process. 
 
JNK promotes epithelial cell death during involution 
To test whether JNK regulates epithelial cell death in mammary glands during 
involution, I performed immunohistochemistry using an antibody specific for 
cleaved caspase 3.  On involution day 0, few cleaved caspase 3 positive (c-C3+) 
cells were detected in the mammary glands of JNKWT and JNKKO mice (Figure 
III.5A).  However, on day 3 of involution a substantial increase in the number of 
c-C3+ cells was found in the glands of JNKWT mice, but not JNKKO mice (Figure 
III.5A).  In contrast, large numbers of c-C3+ cells were found in both JNKWT and 
JNKKO mice on day 7 of involution (Figure III.6).  These data indicate that JNK 
deficiency delays cell death during involution.  To confirm this conclusion, I 
examined terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
of cells on day 3 of involution.  In agreement with the c-C3 data, there were 
reduced numbers of TUNEL+ cells in glands from JNKKO mice compared with 
JNKWT mice (Figure III.5B).  Thus, JNK-deficiency causes delayed epithelial cell 
death in the involuting mammary gland. 
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Figure III.5.  JNK-deficiency suppresses cell death during involution.   
(A)  Sections of #4 mammary glands from single parous female mice on involution day 0 
or on involution day 3 were stained with an antibody to cleaved caspase 3 (c-C3) and 
counter-stained with hematoxylin.  Representative images are presented.  c-C3+ cells 
were quantitated in 6 fields (40x) per section and presented as the % of total cells (mean 
± SEM; JNKWT 0 day n=5, JNKWT 3 day n=4, JNKKO 0 day n=4, JNKKO 3 day n=6 mice).  
Scale bar = 100 µm.   
(B)  Sections of #4 mammary glands from mice on involution day 3 were stained by 
TUNEL assay and counter-stained with DAPI.  Representative images are presented.  
TUNEL+ cells were quantitated in 6 fields (40x) per section and presented as the % of 
total cells (mean ± SEM; JNKWT n=4, JNKKO n=5 mice).  Scale bar = 50 µm.   
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Figure III.6.  Caspase 3 activation in mammary glands after 7 days of involution.   
Sections prepared from mammary glands of 5 JNKWT mice and 5 JNKKO mice on day 7 
of involution were stained with an antibody to cleaved caspase 3 (c-C3+).  
Representative images are presented.  c-C3+ cells were quantitated in 6 fields (40x) per 
section and presented as the % of total cells (mean ± SEM; n = 5 mice; p>0.05).  Scale 
bars = 100 µm.   
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Effect of JNK deficiency on STAT and SMAD transcription factors 
The delayed involution observed in JNKKO mice may be caused by changes in 
the key transcription factors that regulate this process.  It is established that 
decreased activation of SMAD2/3 or STAT3, or increased STAT5 activation, may 
cause delayed involution (Chapman et al. 1999; Cui et al. 2004).  I therefore 
examined the activation state of these transcription factors by 
immunohistochemistry using antibodies to the activating sites of phosphorylation.  
Studies of phospho-STAT3 (Figure III.7A), phospho-STAT5 (Figure III.8A), and 
phospho-SMAD2/3 (Figure III.8B) revealed similar staining of sections prepared 
from mammary glands of JNKWT and JNKKO mice on day 3 of involution.  Indeed, 
quantitation of phospho-STAT3 immunofluorescence revealed no significant 
difference between JNKWT and JNKKO glands (Figure III.7B).  Immunoblot 
analysis performed on tissue lysates supported this conclusion (Figure III.7C).  
Strikingly, the induction of Socs3, a STAT3 target gene, was evident after 3 days 
of involution and was un-affected by JNK deficiency (Figure III.7D).  These data 
demonstrate that the delayed involution caused by JNK deficiency did not reflect 
disruption of the signaling pathways that regulate the STAT3/5 or SMAD2/3 
transcription factors.   
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Figure III.7.  STAT3 signaling is not disrupted in JNKKO glands.  
(A)  Immunohistochemistry (left, scale bar = 100 µm) and immunofluorescence (right, 
scale bar = 30 µm) were performed on sections prepared from #4 mammary glands of 
single parous female mice on involution day 3 (n=5 JNKWT mice and n=4 JNKKO mice) 
using an antibody to phospho-STAT3 (p-STAT3) and counter-stained with hematoxylin 
or DAPI, respectively.  An antibody to keratin 8 (K8) was used to label epithelial cells 
during immunofluorescence staining.  Representative images are presented.   
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(B)  K8, p-STAT3, and DAPI fluorescence intensities of involution day 3 glands from 
JNKWT (n=5 mice) and JNKKO (n=4 mice) were quantitated and p-STAT3 intensity was 
normalized to K8 and DAPI fluorescence intensity.  No significant differences between 
JNKWT and JNKKO glands were detected (p>0.05). 
(C)  Protein extracts prepared from involution day 3 mammary glands were examined by 
immunoblot analysis by probing with antibodies to p-STAT3, STAT3 and Tubulin.  Two 
representative mice are presented.  The quantitative data presented are the mean ± 
SEM (n=9 JNKWT mice and n=5 JNKKO mice).  No significant differences between JNKWT 
and JNKKO glands were detected (p>0.05). 
(D)  The mRNA expression of Socs3 measured by RNA-seq analysis is presented as the 
mean fragments per kilobase of exon model per million mapped fragments (FPKM) ± 
SEM; n=3 JNKWT and 3 JNKKO mice per condition).  No significant differences between 
JNKWT and JNKKO glands were detected (q>0.05). 
  
110 
 
 
 
 
 
 
 
Figure III.8.  JNK deficiency does not alter STAT5 or SMAD2/3 activation during 
involution.   
(A, B)  Sections prepared from mammary glands of 5 JNKWT mice and 5 JNKKO mice on 
involution day 3 were stained with an antibody to p-STAT5 (a) or p-SMAD2/3 (b) and 
counterstained with hematoxylin.  Representative images are presented.  Scale bars = 
100 µm. 
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Effect of JNK deficiency on AP1 transcription factors 
Major targets of JNK signaling include members of the Activator Protein 1 (AP1) 
group of transcription factors that are phosphorylated and activated by JNK 
(Davis 2000) and have been implicated in involution (Jaggi et al. 1996; Marti et 
al. 1999).  The AP1 family includes members of the JUN and FOS groups, as 
well as some members of the ATF group of transcription factors.  I therefore 
examined the expression of these AP1-related transcription factors in mammary 
glands of JNKWT and JNKKO mice on day 0 and day 3 of involution by mRNA 
sequencing (Figure III.9A).  Involution in JNKWT mice caused significantly 
increased expression of many of these AP1-related transcription factors, 
including Atf3, Atf5, Atf7, Fos, FosB, FosL1, FosL2, Jun, JunB, and JunD (Figure 
III.9A).  Comparison of JNKWT and JNKKO mice demonstrated no significant 
differences in AP1-related transcription factor expression on day 0 of involution 
(Figure III.9A).  However, on involution day 3 the increased expression of Atf3, 
FosL2, Jun, and JunD detected in JNKWT mice was suppressed in JNKKO mice 
(Figure III.9B-E).  Thus, JNK-deficiency causes a selective defect in the AP1-
related transcription factor response during involution that is mediated by ATF3, 
FOSL2, cJUN, and JUND.  This observation may be mechanistically relevant to 
involution because AP1 transcription factor function has been implicated in 
mammary gland involution (Marti et al. 1999).   
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Figure III.9.  JNK-deficiency suppresses the increase in AP1-related transcription 
factor expression during involution.   
(A)  Heatmap representation of RNA-seq data showing AP1-related transcription factor 
gene expression.  Asterisks denote genes that are differentially expressed (q<0.05) 
between JNKWT and JNKKO mammary glands on involution day 3 (mean; n=3 JNKWT and 
n=3 JNKKO mice for each condition) 
(B-E)  The mRNA expression of Atf3 (B), Jun (C), Jund (D), and Fosl2 (E) measured by 
RNA-seq analysis is presented as mean FPKM ± SEM; n=3 JNKWT and n=3 JNKKO mice 
for each condition.   
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JNK deficiency disrupts involution-associated gene expression 
Comparison of gene expression on day 0 and day 3 of involution demonstrated 
that 10,358 genes were differentially expressed in JNKWT mammary glands 
(log2|Fold Change|>1; q<0.01) (Figure III.10A).  A similar number of genes 
(10,071) were differentially expressed in JNKKO mammary glands (Figure III.10A) 
and 8,620 genes were co-regulated in both JNKWT and JNKKO mammary glands 
during involution (Figure III.10A).  However, 1,688 genes were differentially 
expressed only in JNKWT mice and 1,401 genes were differentially expressed 
only in JNKKO mice.  These data demonstrate that involution is associated with 
major changes in gene expression and that JNK deficiency causes dysregulation 
of a large fraction (26%) of these genes.   
Comparison of RNA expression in mammary glands of JNKWT and JNKKO 
mice on involution day 0 demonstrated differential expression of 134 genes 
(log2|Fold Change|>1; q<0.01) (Figure III.10B), indicating that JNK deficiency 
causes only small changes in gene expression in the lactating mammary gland.  
In contrast, comparison of JNKWT and JNKKO mice demonstrated 2,236 
differentially expressed genes on involution day 3 (Figure III.10B) and only 92 
genes were co-regulated during both normal lactation and involution (Figure 
III.10B).  These data indicate that while JNK deficiency causes few changes in 
gene expression in the lactating mammary gland, JNK deficiency causes major 
changes in gene expression during involution.  The majority of this differential 
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RNA expression (~94%) corresponded to genes that encode proteins (Figure 
III.11).   
 To characterize involution-associated gene expression in JNKWT and 
JNKKO mammary glands, I performed k-means clustering on the 12,862 genes 
that were differentially expressed in any of the pairwise comparisons (Figure 
III.10C).  Cluster 1 included genes that were up-regulated during involution (day 
3) in JNKWT mice and were more strongly up-regulated in JNKKO mice.  This 
cluster was highly enriched for ribosomal genes (padj=1.88x10-98; Figure III.10D).  
Clusters 2/3 included genes that were highly up-regulated during involution in 
JNKWT mice and modestly up-regulated in JNKKO mice (Cluster 2) or were not up-
regulated in JNKKO mice (Cluster 3).  Both clusters were enriched for metabolic 
pathways (padj<10-71), while Cluster 2 showed additional enrichment for genes 
involved in RNA metabolism (Figure III.10D).  There was no striking enrichment 
of pathways in Cluster 4, which contained genes down-regulated in both JNKWT 
and JNKKO mice during involution (Figure III.10D).  Thus, while JNK is 
dispensable for the regulation of a limited number of genes during involution 
(Cluster 4), the loss of JNK greatly affects the expression of other involution-
associated genes (Clusters 1, 2 and 3).   
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Figure III.10.  JNK promotes involution-associated gene expression.   
(A, B)  RNA-seq analysis of mammary glands of JNKWT and JNKKO mice on involution 
day 0 or day 3 is presented as a Venn diagram of the number of differentially expressed 
(DE) genes (log2|Fold Change|>1; q<0.01; n=3 JNKWT and n=3 JNKKO mice for each 
condition).   
(C)  The heatmap presents k-means clustering (k=4) of DE genes in at least one 
pairwise comparison between JNKWT and JNKKO mammary glands on involution day 0 or 
day 3.   
(D)  Gene set enrichment analysis was performed on the 4 gene clusters.  The 10 KEGG 
pathways identified with lowest padj-value are presented.   
116 
 
 
 
Figure III.11.  Summary of RNA sequencing analysis.   
(A)  RNA sequencing analysis of mammary glands isolated from JNKWT and JNKKO mice 
is summarized.  Each biological group comprises 3 independent replicates.   
(B, C)  Biotypes were determined for both detected gene expression and genes that are 
differentially expressed (log2|Fold Change|>1, q<0.01) between day 0 and day 3 of 
involution in JNKWT mice (B) and JNKKO mice (C).   
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The requirement of JNK for normal involution-associated gene expression 
(Figure III.10) may be a secondary consequence of delayed involution and 
suppression of this developmental program of gene expression.  Alternatively, 
these involution-associated genes may be directly targeted by JNK.  To explore 
these two possible mechanisms, I compared the presence of AP1 binding sites 
(defined by ENCODE ChIP-seq analysis of cJUN and JUND (Mouse et al. 2012)) 
near genes that are developmentally regulated during involution in a JNK-
dependent manner with genes that are not significantly regulated by JNK.  This 
analysis demonstrated significant enrichment of cJUN and JUND binding sites 
(p=2x10-16) with approximately 35% of the JNK-regulated genes during involution 
(Figure III.12).  However, the remaining 65% of the JNK-regulated genes lack 
cJUN/JUND binding sites (Figure III.12).  The JNK-regulated expression of these 
genes may reflect targeting of other transcription factors by JNK or represent a 
consequence of delayed involution.   
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Figure III.12.  Enrichment of AP1 binding sites with genes that exhibit JNK-
dependent expression during involution.   
Genes expressed in a JNK-dependent manner (green) or JNK-independent manner 
(yellow) after 3 days of involution (Figure III.10) were compared with genes identified by 
ChIP-Seq analysis (cJUN, JUND, or JUN plus JUND) to determine overlap between 
JNK-dependent gene expression and genes with AP1 binding sites.  Pearson’s Chi-
squared test was used to determine statistical significance.   
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JNK promotes the expression of genes that remodel the mammary gland 
during involution 
It is established that matrix metalloproteinases (MMPs) are involved in 
remodeling the extracellular matrix (Page-McCaw et al. 2007).  Interestingly, 
differentially expressed genes with enrichment of cJUN/JUND binding include 
several Mmp genes that may contribute to mammary gland involution (Figure 
III.10C; Figure III.12).  Indeed, Mmp3 is implicated in both mammary gland 
development and involution (Lund et al. 1996; Page-McCaw et al. 2007).  I found 
that JNK deficiency markedly suppressed the increased Mmp3 expression 
detected in JNKWT mice on involution day 3 (Figure III.13), consistent with the 
observation that JNKKO mice exhibit delayed involution (Figure III.2 & III.3).  I also 
found that the expression of Mmp2, Mmp9, Mmp11, Mmp12, Mmp13, and 
Mmp14 were significantly decreased in JNKKO mice compared with JNKWT mice 
after 3 days of involution (Figure III.13). 
Alterations in the tissue inhibitors of metalloproteases (TIMPs) could also 
impact mammary gland involution.  Indeed, Timp1 overexpression results in 
more rapid adipocyte repopulation of the gland, while Timp3 loss can promote 
epithelial cell apoptotic signaling (Alexander et al. 2001; Hojilla et al. 2011).  
Unexpectedly, I found that Timp2 and Timp3 expression was increased during 
involution in JNKWT mice and that this was suppressed in JNKKO mice (Figure 
III.13).   
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Figure III.13.  Mammary gland expression of Mmp and Timp genes. 
Heatmap representation of RNA-seq data showing matrix metalloproteinase and tissue 
inhibitor of metalloproteinase gene expression.  Asterisks denote genes that are 
differentially expressed (q<0.05) between JNKWT and JNKKO mammary glands on 
involution day 3 (mean; n=3 JNKWT and n=3 JNKKO mice for each condition).   
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Epithelial cell death during involution is caused, in part, by a lysosomal 
pathway mediated by Cathepsins (Kreuzaler et al. 2011) and it is established that 
increased Ctsb (encodes Cathepsin B) and Ctsl (encodes Cathepsin L) 
expression, together with reduced expression of Serpina3g (encodes the 
protease inhibitor Spi2A), contribute to STAT3-induced involution (Chapman et 
al. 1999; Kreuzaler et al. 2011).  Interestingly, the Ctsb gene binds the AP1 
transcription factors cJUN / JUND and therefore might exhibit JNK-dependent 
expression (Figure 5 & S7).  Indeed, I found that the expression of Ctsb was 
increased on involution day 3 in JNKWT mice and that this increased expression 
was suppressed in JNKKO mice (Figure III.14A).  A similar pattern of expression 
was observed for Ctsl (Figure III.14B).  In contrast, JNK deficiency caused no 
significant change in Serpina3g expression during involution (Figure III.14C).  
Thus, reduced Cathepsin expression may contribute to the delayed involution 
phenotype caused by JNK-deficiency.   
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Figure III.14.  Mammary gland expression of cathepsin.   
(A-C)  The mRNA expression of Ctsb (A), Ctsl (B), and Serpina3g (C) was measured by 
RNA-seq analysis.  The data are presented as mean FPKM ± SEM; n=3 JNKWT and n=3 
JNKKO mice for each condition).   
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Epithelial cell death during involution is also caused by the mitochondrion-
mediated apoptotic pathway induced by members of the BCL2 family (Schmelzle 
et al. 2007; Sakamoto et al. 2016; Schuler et al. 2016).  Previous studies have 
implicated a key role for the BH3-only gene Bcl2l11 (encodes BIM) in the 
promotion of epithelial cell death during the involution response (Sakamoto et al. 
2016; Schuler et al. 2016).  Moreover, it is established that the Bcl2l11 gene is 
regulated by AP1 transcription factor binding to the promoter (Whitfield et al. 
2001; Biswas et al. 2007).  I therefore anticipated that Bcl2l11 gene expression 
may depend on JNK.  Indeed, I found that involution caused increased 
expression of Bcl2l11 mRNA in the mammary glands of JNKWT mice during 
involution and that this response was suppressed in JNKKO mice (Figure 
III15.A,C).  The increased expression of Bik detected in JNKWT mice was also 
suppressed in JNKKO mice (Figure III.15A,B,D).  In contrast, expression of the 
pro-apoptotic BH3-only genes Bad, Bbc3, Bid, Bmf, Bnip3, Bnip3l, and Pmaip1 
was similar in the involuting mammary glands of JNKKO and JNKWT mice (Figures 
III.15A & III.16).   
Collectively, these data demonstrate that the delayed involution defect in 
JNK-deficient mice is associated with dysregulation of the gene expression 
program that promotes involution.   
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Figure III.15.  JNK-deficiency suppresses the expression of pro-apoptotic BH3-
only genes.   
(A)  Heatmap representation of RNA-seq data showing pro-apoptotic BH3-only gene 
expression.  Asterisks denote genes that are differentially expressed (q<0.05) between 
JNKWT and JNKKO mammary glands on involution day 3 (mean; n=3 JNKWT and n=3 
JNKKO mice for each condition).   
(B-D)  Quantitative RT-PCR was performed on RNA isolated from mammary glands on 
involution day 0 and day 3.  The relative expression of Bcl2l11 (B) and Bik (C) mRNA 
was measured using Taqman® assays (mean ± SEM; JNKWT 0 days n=6 mice, JNKWT 3 
days n=8 mice, JNKKO 0 days n=6 mice, JNKKO 3 days n=6 mice).   
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Figure III.16.  Mammary gland expression of BH3-only genes.   
Quantitative RT-PCR was performed on RNA isolated from mammary glands on 
involution day 0 and day 3.  The relative expression of Bad, Bbc3, Bid, Bmf, Bnip3, 
Bnip3l, and Pmaip mRNA was measured using Taqman® assays (mean ± SEM; JNKWT 0 
days n = 6, JNKWT 3 days n = 8, JNKKO 0 days n = 6, JNKKO 3 days n = 6 mice).   
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Discussion 
Weaning initiates the process of mammary gland involution that causes collapse 
of the epithelial cell compartment and its replacement by adipose tissue.  Here I 
demonstrate that the JNK signaling pathway plays a key role in the involution 
response.  This program of mammary gland remodeling involves differential 
expression of 10,385 genes (Figure III.10).  I show that 26% of this gene 
expression program requires JNK (Figure III.10).   
Previous studies have demonstrated that involution is associated with 
activation of JNK (Marti et al. 1999) and increased AP1 transcription factor 
activity (Jaggi et al. 1996; Marti et al. 1999).  My analysis shows that JNK 
deficiency in the mammary epithelium suppresses the involution response 
mediated by increased expression of Atf3, Fosl2, Jun, and Jund (Figure III.9).  
Indeed, approximately 35% of JNK-regulated gene expression during involution 
is associated with the presence of AP1 binding sites (Figure III.12).  These data 
confirm that the JNK/AP1 signaling axis plays an important role during involution 
(Jaggi et al. 1996; Marti et al. 1999).  However, the remaining 65% of JNK-
regulated expression during involution is not associated with genes in close 
proximity to AP1 binding sites.  Some of this JNK-mediated regulation may be 
caused by AP1 binding to sites localized to distant enhancer elements, but there 
may also be roles for other JNK-regulated transcription factors (Davis 2000).  It is 
also possible that some JNK-dependent gene expression may represent a 
consequence of a delayed involution response.   
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Examples of genes that may be directly targeted by JNK signaling during 
involution include matrix metalloproteases (Figure III.13) that are regulated by 
AP1, including JUN  (Chakraborti et al. 2003; Yan and Boyd 2007), and are 
implicated in both epithelial cell death (Talhouk et al. 1991) and adipocyte 
repopulation (Alexander et al. 2001) during involution.  Indeed, JNK-regulated 
Mmp expression may contribute to epithelial cell detachment during involution.  A 
second example is represented by Ctsb and Ctsl which encode Cathepsins that 
promote lysosomal cell death during involution and are targeted by AP1 (Figures 
III.10 & III.12).  A third example is represented by pro-apoptotic BH3-only 
members of the BCL2 family (Figure III.15) that can promote epithelial cell 
apoptosis during involution, including Bcl2l11 that is required for normal 
involution (Sakamoto et al. 2016; Schuler et al. 2016) and is a JNK/AP1 target 
gene (Whitfield et al. 2001; Biswas et al. 2007; Girnius and Davis 2017b).  
Defects in the expression of these genes most likely contribute to the delayed 
involution observed in mice with JNK deficiency in the mammary epithelium 
(Figure III.2).   
It is established that STAT3 is a key driver of the involution response (Li et 
al. 1997).  Interestingly, STAT3 target genes that are required for cell death 
during involution, including Ctsb and Bcl2l11, are also targets of AP1 
transcription factors.  For example, the Bcl2l11 promoter binds both STAT3 
(Sakamoto et al. 2016) and AP1 (Whitfield et al. 2001; Biswas et al. 2007; 
Girnius and Davis 2017b) at independent sites.  The combinatorial actions of 
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these transcription factors on the same promoter may lead to a synergistic 
increase in gene expression.  This mechanism would account for the non-
redundant functions of STAT3 and JNK/AP1 in the expression of these 
involution-related genes.   
The discovery that JNK plays a major role in mammary gland involution 
suggests that other members of the MAP kinase group of signaling proteins may 
also contribute to involution.  Indeed, the ERK pathway is activated during early 
involution and may contribute to mammary gland remodeling (Zhao et al. 2002).  
For example, STAT3, a master regulator of involution, is phosphorylated and 
inhibited by ERK (Chung et al. 1997).  Moreover, the BH3-only protein BIM is 
required for involution (Schuler et al. 2016) and is down-regulated by ERK-
mediated phosphorylation and ubiquitin-mediated degradation (Ley et al. 2003; 
Hubner et al. 2008).  Studies to test whether the ERK pathway contributes to 
involution are therefore warranted.   
The p38 MAP kinases represent another group of MAP kinases that is 
implicated in involution (Avivar-Valderas et al. 2014).  It is established that p38 
MAP kinase plays a key role in luminal mammary epithelial cell fate by regulating 
RUNX1 expression in progenitor cells (Del Barco Barrantes et al. 2017).  The 
p38 MAP kinase pathway therefore plays an important role in mammary gland 
development.  Moreover, p38 MAP kinase promotes epithelial cell anoikis and 
clearance of occluded mammary gland ducts by increasing the expression of the 
BH3-only protein BIM (Wen et al. 2011).  Since BIM is required for normal 
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mammary gland remodeling during involution (Schuler et al. 2016), it is therefore 
possible that p38 MAP kinase contributes to the involution response.  This 
prediction remains to be tested.   
It is interesting that there are functional similarities between the JNK and 
p38 MAP kinases in mammary epithelial cells.  For example, both p38 MAP 
kinase (Wen et al. 2011) and JNK (Girnius and Davis 2017b) can promote 
mammary epithelial cell anoikis by increasing the expression of BIM by an AP1 
transcription factor-dependent mechanism.  It is likely that the non-redundant 
functions of p38 MAP kinase and JNK are mediated by different repertoires of 
AP1-related transcription factors.  For example, ATF2 is preferentially 
phosphorylated and activated by p38 MAP kinase while JUN is phosphorylated 
by JNK in mammary epithelial cells (Avivar-Valderas et al. 2014).  Moreover, JNK 
is required for the expression of the AP1-related transcription factors ATF3, 
FOSL2, JUN, and JUND during involution (Figure III.9).  It is likely that p38 MAP 
kinase leads to the activation of a different group of AP1-related transcription 
factors.  JNK and p38 MAP kinase may therefore act in a non-redundant manner 
to regulate AP1-dependent gene expression.  These separate signaling functions 
of p38 MAP kinase and JNK can lead to different pathological consequences; for 
example, p38 MAP kinase increases (Del Barco Barrantes et al. 2017) and JNK 
decreases (Cellurale et al. 2012) mammary tumor development.   
In summary, I show that JNK promotes mammary gland involution by a 
mechanism that is independent of changes in STAT3/5 or SMAD2/3 
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phosphorylation.  Loss of JNK signaling causes delayed involution, reduced 
expression of AP1 transcription factors, and dysregulation of gene expression.  
Collectively, my analysis identifies JNK as a key signaling pathway that promotes 
mammary gland involution.   
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Materials and Methods 
Mice 
Mapk8LoxP/LoxP mice and Mapk9 LoxP/LoxP mice have been previously described 
(Das et al. 2007; Han et al. 2013).  B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-
EGFP)Luo/J mice (Muzumdar et al. 2007) (RRID:IMSR_JAX:007676) and B6.Cg-
Tg(Wap-cre)11738Mam/JKnwJ mice (Wagner et al. 1997) 
(RRID:IMSR_JAX:008735) were purchased from Jackson Laboratories.  Female 
mice were bred at age 10-12 wks.  Mammary glands from single-parous females 
were harvested at 0, 3, 7, and 14 days after forced weaning following 9 days of 
lactation.  The mice were housed in a specific pathogen-free facility accredited by 
the American Association of Laboratory Animal Care (AALAC).  The animal 
studies were approved by the Institutional Animal Care and Use Committee at 
the University of Massachusetts Medical School.   
 
Genomic DNA analysis 
The polymerase chain reaction (PCR) amplimers 5’-
CTCTGCTGCCTCCTGGCTTCT-3’, 5’-CGAGGCGGATCACAAGCAATA-3’ and 
5’-TCAATGGGCGGGGGTCGTT-3’ were used to detect presence of the mTmG 
(250 bp) and WT alleles (330 bp).  The amplimers 5’-
TTACTGACCGTACACCAAATTTGCCTGC-3’ and 5’-
CCTGGCAGCGATCGCTATTTTCCATGAGTG-3’ were used to detect the Cre+ 
allele (450 bp).  The amplimers 5’-AGGATTTATGCCCTCTGCTTGTC-3’ and 5’-
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GACCACTGTTCCAATTTCCATCC-3’ were used to detect the Mapk8+ (540 bp) 
and Mapk8LoxP (330 bp) alleles.  The amplimers 5’-
GTTTTGTAAAGGGAGCCGAC-3’ and 5’-CCTGACTACTGAGCCTGGTTTCTC-
3’ were used to detect the Mapk9+ (224 bp) and Mapk9LoxP alleles (264 bp).  The 
amplimers 5’-CCTCAGGAAGAAAGGGCTTATTTC-3’ and 5’-
GAACCACTGTTCCAATTTCCATCC-3’ were used to detect the Mapk8+ (1550 
bp), Mapk8LoxP (1,095 bp), and the Mapk8∆ alleles (395 bp).  The amplimers 5’-
GGAATGTTTGGTCCTTTAG-3’, 5’-GCTATTCAGAGTTAAGTG-3’, and 5’-
TTCATTCTAAGCTCAGACTC-3’ were used to detect the Mapk9LoxP (560 bp) 
and Mapk9∆ alleles (400 bp).   
 
Mammary Gland Analysis 
Female mice were euthanized and mammary glands #2-5 were harvested, fixed 
in 10% formalin, dehydrated, and embedded in paraffin.  Sections (5 µm) were 
cut and stained with hematoxylin and eosin (H&E) for analysis. Additional 
sections of #4 glands were stained with antibodies against cleaved-caspase-3 
(1:100; Cell Signaling Technology Cat# 9662 RRID:AB_331439), phospho-
STAT3 (1:400; Cell Signaling Technology Cat# 9145 RRID:AB_2491009), 
phospho-STAT5 (1:50; Abcam Cat# ab32364 RRID:AB_778105), phospho-
SMAD2/3 (1:200; Santa Curz Biotechnology Cat# sc-11769-R), smooth muscle 
actin (Millipore Sigma Cat# A2547, RRID:AB_476701; 1:100 dilution), keratin 5 
(BioLegend Cat# 905501 RRID:AB_2565050; 1:50 dilution), keratin 8 (DSHB 
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Cat# TROMA-I RRID:AB_531826; 1:100 dilution), and GFP (Thermo Fisher Cat# 
A21311 RRID:AB_221477).  Immunohistochemistry was performed using a 
biotinylated goat anti-IgG antibody (Biogenex Cat# HK340-5K) plus streptavidin-
conjugated horseradish peroxidase (Vector Laboratories Cat# PK-6100) and 3,3’-
diaminobenzidene (Vector Laboratories Cat# SK-4100).  Sections were 
counterstained with hematoxylin (Thermo Fisher).  Images were acquired using a 
Zeiss Axiovert microscope.  Immunofluorescence was performed using 
AlexaFluor 546 conjugated-goat anti-rabbit IgG (H+L) antibody (Thermo Fisher 
Cat# A11035 RRID:AB_143051), AlexaFluor 488 conjugated-goat anti-rabbit IgG 
(H+L) antibody (Thermo Fisher Cat# A-11008 RRID:AB_143165), AlexaFluor 633 
conjugated-goat anti-mouse IgG (H+L) antibody (Thermo Fisher Cat# A-21052, 
RRID:AB_141459), AlexaFluor 633 conjugated-goat anti-rat igG (H+L) antibody 
(Thermo Fisher Cat# A-21094, RRID:AB_141553), or AlexaFluor 488 
conjugated-goat anti-rat IgG (H+L) antibody (Thermo Fisher Cat# A11006 
RRID:AB_141373), and counterstained with 2-(4-amidinophenyl)-1H -indole-6-
carboxamidine (DAPI).  TUNEL staining was performed following the 
manufacturer’s recommendations (Sigma Cat# 11684795910).  Fluorescence 
images were acquired using a Leica SP2 confocal microscope.  
Immunofluorescence staining of phospho-STAT3 was quantitated using ImageJ 
(Schneider et al. 2012) on 10-15 images per mouse; the amount of phospho-
STAT3 was normalized to keratin 8 or DAPI fluorescence and the mean value 
per mouse was calculated.  Sections were examined in a blinded fashion for 
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days 0, 3, 7 and 14 of involution. However, the marked histological differences on 
involution day 3 prevented blinded analyses.   
 
Immunoblot Analysis 
Tissue lysates from #2-3 glands were prepared using Triton lysis buffer (20 mM 
Tris [pH 7.4], 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM 
β-glycerophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl 
fluoride, and 10 μg/mL of aprotinin plus leupeptin).  Extracts (30 µg) were 
subjected to immunoblot analysis with antibodies to STAT3 (Cell Signaling 
Technology Cat# 9139 RRID:AB_331757; dilution 1:1000), phospho-STAT3 (Cell 
Signaling Technology, Cat# 9145 RRID:AB_2491009; dilution 1:2000), and 
αTubulin (Sigma-Aldrich Cat# T5168; RRID:AB_477579).  IRDye 680LT 
conjugated-donkey anti-mouse IgG antibody (LI-COR Biosciences Cat# 926-
68022 RRID:AB_10715072) and IRDye 800CW conjugated-goat anti-rabbit IgG 
(LI-COR Biosciences Cat# 926-32211 RRID:AB_621843) were used to detect 
immune complexes, and these were quantitated using the Odyssey infrared 
imaging system (LI-COR Biosciences). 
 
Mammary epithelial cell isolation 
Mammary epithelial cells were isolated as previously described (Kittrell et al. 
1992; Novaro et al. 2003) with minor modifications (Cellurale et al. 2012).  Briefly, 
lymph nodes were removed and whole mammary glands were placed in 
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DMEM/F12 supplemented with penicillin/streptomycin and nystatin.  The glands 
were washed once in PBS before being minced and placed in DMEM/F12 
containing 0.2% trypsin, 0.2% collagenase A, 5% fetal calf serum, and 5µg/ml 
gentamicin (2 h) on a rotator at 37°C.  Cells and organoids were pelleted by 
centrifugation at 1,500 rpm (10 min).  The fatty layer was transferred to a second 
tube and dispersed with pipetting while the pellet was resuspended in 
DMEM/F12.  The pellet and fatty layer were centrifuged again at 1,500 rpm (10 
min) and combined in one tube prior to incubation (2~5 mins at 25°C with 
shaking) in DMEM/F12 supplemented with 10 µg/ml DNAse I.  The cells were 
centrifuged at 1,500 rpm (10 min) and resuspended in 10 ml of DMEM/F12.  The 
epithelial cells and organoids were briefly (0.2 min) centrifuged at 1,500 rpm 6-7 
times and resuspended in fresh DMEM/F12 to wash out fibroblasts.   
 
RT-PCR analysis 
The expression of Bad (Mm00432042_m1), Bbc3 (Mm00519268_m1), Bcl2l11 
(Mm00437797_m1), Bmf (Mm00506773_m1), Bid (Mm00432073_m1), Bik 
(Mm00476123_m1), Bnip3 (Mm01275601_g1), Bnip3l (Mm00786306_s1), and 
Pmaip1 (Mm00451763_m1) mRNA and 18S RNA (4308329) was measured 
using TaqMan® assays using QuantStudio 12K Flex machine (Thermo Fisher).  
The amount of mRNA was normalized to the amount of 18S detected in the 
same sample.  
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RNA-seq analysis 
Mammary glands #2-5 were flash frozen in liquid nitrogen and RNA was isolated 
using the RNeasy kit with DNase treatment (Qiagen).  RNA quality (RIN>8) was 
confirmed using a Bioanalyzer 2100 (Agilent Technologies).  Libraries were 
constructed according to the manufacturer’s instructions using the NeoPrep kit 
(Illumina).  Paired-end RNA sequencing with reads (40 bp) were performed using 
a NextSeq500 (Illumina).  Three independent libraries were analyzed for each 
condition.  These RNA-seq data were deposited in the Gene Expression 
Omnibus (GEO) database with accession number GSE89495.  FastQC (version 
0.10.1) (Andrews 2010) was used to generate sequence quality reports.  Poor 
quality reads, adapter sequence and reads less than 20 bp were removed using 
Trimmomatic (version 0.36) (Bolger et al. 2014).  The pre-processed Illumina 
paired-end Fastq datasets were aligned to the mouse reference genome 
(Ensembl GRCm38).  Alignment was performed using Bowtie2 (v 2-2.1.0) 
(Langmead and Salzberg 2012) and Tophat2 (v 2.0.14) (Kim et al. 2013).  
Samtools (version 0.0.19) (Li et al. 2009) and IGV (version 2.3.60) 
(Thorvaldsdottir et al. 2013) were used for indexing the alignment files and 
viewing the aligned reads respectively.  Gene expression was quantitated as 
fragments per kilobase of exon model per million mapped fragments (FPKM) 
using Cufflinks (v 2.2.1) (Trapnell et al. 2010; Trapnell et al. 2012) and differential 
expression was identified using the Cuffmerge and Cuffdiff tools.  The library 
normalization method used for Cuffdiff was set to “classic-fpkm” and the 
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dispersion method was set to “per-condition”.  Cummerbund (version 2.4.1) 
(Trapnell et al. 2012) was used to assess replicate concordance between sample 
groups.  Gene set enrichment analysis was performed using differentially 
expressed gene lists with the WEB-based GEne SeT AnaLysis Toolkit 
(Webgestalt) (Wang et al. 2013) by selecting the KEGG database and viewing 
the 10 pathways with lowest padj-value.  
 
Clustering analysis 
The complex heatmap package (version 1.12.0) (Gu et al. 2016) was used to 
cluster RNA-seq data (Figure III.10C).  The “clustering distance rows” parameter 
was set to “maximum”; the “clustering method rows parameter” was set to 
“ward.D”.  Genes were included in the clustering analysis if they were 
differentially expressed (log2|Fold Change|>1; q<0.01) between one or more 
pairwise group comparisons. Over 12,000 genes together with the gene 
expression levels were examined by k-means (k=4) clustering.   
 
Enrichment analysis 
I used RNA-seq data (Figure 5) and Mouse ENCODE ChIPSeq datasets (Mouse 
et al. 2012) (accession numbers GSM912901 and GSM912902) to evaluate the 
overlap between genes that were non-differentially expressed or differentially 
expressed between JNKWT and JNKKO on involution day 3 (Figure III.10C), and 
genes that bind the transcription factors cJUN and JUND.  Peaks that passed the 
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irreproducible discovery rate at a threshold of 2% were selected from the 
ENCODE project.  The Mouse ENCODE ChIPSeq bed files with mm10 
coordinates were entered as input into PAVIS (Huang et al. 2013) and the 
nearest genes to the peaks from the ChIPSeq data were annotated.  The 
“genome assembly” and the “gene set” were set to “Ensembl GRCm38” and 
“mm10 all genes” respectively.  The upstream distance from the transcription 
start site and the downstream distance from the transcript termination site were 
each set to 20,000 bp.  The intersections between the differentially expressed 
genes (identified by RNA-seq analysis (Figure III.10C)) and the genes that bind 
the transcription factors JUN and JUND (identified using ENCODE ChIP-seq 
data) were identified using Interactivenn (http://www.interactivenn.net/) (Heberle 
et al. 2015).  Statistical significance between two groups was determined by 
Pearson’s Chi-squared test. 
 
Statistical Analysis 
Data are presented as the mean and standard error.  Statistical analysis was 
performed using GraphPad Prism version 7 (GraphPad Software, La Jolla).  
ANOVA with Bonferroni’s test was used to determine significance with an 
assumed confidence interval of 95%.  The significance of pair-wise comparisons 
was determined using Students T-test (p<0.05).  The false discovery rate (q 
value) was obtained by applying the Benjamini-Hochberg method to the p-value. 
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CHAPTER IV 
THE cJUN NH2-TERMINAL KINASE (JNK) SIGNALING PATHWAY 
PREVENTS BREAST CANCER INITIATION  
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Abstract 
Breast cancer is the most commonly diagnosed malignancy in women. Analysis 
of breast cancer genomic DNA indicates frequent loss-of-function mutations in 
components of the cJUN NH2-terminal kinase (JNK) signaling pathway. Since 
JNK signaling can promote cell proliferation by activating the AP1 transcription 
factor, this apparent association of reduced JNK signaling with tumor 
development is unexpected. I examined the effect of JNK deficiency in the 
murine breast epithelium. Loss of JNK signaling was sufficient for genomic 
alterations and the development of breast cancer. Moreover, JNK deficiency 
rapidly accelerated tumorigenesis in a murine model of breast cancer. This tumor 
suppressive function was not mediated by a role of JNK in the growth of 
established tumors, but by a requirement of JNK to prevent tumor initiation. 
Together, these data identify JNK pathway defects as “driver” mutations that 
promote the acquisition of mutations and tumor initiation. 
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Introduction 
Breast cancer is the most frequently diagnosed tumor in women (Siegel et al. 
2015). The etiology of breast cancer has been studied in detail, but the causes of 
breast cancer remain incompletely understood. Nevertheless, it is established 
that familial breast cancers result from germ-line mutations that increase the risk 
of cancer development (Afghahi and Kurian 2017). Examples of inherited 
mutations that can cause breast cancer predisposition include ATM, BRCA1/2, 
CDH1, CHEK2, NBN, and TP53. Moreover, sporadic mutation of these and other 
genes promote the development of non-familial breast cancer (Hanahan and 
Weinberg 2011). Changes in the tumor genome are therefore important for 
breast cancer development (Hanahan and Weinberg 2011).  
 Recent advances in breast cancer genome analysis have led to significant 
progress towards the identification of sporadic mutations in breast cancer (Kan et 
al. 2010; Cancer Genome Atlas 2012; Ellis et al. 2012; Shah et al. 2012; 
Stephens et al. 2012; Wang et al. 2014; Ciriello et al. 2015; Nik-Zainal et al. 
2016b). These genetic changes include “driver” mutations that promote tumor 
development and “passenger” mutations that do not functionally contribute to the 
tumor phenotype. Genes mutated in familial cancer syndromes constitute a prime 
example of “driver” mutations that can contribute to cancer development. The 
presence of “passenger” mutations complicates the analysis of cancer genomes 
for the development of targeted tumor therapy. For example, some “driver” 
mutations cause genetic instability (e.g. ATM, BRCA1/2, CHEK2, NBN and 
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TP53) that can result in the accumulation of additional mutations in developing 
tumors.  
 Computational methods have been employed to distinguish “driver” and 
“passenger” mutations based on mutation frequency (Parmigiani et al. 2009), 
gene function in pathways (Lin et al. 2007; Wendl et al. 2011), level of gene 
expression (Berger et al. 2016) and predictions based on gene function 
(Kaminker et al. 2007; Carter et al. 2009; Youn and Simon 2011) and protein 
interactions (Cerami et al. 2010; Babaei et al. 2013). These computational 
approaches to identify “driver” mutations have been complemented by functional 
siRNA screens on breast tumor cell lines (Sanchez-Garcia et al. 2014; Marcotte 
et al. 2016). Collectively, these approaches have led to the identification of 
“driver” mutations in human cancer, but it is likely that many more “driver” 
mutations remain to be discovered (Garraway and Lander 2013).  
 Examples of “driver” mutations in breast cancer include the TP53, 
PIK3CA, and PTEN genes. Mutational inactivation of PTEN or activation of PI3K 
increases AKT / mTOR signaling that promotes growth, proliferation, and survival 
(Yuan and Cantley 2008), while mutation of TP53 promotes cell survival and 
proliferation (Vousden and Prives 2009). The appreciation of the importance of 
these pathways in cancer has spurred research into potential therapies (Yuan 
and Cantley 2008; Vousden and Prives 2009). These well-established “driver” 
mutations contribute to the etiology of breast cancer. In contrast, the role of some 
other highly mutated genes in breast cancer is unclear.  
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 One frequently mutated pathway in breast cancer is the cJUN NH2-
terminal kinase (JNK) pathway (Garraway and Lander 2013). The JNK pathway 
is a three-tiered cascade that includes a MAP kinase kinase kinase (MAP3K) that 
phosphorylates and activates MAP kinase kinases (MAP2K) that, in turn, 
phosphorylate and activate JNK (Davis 2000). This pathway requires two MAP2K 
isoforms that co-operate to activate JNK by phosphorylation on tyrosine (by 
MAP2K4) and threonine (by MAP2K7) (Tournier et al. 2001). The sequencing of 
breast tumor genomic DNA has revealed mutations in genes that encode 
members of this pathway, including MAP3K1, MAP2K4, and MAP2K7 (Kan et al. 
2010; Banerji et al. 2012; Cancer Genome Atlas 2012; Ellis et al. 2012; Shah et 
al. 2012; Stephens et al. 2012; Wang et al. 2014; Ciriello et al. 2015; Nik-Zainal 
et al. 2016b). The genetic changes include frequent deletion of the gene locus 
and mutations that cause protein truncation and loss of protein kinase activity. 
This analysis suggests that breast cancer is associated with loss of JNK 
signaling. Indeed, since AKT phosphorylates and inactivates MAP2K4 (Park et 
al. 2002), breast cancer “driver” mutations that activate AKT (e.g. PTEN and 
PI3K) also cause loss of JNK signaling. The JNK signaling pathway may 
therefore be suppressed in many breast cancers.  
 The association of breast cancer with reduced JNK signaling represents a 
correlation. What is the significance of loss-of-function JNK pathway mutations? 
Are these “driver” or “passenger” mutations? The purpose of this study was to 
test the role of JNK signaling in breast cancer development. I found that loss of 
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JNK signaling was sufficient for breast cancer development in a mouse model 
with JNK deficiency in mammary epithelial cells. Furthermore, JNK deficiency 
accelerated tumor formation in a murine model of breast cancer. I conclude that 
the frequent loss-of-function JNK pathway mutations in breast tumors represent 
“driver” mutations that promote breast cancer development. This finding presents 
opportunities for therapeutic intervention in patients with breast cancer. 
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Results 
Disruption of JNK signaling is sufficient for breast cancer development 
Loss-of-function mutations in the JNK signaling pathway (e.g. MAP3K1, 
MAP2K4, and MAP2K7) are implicated in the etiology of breast cancer (Kan et al. 
2010; Banerji et al. 2012; Cancer Genome Atlas 2012; Ellis et al. 2012; Shah et 
al. 2012; Stephens et al. 2012; Wang et al. 2014; Ciriello et al. 2015; Nik-Zainal 
et al. 2016b). These potential “driver” mutations in breast cancer cause disruption 
of JNK signaling. To test whether JNK pathway disruption influences breast 
cancer development, I examined the effect of JNK-deficiency in the mammary 
epithelium. The JNK1 (encoded by Mapk8) and JNK2 (encoded by Mapk9) 
isoforms exhibit partially redundant functions (Davis 2000). I therefore examined 
compound JNK deficiency in the mammary epithelium using control (MEWT) mice 
(Mapk8LoxP/LoxP Mapk9 LoxP/LoxP) and JNK-deficient (MEKO) mice (Wap-Cre-/+ 
Mapk8LoxP/LoxP Mapk9 LoxP/LoxP). Lactation induces Wap-Cre expression (Wagner 
et al. 1997). Studies using Rosa26 mTmG+/- female reporter mice demonstrated 
Cre-mediated recombination in keratin 8 (CK8) positive luminal epithelial cells 
(Figure IV.1A), but not in keratin 5 (CK5) positive myoepithelial cells (Figure 
IV.1B).  
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Figure IV.1. JNK deficiency in mammary epithelial cells is sufficient for tumor 
formation and the acquisition of mutations.  
A, B) Mammary gland tissue sections were prepared from parous Wap-Cre+-/ Rosa26 
mTmG+/- female mice (n=6). These sections were stained with antibodies to keratin 8 (CK8, 
red (A)) or keratin 5 (CK5, red (B)), and GFP (green), and counterstained with DAPI 
(blue). Representative images are presented (upper panel, scale bar=48 µM). Boxed 
area was magnified (lower panel, scale bar=24 µM). 
C) Summary of the study cohort showing the total number of Mapk8LoxP/LoxP 
Mapk9LoxP/LoxP (MEWT) and Wap-Cre+/- Mapk8LoxP/LoxP Mapk9LoxP/LoxP (MEKO) mice 
examined, the number of mice exhibiting mammary intraepithelial neoplasia (MIN) or 
tumors (*p<0.05, **p<0.01, Fisher’s exact test) (left panel). The type of carcinoma is 
presented (right panel). 
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D) Extracts prepared from MEKO and Wap-Cre+/- Trp53LoxP/LoxP (JNKWT) tumor cells were 
subjected to immunoblot analysis using antibodies to JNK and α-Tubulin. 
E, F) Representative hematoxylin and eosin (H&E) -stained sections of adenosquamous 
carcinomas (E) and adenocarcinomas (F) from MEKO females are presented. Scale 
bar=100 µm.  
G) Exome sequencing was performed on MEKO tumor cell lines (n=3). Mammary tissue 
from a virgin female of the same genotype (WapCre-/+ Mapk8LoxP/LoxP Mapk9LoxP/LoxP) was 
used as the reference genome. Circos plots showing copy number variations (CNVs) in 
MEKO tumor cells are presented. The outermost ring shows chromosome ideograms. 
The next track indicates high (red) and moderate (yellow) impact single nucleotide 
variants and indels marked by rectangles and triangles, respectively. The innermost 
track shows chromosome amplifications and deletions, with red and blue lines indicating 
chromosomal fragments present at log2(ratio Tumor/Normal)>0.2 or log2(ratio 
Tumor/Normal)<-0.2, respectively. 
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I examined MEWT and MEKO female mice to determine whether JNK 
deficiency is sufficient for breast tumor development. Studies of a cohort of 21 
control MEWT mice identified one palpable breast tumor (adenosquamous 
carcinoma) in a 78 wk old mouse (Figure IV.1C). In addition, mammary 
intraepithelial neoplasia (MIN) was detected in one MEWT mouse during 
microscopic analysis of tissue sections following necropsy. In contrast, the 
incidence of MIN lesions (41% of mice; p<0.01; Fisher’s Exact Test) and palpable 
breast tumors (31% of mice, median age 80 wk; p<0.05; Fisher’s Exact Test) in 
MEKO mice was significantly greater than MEWT mice (Figure IV.1C). Immunoblot 
analysis confirmed that the MEKO tumor cells do not express JNK proteins 
(Figure IV.1D). These data indicate that JNK deficiency is sufficient to promote 
breast tumor development.  
Microscopic analysis of tumor sections demonstrated the presence of 
adenosquamous carcinoma in MEWT mice, but both adenocarcinoma and 
adenosquamous carcinoma were detected in MEKO mice (Figure IV.1C,E,F). The 
adenocarcinomas were primarily CK8 positive and variably expressed estrogen 
receptor (ER) and progesterone receptor (PR), while the adenosquamous 
carcinomas expressed CK5 and did not express ER (Figure IV.2A, B). CK8 
expression by MEKO adenocarcinomas is consistent with both a luminal epithelial 
cell origin and the expression of Wap-Cre in luminal epithelial cells (Figure 
IV.1A,B). In contrast, CK5 expression by the MEKO adenosquamous carcinomas  
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Figure IV.2. Expression of estrogen and progesterone receptors in breast tumors 
caused by JNK deficiency in the mammary epithelium. 
A, B) Representative adenocarcinoma (upper panel) and adenosquamous carcinoma 
(lower panel) sections stained for progesterone receptor (PR), estrogen receptor (ER) 
(Scale bar=100 µm), and cytokeratin 8 (CK8, green) and cytokeratin 5 (CK5) (Scale 
bar=50 µm) are presented (A). Sections were counter-stained with hematoxylin or DAPI. 
Adenocarcinomas (AC) and adenosquamous carcinomas (ASC) were scored for 
hormone receptor positivity (B). 
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suggests that these tumor cells partially differentiate to express a marker of 
myoepithelial cells. 
 
JNK deficiency impairs genome maintenance and alters gene expression 
The JNK pathway has been implicated in genome maintenance (Lu et al. 2006; 
Van Meter et al. 2016; Calses et al. 2017). To test whether JNK deficiency 
caused defects in genome stability, I examined the exome sequences of three 
independent MEKO breast tumor cell lines (Figures IV.1D & IV.3A). This analysis 
demonstrated single nucleotide variants (SNVs) and short insertions / deletions 
(Indels) (Figure IV.1G), including SNVs and Indels that resulted in frame shifts 
and truncations within gene coding regions (Figure IV.3B,C). Moreover, many 
chromosome segment amplifications and deletions (copy number variations, 
CNVs) were detected (Figure IV.1G). These data demonstrate that JNK signaling 
promotes genome maintenance.  
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Figure IV.3. Summary of exome sequence data. 
A) The NCBI SRA accession information (Project ID and Sample ID) for the exome 
sequence data is presented. The mean number of single nucleotide variants (SNVs) and 
insertions/deletions (Indels) is shown for each tumor genotype. An examination of 
frequent nucleotide changes revealed that MEKO tumor cells favored G to A (2/3 tumor 
cell lines) and JNKKO favored C to T (4/6 tumor cell lines) replacements, but no favored 
replacements were identified in JNKWT tumor cells.  
B, C) High impact SNVs (B) and Indels (C) identified in JNKWT (n=2), MEKO (n=3) and 
JNKKO (n=6) cells. No well-established driver mutations were found among the high 
impact indels or SNVs identified and there were no recurring mutations within or across 
genotypes.  
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I compared gene expression profiles of three independent MEKO tumor-
derived cell lines and three independent primary Wap-Cre-/+ mammary epithelial 
cell (MEC) preparations. RNA-seq analysis identified 2,218 differentially 
expressed genes (q<0.05, |log2Fold Change|>0.75) that formed two clusters 
(Figure IV.4A). Gene set enrichment analysis (GSEA) using the KEGG database 
revealed that both clusters were highly enriched for “Pathways in Cancer” (Figure 
IV.4B). Cluster 1 was also enriched for “Focal Adhesion”, while Cluster 2 was 
enriched for “Metabolic Pathways” and “p53 Signaling” (Figure IV.4B). As 
expected, JNK deficiency caused reduced expression of AP1 transcription 
factors (Ventura et al. 2003) in MEKO tumor cells compared with primary MEC 
(Figure IV.4C). Ingenuity Pathway Analysis (IPA) identified a significant increase 
in “WNT/β-Catenin Pathway” activity (Figure IV.4D). This finding is consistent 
with the observed enrichment of WNT signaling genes in GSEA (Figure 2B, 
Cluster 2), including increased expression of Wnt7b and Wnt10a (Figure IV.4E) 
and increased expression of the WNT target genes Axin2, Ccnd1, and Myc in 
MEKO cells compared with MEC (Figure IV.4F). These data suggest that MEKO 
tumors may exploit the WNT pathway to maintain proliferation. 
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Figure IV.4. JNK deficiency is sufficient to promote tumor-associated gene 
expression.  
A-D) RNA-seq analysis was performed using primary mammary epithelial cells (MEC, 
n=3) and MEKO tumor cell lines (n=3). K-means clustering was performed on differentially 
expressed genes and is presented as a heatmap (A). Gene set enrichment analysis 
using the KEGG database was performed on genes from each of the clusters. The 
pathways with the 10 lowest padj values are presented (B). The mean expression Jun, 
Junb, Jund, Fos, and Fosb mRNA is presented as a heatmap (C). Ingenuity Pathway 
analysis of the RNA-seq data was used to predict signaling pathway activity (D).  
E) Wnt7b and Wnt10a expression in MEC (n=3) and MEKO tumor cells (n=3) is presented 
as the mean fragments per kilobase of exon model per million mapped fragments 
(FPKM) ± SEM (*q<0.05, ***q<0.001). 
F) WNT target gene expression (Axin2, Ccnd1, and Myc) in MEC (n=3) and MEKO (n=3) 
cells is presented as FPKM (mean ± SEM; **q<0.01, ***q<0.001). 
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 JNK deficiency rapidly accelerates tumor development in a mouse model 
of breast cancer 
The observation that JNK deficiency is sufficient for breast tumorigenesis (Figure 
IV.1) suggests that defects in JNK signaling may accelerate tumor development 
in a sensitized genetic background. To test this hypothesis, I examined the 
genetic interaction between JNK inactivation and loss of TRP53. Since TP53 is 
the most frequently mutated gene in human breast cancer, this model is relevant 
to human disease (Nik-Zainal et al. 2016b).  
I established TRP53-deficient (JNKWT) mice (Wap-Cre-/+ Trp53LoxP/LoxP ) 
and TRP53/JNK compound mutant (JNKKO) mice (Wap-Cre-/+ Trp53LoxP/LoxP 
Mapk8LoxP/LoxP Mapk9LoxP/LoxP). Loss of JNK on the TRP53 deficient background 
dramatically accelerated tumor formation (Figure IV.5A).  Histological 
examination of the JNKWT and JNKKO tumors confirmed that the majority of 
lesions were adenocarcinomas (Figure IV.5B & IV.6A). JNKWT and JNKKO tumors 
presented with variable ER and PR staining patterns (Figures IV.5C & IV.6B). 
Moreover, both JNKWT and JNKKO tumor cells primarily expressed the luminal 
marker CK8, rather than the myoepithelial cell marker CK5, consistent with a 
luminal epithelial cell origin (Figure IV.5C).  Tumor latency did not correlate with 
parity (Figure IV.7A) and litter sizes were comparable across the genotypes 
(Figure IV.7B).  However, JNK deficiency in the maternal mammary epithelium 
caused a substantial decrease in pup survival after the first liter (Figures IV.7C). 
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Figure IV.5. JNK deficiency accelerates tumor formation in a mouse model of 
breast cancer. 
A) Mammary tumor-free survival was monitored in Wap-Cre-/+ Trp53LoxP/LoxP (JNKWT) 
mice and Wap-Cre-/+ Trp53LoxP/LoxP Mapk8LoxP/LoxP Mapk9LoxP/LoxP (JNKKO) mice. Animals 
euthanized before a palpable mammary tumor had formed were censored in the log-rank 
analysis (p<0.0001).  
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B) Tissue sections were prepared from mammary tumors. Representative images of 
H&E-stained sections from JNKWT (upper panel) and JNKKO (lower panel) mice are 
presented. Scale bar=100 µm.  
C) Adenocarcinoma tissue sections from JNKWT mice (upper panel) and JNKKO mice 
(lower panel) were stained with antibodies to (from left to right) estrogen receptor (ER), 
progesterone receptor (PR), keratins 5 (red) and 8 (green) (CK5 and CK8 respectively), 
PCNA (Scale bars=50 µm), and cleaved caspase 3 (Scale bar=100 µm). 
Immunofluorescent stains were counterstained with DAPI, and peroxidase-based 
staining was counterstained with hematoxylin. 
D, E) Exome sequencing was performed on JNKWT (n=2) and JNKKO (n=6) tumor cell 
lines. Mammary tissue from a virgin female of the same genotype (WapCre-/+ 
Trp53LoxP/LoxP for JNKWT and WapCre-/+ Trp53LoxP/LoxP Mapk8LoxP/LoxP Mapk9LoxP/LoxP for 
JNKKO) was used as the reference genome. Representative Circos plots showing CNVs 
are presented for JNKWT (D) and JNKKO (E) tumor cells. The outermost ring shows 
chromosome ideograms. The next track indicates high (red) and moderate (yellow) 
impact single nucleotide variants and indels marked by rectangles and triangles, 
respectively. The innermost track shows chromosome amplifications and deletions, with 
red and blue lines indicating chromosomal fragments present at log2(ratio 
Tumor/Normal)>0.2 or log2(ratio Tumor/Normal)<-0.2, respectively.  
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Figure IV.6. Tumors in JNKKO mice are primarily adenocarcinomas and display a 
spectrum of hormone receptor expression patterns. 
A) The JNKWT and JNKKO mouse cohorts are summarized.  
B) Adenocarcinomas from JNKWT and JNKKO mice were stained for PR and ER and 
scored for expression. Numbers in parentheses indicate percentages. 
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Figure IV.7.  Tumor latency in JNKWT and JNKKO mice is not influenced by parity. 
A)  The number of litters born to JNKWT and JNKKO females was plotted against the time 
of euthanasia.  Only females that developed mammary carcinomas were included in this 
analysis.  No correlation was found between parity and tumor development. 
B)  The number of pups in the first and second litters of JNKWT (Wap-Cre-/+ 
Trp53LoxP/LoxP), MEKO (Wap-Cre-/+ Mapk8LoxP/LoxP Mapk9LoxP/LoxP), and JNKKO (Wap-Cre-/+ 
Trp53LoxP/LoxP Mapk8LoxP/LoxP Mapk9LoxP/LoxP) dams that survived to weaning was counted 
(mean ± SEM).  No significant differences were detected (p>0.05), indicating that 
females of all three genotypes had similar lactation histories. 
C)  The percentage of litters surviving to weaning age was monitored for JNKWT, MEKO, 
and JNKKO dams (*p<0.05, **p<0.01).  
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 To test whether JNK deficiency promotes tumorigenesis by disrupting the 
balance of proliferation and cell death, I stained tumor tissue sections with 
antibodies to detect the proliferation marker PCNA and the apoptotic marker 
cleaved caspase 3. No differences were detected in PCNA-stained sections, 
indicating that JNKKO tumors were not more proliferative than JNKWT tumors 
(Figure IV.5C). Similarly, I did not detect differences in cleaved caspase 3 
staining between JNKWT and JNKKO tumors (Figure IV.5C). Collectively, these 
data show that JNK deficiency causes significantly accelerated disease 
progression without greatly changing the tumor phenotype.  
To assess whether there are differences in mutational load, and to 
determine if there are recurring mutations or chromosomal alterations associated 
with the different tumor genotypes, I performed exome sequencing of JNKWT and 
JNKKO tumor cell lines (Figures IV.5D,E & IV.8A). SNVs and Indels resulting in 
frame shifts, truncations, and splice site mutations were identified (Figure 
IV3.B,C). CNV analysis demonstrated that chromosome 6 was amplified and no 
chromosome was consistently deleted in JNKWT tumor cells (Figure IV.5D). 
Chromosome 6 was also amplified in some (two of six) JNKKO tumor cells 
(Figures IV.5E & IV.8A). The proto-oncogene Kras resides on chromosome 6 
and CNV analysis demonstrated that the Kras locus was recurrently amplified in 
JNKWT tumor cells (Figures IV.5D & IV.8A) and was more highly expressed 
(Figure IV.8B).  
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Figure IV.8. Exome sequencing of Control and JNK deficient tumor cells. 
A) Circos plots showing copy number variations (CNV) in additional JNKKO tumor cell 
lines are presented. The outermost ring shows chromosome ideograms. The next track 
indicates high (red) and moderate (yellow) impact single nucleotide variants and indels 
marked by rectangles and triangles, respectively. The innermost track shows 
chromosome amplifications and deletions, with red and blue lines indicating 
chromosomal fragments present at log2(ratio Tumor/Normal)>0.2 or log2(ratio 
Tumor/Normal)<-0.2, respectively.  
B) Kras expression in MEC (n=3), JNKWT (n=2), and JNKKO (n=2) cells was measured by 
RNA sequencing and is presented as mean FPKM ± SEM (*q<0.05).  
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Effects of JNK deficiency on tumor-associated gene expression 
I performed RNA-seq on primary mammary epithelial cells (MEC) and tumor cells 
(Figure IV.9A) to test whether JNK deficiency caused changes in tumor-
associated gene expression. An examination of genes differentially expressed 
(|log2Fold Change|>0.75; q<0.05) in tumor cells compared to MEC revealed 
distinct gene expression patterns between JNKWT, JNKKO, and MEKO tumor cells 
(Figure IV.10A & IV.9B). GSEA using the KEGG database (Figure IV.10B) 
demonstrated that up-regulated genes in JNK-deficient tumors were enriched for 
“Metabolic Pathways” (Clusters 1 & 2), while genes up-regulated in JNKWT 
tumors were enriched for “Cytokine-Cytokine Receptor Interactions” (Cluster 3). 
In contrast, down-regulated genes in all of the tumor cells were enriched for 
“Focal Adhesion Proteins” (Cluster 4). These data indicate that JNK deficiency 
selectively alters a subset of tumor-associated gene expression.  
 To understand how JNK deficiency may alter tumor signaling pathways, I 
used IPA to predict pathway activation status by examining differential 
expression between each tumor type and MEC. The pathways were ranked by 
Activation z-Score (total -log10 p of Fisher’s exact test across the tumors) and the 
top 100 were considered (Figure IV.9C). Two dominant categories emerged from 
the comparative analysis: down-regulated “Chemokine/Cytokine Signaling”; and 
down-regulated “Integrin/Cytoskeleton Signaling” (Figure IV.10C).  
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Figure IV.9. Gene expression analysis of control and JNK deficient tumor cells. 
A) Summary of the RNA sequencing data together with database accession information 
(GEO accession numbers and Sample ID). The number of samples per biological group 
is shown in parentheses. 
B) Venn diagram showing differentially expressed (DE) genes in JNKWT (n=2), MEKO 
(n=3), and JNKKO (n=2) tumors compared to MEC (n=3). 
C) Ingenuity Pathway Analysis was used to predict pathway activation and inhibition in 
JNKWT (n=2), MEKO (n=3), and JNKKO (n=2) tumor cells. The heatmap shows pathways 
ranked (top to bottom) by their score (total -log10p of Fisher’s exact test across the 
tumors). The top 100 pathways are shown. Coloring corresponds to the activation z-
Score, with green representing inhibited pathways and red activated pathways. A cutoff 
of score=1.31 was set (equates to p=0.049; Fisher’s exact test).  
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Figure IV.10. RNA-seq analysis demonstrates that a sub-set of tumor-associated 
gene expression requires JNK.  
A, B) RNA isolated from primary mammary epithelial cells (MEC, n=3) and also JNKWT 
(n=2), MEKO (n=3), and JNKKO (n=2) tumor cell lines was sequenced. The heatmap 
presents k-means clustering (k=4) of genes differentially expressed in any of the 
pairwise comparisons (q<0.05, |log2Fold Change|>0.75; mean) (A). Gene set enrichment 
analysis was performed on each of the four clusters using the KEGG database (B). The 
pathways with the lowest padj values for each cluster are presented. 
C) Comparative analysis was performed on genes differentially expressed between MEC 
and each of the tumor cell lines using Ingenuity Pathway Analysis (IPA). Heatmaps show 
the predicted activation (Activation z-score) of canonical pathways involved in immune 
(left panel) and integrin/cytoskeleton (right panel) signaling ranked by score. A cutoff 
score=1.31 was set (equates to p=0.049; Fisher’s exact test). 
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I also examined signaling pathways by immunoblot analysis. Studies of 
JNKWT tumor cells demonstrated the presence of a functional JNK signaling 
pathway, including stress-induced phosphorylation of both JNK and cJUN (Figure 
IV.11A). However, JNK was not detected in JNKKO tumor cells (Figure IV.11B). 
The activation state of other MAPK pathways (ERK and p38) and the AKT 
pathway were similar between JNKWT and JNKKO tumor cells (Figure IV.11B).  
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Figure IV.11. Comparison of signaling pathways in control and JNK deficient 
tumor cells. 
A) Two independently-derived JNKWT tumor cell lines (JNKWT 1 and JNKWT 2) were left 
untreated (-) or were exposed (+) to 60 J/m2 ultraviolet light. Lysates from these cells 
were harvested at 30 min post-irradiation and were examined by immunoblot analysis by 
probing with antibodies to α-Tubulin, p-JNK, JNK, p-cJUN, and cJUN.  
B) JNKWT (n=2) and JNKKO (n=6) tumor cell lines were cultured and protein lysates were 
prepared for immunoblot analysis. Lysates were probed for JNK, p-ERK, ERK2, p-p38, 
p38, p-AKT (T308), p-AKT (S473), AKT, and α-Tubulin. Representative blots showing 
one JNKWT cell line and three JNKKO cell lines are presented. 
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JNK deficiency does not increase tumor stem cell activity 
The increased tumor burden caused by JNK deficiency may reflect a role of JNK 
in tumor stem cells. To examine this potential role of JNK, I monitored 
mammosphere formation and maintenance using JNKWT and JNKKO tumor cells. 
No evidence of increased mammosphere propagation by the JNKKO tumor cells 
was obtained (Figure IV.12A,B). Moreover, I did not detect enhanced sphere 
formation by MEKO tumor cells (Figure IV.13A,B). Staining of agarose-embedded 
JNKWT and JNKKO mammospheres revealed a similar organization with 
peripheral CK5+ cells and central CK8+ cells (Figure IV.12C). Finally, the 
expression of stem cell markers (Bmi1, Nanog, and Pou5f1) was not significantly 
different between JNKWT and JNKKO mammospheres (Figure IV.12D). This 
analysis does not support the conclusion that differences in cancer stem cell 
activity account for the accelerated tumor formation by JNKKO mice compared 
with JNKWT mice.  
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Figure IV.12. Stem cell populations are comparable in JNKWT and JNKKO tumor 
cells. 
A) JNKWT and JNKKO tumor cells formed mammospheres when grown in suspension. 
Representative phase contrast (upper panel) and H&E-stained agarose-embedded 
sphere sections (lower panel) are presented. Scale bar=100 µm. 
B) The number of mammospheres formed per 1,000 plated cells each passage (P) was 
quantitated for JNKWT and JNKKO tumor cells. Two independent cell lines were tested for 
each genotype. The data presented are the mean ± SEM (n=3 independent 
experiments; **p<0.01).  
C) Representative agarose-embedded mammosphere sections stained with antibodies 
to keratin 5 (CK5, red) and keratin 8 (CK8, green), and counterstained with DAPI are 
presented. Scale bar=50µm. 
D) RNA was isolated from JNKWT and JNKKO tumor cell mammospheres at different 
passages to quantify mRNA expression of Bmi1, Nanog, and Pou5f1. Two independent 
cell lines were tested for each genotype. The data presented are the mean ± SEM (n=2 
independent experiments). No significant differences were observed (p>0.05).  
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Figure IV.13. JNK-deficient tumor cells do not exhibit enhanced tumor stem cell 
activity. 
A) JNKWT (n=2) and MEKO (n=3) tumor cells grown in suspension formed 
mammospheres. Representative phase contrast (upper panel) and agarose-embedded 
H&E-stained sections (lower panel) are shown. Scale bar= 100 µm. 
B) Sphere formation per 1,000 cells plated over 2 passages (P) was quantitated for 
JNKWT and MEKO tumor cells (mean ± SEM of 3 independent experiments, *p<0.05).  
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JNK deficiency does not increase tumor cell proliferation, but does 
promote survival 
Transformed cells co-opt cellular processes to block anti-proliferative and death 
mechanisms while increasing cell proliferation, invasion, and migration (Hanahan 
and Weinberg 2011). A change in one of these processes may account for the 
increased tumor burden detected in JNKKO mice. No differences between JNKWT 
and JNKKO tumor cell proliferation were detected (Figure IV.14A). Similarly, I 
found no difference in JNKWT and JNKKO tumor cell migration during wound 
healing (Figure IV.14B) or in response to a serum gradient (Figure IV.14C). 
Moreover, JNKWT and JNKKO tumor cell invasion through matrigel-coated 
membranes (Figure IV.14C) and collagen I-filled wounds (Figure IV.14D) was 
similar. These data demonstrate that JNK deficiency does not alter breast tumor 
cell proliferation, invasion, or migration. Consistent with this conclusion, I found 
no differences between the growth of JNKWT and JNKKO tumor cells in 
orthotopically transplanted syngeneic mice (Figure IV.14E-G).  
 While many properties of JNKWT and JNKKO tumor cells are similar (Figure 
IV.14A-G), I did detect some JNK-dependent differences in the tumor cell 
phenotype (Figure IV.14H-J). Thus, JNKKO tumor cells formed more colonies 
than JNKWT tumor cells when grown in soft agar (Figure IV.14H,I) and JNKKO 
cells exhibited greater resistance to anoikis than JNKWT tumor cells (Figure 
IV.14J). These data indicate that JNK deficiency can promote tumor cell survival.  
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Figure IV.14. JNKWT and JNKKO tumor cells exhibit similar phenotypes. 
A) JNKWT (n=2) and JNKKO (n=6) tumor cell lines were cultured (8 h) in growth media 
and the change in confluence was measured using an IncuCyte ZOOM (mean ± SEM). 
No significant differences (p>0.05) were observed. Similar data were obtained in four 
independent experiments.  
B) Monolayers of JNKWT (n=2) and JNKKO (n=4) cells were wounded and cell migration 
rates were assessed by measuring the change in wound width 48 h after wounding 
using an IncuCyte ZOOM (mean ± SEM). No significant differences (p>0.05) were 
observed. Similar data were obtained in two independent experiments.  
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C) JNKWT (n=2) and JNKKO (n=6) tumor cell chemotaxis in response to a serum gradient 
in the absence (Control) or presence of Matrigel was examined (mean ± SEM). No 
significant differences were observed (p>0.05). Similar data were obtained in two 
independent experiment.  
D) Monolayers of JNKWT (n=2) and JNKKO (n=3) tumor cells were wounded, overlayed 
with 0.5mg/ml collagen I in growth serum, and cultured for up to 48 h in media containing 
2% serum. Tumor cell migration into the collagen-filled wound was quantitated by 
measuring cell density in the initial wound area using an IncuCyte ZOOM (mean ± SEM). 
No significant differences were observed (p>0.05). Similar data were obtained in two 
independent experiments. 
E-G) Orthotopic transplantation of JNKWT and JNKKO tumor cells (two independent cell 
lines per genotype) into the mammary fat pads of 26 (JNKWT) and 27 (JNKKO) syngeneic 
mice was performed using 2x106 (E).  Orthotopic transplantation of 0.5x106 cells was 
performed using 30 (JNKWT) and 26 (JNKKO) syngeneic wild-type hot mice (F). No 
significant differences were observed (p>0.05). Representative H&E stained tumor 
sections from JNKWT (upper panel) and JNKKO (lower panel) tumors are presented (G). 
Scale bar=100 µM.  
H, I) JNKWT (n=4) and JNKKO (n=9) tumor cell lines were cultured in soft agar and colony 
formation was quantitated (mean ± SEM; *p<0.05) (H). Similar data were obtained from 
2 independent experiments and representative images of crystal violet-stained colonies 
are presented (I). Scale bar=100 µM. 
J) JNKWT (n=7) and JNKKO (n=16) tumor cell lines were cultured in suspension (24 h) 
and apoptotic cells (7AAD- annexin V+) were quantified by flow cytometry (mean ± SEM; 
*p<0.05). Similar data were obtained in two independent experiments.  
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JNK deficiency causes early disease initiation 
Comparative studies of JNKWT and JNKKO tumor cells demonstrated that JNK-
deficiency does not contribute to differences in proliferation, migration, or 
invasion phenotypes in vitro (Figure IV.14A-D) or to tumor growth in 
orthotopically transplanted syngeneic mice (Figure IV.14E-G). I therefore 
considered the possibility that JNK may influence tumor initiation rather than the 
function of fully developed tumor cells. To test this hypothesis, I examined 
sections of mammary glands from female mice at 18 weeks after gene ablation. 
JNKWT mice presented normal mammary gland morphology (Figure IV.15A). In 
contrast, multifocal mammary intraepithelial neoplasia (MIN) was observed in 
JNKKO glands (Figure IV.15A). The presence of MIN lesions in young JNKKO mice 
indicates that JNK-deficient mammary epithelial cells exhibit defects in apical-
basal polarity, a hallmark of mammary tumor development (Zhan et al. 2008; 
Halaoui et al. 2017). Moreover, it is likely that mammary tumor development is 
further promoted by the increased survival of JNKKO cells in vitro (Figure IV.14H-
J) and increased proliferation of JNKKO epithelial cells compared with JNKWT 
epithelial cells in vivo (Figure IV.15B,C). These data indicate that one 
physiological function of JNK in mammary epithelial cells is to suppress breast 
cancer development by preventing the initiation of carcinogenesis.  
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Figure IV.15. JNK deficiency promotes early disease lesions.  
A) Eighteen weeks after gene deletion, tissue sections were prepared from mammary 
glands of JNKWT (n=5) and JNKKO (n=12) female mice. Representative H&E-stained 
sections are presented. Scale bar=100 µm.  
B, C) Proliferation was examined in mammary glands at 18 weeks after gene ablation by 
staining tissue sections with an antibody to PCNA (JNKWT n=4, JNKKO n=5). 
Representative PCNA-stained and DAPI counter-stained glands are presented (B, Scale 
bar=50 µm). The percent of PCNA+ cells was quantified (mean ± SEM, *p<0.05) (C).  
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Discussion 
The frequent mutation of the JNK pathway in human breast cancer (including the 
genes MAP3K1, MAP2K4, and MAP2K7) implicates reduced JNK signaling in the 
etiology of mammary carcinoma (Kan et al. 2010; Banerji et al. 2012; Cancer 
Genome Atlas 2012; Ellis et al. 2012; Shah et al. 2012; Stephens et al. 2012; 
Wang et al. 2014; Ciriello et al. 2015; Nik-Zainal et al. 2016b). Mutation of Mapk8 
(encodes JNK1) and Mapk9 (encodes JNK2) is not frequently detected, most 
likely because of the functional redundancy of these JNK isoforms (Davis 2000). 
In contrast, MAP2K4 and MAP2K7 serve as non-redundant activators of JNK and 
mutation of either MAP2K4 or MAP2K7 causes JNK inhibition (Tournier et al. 
2001). Similarly, MAP3K1 acts in a non-redundant manner to activate JNK (Yujiri 
et al. 2000). Tumor-associated ablation or mutation of these genes therefore 
causes JNK inhibition. Moreover, JNK signaling is also inhibited by 
phosphorylation of MAP2K4 by AKT (Park et al. 2002) in breast tumors with AKT 
activation caused by “driver” mutations in PTEN or PIK3CA (Garraway and 
Lander 2013). Suppression of JNK signaling is therefore a characteristic of many 
breast cancers. Nevertheless, the significance of JNK pathway inactivation in 
breast cancer is unclear (Cellurale et al. 2010; Chen et al. 2010; Cellurale et al. 
2012). Here I demonstrate that loss of JNK signaling is sufficient for murine 
breast cancer development (Figure IV.1). Furthermore, JNK deficiency 
accelerated tumor development in a murine model of breast cancer (Figure IV.5). 
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The frequent JNK pathway loss-of-function mutations in human breast cancer 
may therefore represent “driver” mutations that promote tumor development.  
 I find that JNK loss plays a key role at the early stages of breast cancer 
development by promoting mammary gland neoplasia (Figure IV.15). This 
observation likely accounts for the effect of mutational inactivation of JNK 
signaling to promote tumor development (Figures IV.1 & IV.5). In contrast to this 
tumor-suppressive role of JNK during early stages of carcinogenesis (Figure 
IV.15), JNK does not markedly influence the late-stage tumor phenotype (Figure 
IV.14). Thus, JNK does not change tumor cell proliferation, invasion or migration 
in vitro or tumor formation in orthotopically transplanted mice in vivo (Figure 
IV.14). However, JNK deficiency does repress tumor cell anoikis and promotes 
growth in soft agar in vitro (Figure IV.14). JNK therefore plays a major role in 
early tumor development, but only a minor role in established tumors.  
An important question relates to the mechanism of breast tumor 
suppression by the JNK signaling pathway. Part of the mechanism may reflect 
the pro-apoptotic role of JNK (Tournier et al. 2000). Mutations in key genes can 
enable epithelial cell survival in the luminal space, resulting in ductal carcinoma 
in situ (DCIS) and cancer (Taraseviciute et al. 2010; Leung and Brugge 2012; 
Pradeep et al. 2012; Halaoui et al. 2017). Indeed, JNK has been shown to be 
required for efficient epithelial cell death in response to cell detachment (anoikis) 
in vitro and JNK deficiency results in occluded mammary ducts in vivo (Cellurale 
et al. 2012; Girnius and Davis 2017a). However, this mechanism may not be 
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sufficient to account for tumor formation caused by JNK deficiency (Figure IV.1) 
or the observed acceleration of tumor formation caused by JNK deficiency in a 
mouse model of breast cancer (Figure IV.5). For example, both JNK and p38 
MAPK promote mammary gland epithelial cell anoikis by a BIM-dependent 
mechanism and are required for luminal clearance of mammary ducts (Wen et al. 
2011; Cellurale et al. 2012; Girnius and Davis 2017a), but JNK inhibition 
promotes breast cancer (Figures IV.1 & IV.5) while p38 MAPK pathway inhibition 
suppresses breast cancer development and the dissemination of metastatic 
tumor cells (Harper et al. 2016; Del Barco Barrantes et al. 2018; Gawrzak et al. 
2018). These data indicate that anoikis defects and ductal occlusion by detached 
epithelial cells caused by stress-activated MAPK inhibition is not sufficient for 
tumor formation. This reasoning implicates a second pathway of JNK-mediated 
suppression of mammary tumor development.  
Insight into JNK-mediated tumor suppression was obtained from the 
analysis of tumor genomic DNA. I found that JNK deficiency resulted in the 
accumulation of SNVs, Indels, and CNVs (Figure IV.1G). It is likely that these 
genetic changes caused by JNK deficiency contribute to tumor development. 
This accumulation of mutations reflects the function of JNK to promote genome 
maintenance in response to stress. Examples include JNK-mediated 
phosphorylation of SIRT6 to stimulate double-stranded DNA break repair (Van 
Meter et al. 2016) and JNK-mediated phosphorylation of DGCR8 to induce 
transcription-coupled nucleotide excision repair (Calses et al. 2017). Loss of JNK 
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signaling would therefore be expected to cause defects in DNA repair that result 
in increased genomic instability. Indeed, my analysis demonstrates that JNK 
deficiency in the mammary epithelium is sufficient to cause genomic alterations  
(Figure IV.1G) and breast cancer (Figure IV.1C).  
The identification of JNK pathway mutations as “driver” mutations for 
breast cancer was not anticipated. For example, the JNK pathway can promote 
cell proliferation and survival through regulation of AP1 transcription factors 
(Lamb et al. 2003; Ventura et al. 2003; Das et al. 2007). Indeed, the JNK/JUN 
signaling pathway may promote the proliferation of some breast tumor cells in 
vitro (Guo et al. 2006; Xie et al. 2017). It is therefore possible that JNK signaling 
may have pro-oncogenic functions in certain tumor types or under specific 
conditions (Whitmarsh and Davis 2007). Nevertheless, my analysis establishes 
that a major role of JNK signaling in the breast epithelium is tumor suppression 
(Figures IV.1 & IV.5). This role of JNK signaling is consistent with the discovery 
of frequent JNK pathway gene ablation and mutation in human breast cancer 
(Kan et al. 2010; Banerji et al. 2012; Cancer Genome Atlas 2012; Ellis et al. 
2012; Shah et al. 2012; Stephens et al. 2012; Wang et al. 2014; Ciriello et al. 
2015; Nik-Zainal et al. 2016b).  
 My analysis demonstrates that JNK deficiency in the mammary epithelium 
is sufficient to cause breast cancer in mice and that JNK deficiency causes rapid 
acceleration of tumor development in a mouse model of breast cancer. These 
observations indicate that JNK can act as a tumor suppressor for breast cancer 
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development. Inactivating mutation of genes that encode JNK pathway 
components may therefore promote human breast cancer. This conclusion 
presents an opportunity for therapeutic intervention in patients with breast 
cancer.  
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Materials and Methods 
Mice 
Mapk8LoxP/LoxP Mapk9LoxP/LoxP mice have been previously described (Han et al. 
2013). C57BL6/J (RRID:IMSR_JAX:000664), B6129-TG(Wap-cre)11738Mam/J 
(RRID:IMSR_JAX:008735) (Wagner et al. 1997), B6.129P2-Trp53tm1Brn/J 
(RRID:IMSR_JAX:008462) (Marino et al. 2000), and B6.129(Cg)-
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J mice (RRID:IMSR_JAX:007676) 
(Muzumdar et al. 2007) were purchased from The Jackson Laboratories. All mice 
were on a C57BL6/J strain background and were randomly assigned to groups. 
Female mice were bred at 10-12 weeks of age and monitored for tumor 
development by palpation following weaning. Reasons for euthanasia included a 
mass of 1 cm in diameter, ulceration due to the tumor, poor health, or weight loss 
(>20% body weight). The animals were housed in a specific pathogen-free facility 
accredited by the American Association of Laboratory Animal Care (AALAC).  
 
Tumor-derived Cell Lines 
Tumors were harvested and placed in DMEM/F12 containing 1% 
penicillin/streptomycin and 1% nystatin (Thermo Fisher Scientific). The tissue 
was washed with phosphate-buffered saline (PBS), minced, and digested (37°C 
for up to 2 h, shaking) in DMEM containing 2mg/ml collagenase, 0.1% trypsin, 
and 1% penicillin/streptomycin. Following digestion, cells were pelleted and re-
suspended in DMEM/F12 supplemented with 2% bovine growth serum and 1% 
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penicillin/streptomycin, then plated on collagen I (Thermo Fisher Scientific Cat# 
A1048301) coated dishes. After two passages, the cells were plated on standard 
tissue culture dishes and maintained in Growth Medium (DMEM/F12 
supplemented with 10% fetal bovine serum plus 1% penicillin/streptomycin) prior 
to cryogenic storage.  
 
Genotype Analysis 
Genomic DNA was genotyped using a PCR-based method.  Mapk8LoxP (540 bp) 
and Mapk8+ (330 bp) were detected using amplimers 5’-
AGGATTTATGCCCTCTGCTTGTC-3’ and 5’-
GACCACTGTTCCAATTTCCATCC-3’.  Mapk9LoxP (264 bp) and Mapk9+ (224 bp) 
were detected using amplimers 5’-GTTTTGTAAAGGGAGCCGAC-3’ and 5’-
CCTGACTACTGAGCCTGGTTTCTC-3’.  Trp53LoxP (370 bp) and Trp53+ (288 bp) 
were detected using amplimers 5’-AGCACATAGGAGGCAGAGAC-3’ and 5’-
CACAAAAACAGGTTAAACCCAG-3’.  Cre+ (450 bp) was detected using 
amplimers 5’-TTACTGACCGTACACCAAATTTGCCTGC-3’ and 5’-
CCTGGCAGCGATCGCTATTTTCCATGAGTG-3’.  Mapk8Δ (395 bp), Mapk8+ 
(1550 bp), and Mapk8LoxP (1,095 bp) were detected using amplimers 5’-
CCTCAGGAAGAAAGGGCTTATTTC-3’ and 5’-
GAACCACTGTTCCAATTTCCATCC-3’.  Mapk9Δ (400 bp) and Mapk9LoxP (560 
bp) were detected using 5’-GGAATGTTTGGTCCTTTAG-3’, 5’-
GCTATTCAGAGTTAAGTG-3’, and 5’-TTCATTCTAAGCTCAGACTC-3’.  Trp53Δ 
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(612 bp) was detected using amplimers 5’-GAAGACAGAAAAGGGGAGGG-3’ 
and 5’-CACAAAAACAGGTTAAACCCAG-3’.   
 
Orthotopic Transplantation 
Tumor-derived cell lines were screened for common pathogens using the 
Rapidmap panel 21 (Taconic). The cells were pelleted and washed 5 times with 
PBS before resuspension at a final concentration of 2x106 or 0.5x106 cells/40 µl 
of PBS. A 26 guage needle was used to inject the cells into the thoracic 
mammary gland. The presence of tumors was monitored weekly and palpable 
tumors were measured using calipers. Mice meeting euthanasia criteria or mice 
that remained 80 days post-inoculation were euthanized.  
 
Cell Proliferation 
Cells were seeded in 96-well plates (1,000 cells/well) and cultured in an IncuCyte 
Zoom (Essen Bioscience). The cells were kept in growth media and fed every 2 
days for the duration of the assay. Images were taken every 4h and cell 
confluence was measured at these time points.  
 
Soft Agar Growth 
Agarose (Lonza) was dissolved in water (4% or 2% (w/v) solution) and 
autoclaved. The 4% agarose was mixed with growth media to yield a 1% agarose 
solution, which was plated and allowed to solidify (4°C). Tumor cells in growth 
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media (100,000/ 6cm dish) were mixed with the 2% agarose to a final 
concentration of 0.5% agarose, and overlayed onto the solidified 1% agarose. 
The cells were fed with Growth Medium every 3~4 days for the duration of the 
assay. After 3 weeks, the cells were fixed with 100% methanol (-20°C) and 
stained with 0.1% crystal violet dissolved in 20% methanol / 80% PBS. Images 
were taken using a Zeiss AxioVert 200M. Six 10x-fields/plate were used to 
quantify colony formation using FIJI software (Schindelin et al. 2012). 
 
Mammosphere Assay 
Tumor cells were seeded 25,000/ml in a 24-well ultra-low attachment plate in 
DMEM/F12 media containing 1% penicillin/streptomycin, B27 supplement (1:50), 
20 ng/ml bFGF, 2.5 µg/ml insulin, and 20 ng/ml EGF. Six wells were plated for 
each cell line. Three to four days later, before passaging, colonies larger than 50 
µm were counted using a Zeiss AxioVert 200M microscope. The spheres were 
dissociated by incubation (15 min) with 0.25% trypsin (Thermo Fisher Scientific) 
with pipetting. The digestion was terminated by addition of 0.5% soybean trypsin 
inhibitor (ATCC) and single cells were plated. Spheres used for embedding in 
agarose or for RNA isolation were treated similarly, but were cultured in 100 mm 
ultra-low attachment dishes. Spheres prepared for embedding were resuspended 
in 4% agarose (IBI Scientific Cat# IB70050), and fixed in 10% formalin before 
processing.  
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Anoikis Assay 
Tumor cells were suspended in serum-free DMEM/F12 media with 0.5% 
methylcellulose (Millipore-Sigma), placed in poly-HEMA (Millipore-Sigma) coated 
plates (1.2x105 cells/ml), and incubated for 24 h. After incubation, the cells were 
washed twice with PBS, then stained with phycoerythrin-conjugated Annexin V 
and 7-aminoactinomycin D (7-AAD) using the PE annexin apoptosis detection kit 
I (BD Pharmingen #559763). A FACSCalibur (BD Bioscience) was used to 
quantify the apoptotic cells (7AAD- Annexin V+). Single-stained controls were 
used to gate 7AAD- and 7AAD+ cells while cells suspended for 1 h were used to 
define the annexin V+ and annexin V- populations. FlowJo version 9.7.6 (Tree 
Star) was used to analyze the data (Girnius and Davis 2017a). 
 
Wound Healing 
Tumor cells were seeded at a density of 100,000 cells/well in a 96-well 
ImageLock plate (Essen Bioscience) and allowed to adhere overnight. The 
following day, a Wound Maker (Essen Bioscience) was used to scratch the 
confluent monolayers of cells. The cells were washed 2 times with PBS and then 
maintained in serum-free media for the remainder of the assay. Invasion assays 
were performed using cells plated in 96-well ImageLock plates coated with 300 
µg/ml collagen I. Cells adhered overnight, were scratched using a WoundMaker, 
and washed twice with media before being placed on ice (5 min). The cells were 
then overlayed with growth media containing collagen I (0.5 mg/ml). The cells 
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were incubated (30min at 37°C) to solidify the collagen prior to the addition of 
DMEM/F12 supplemented with 2% FBS. All plates were imaged every 4h using 
an IncuCyte Zoom (Essen Bioscience). 
 
Transwell Migration 
Tumor cells (30,000 cells/well) were plated in triplicate using Growth Medium in 
transwells with 8 µm pores (Millipore Sigma) and allowed to adhere. For invasion 
assays, inserts coated with Matrigel (Millipore Sigma) were rehydrated according 
to the manufacturer’s instructions before plating cells. To create a serum 
gradient, media from the upper chambers was replaced with serum-free media. 
Cells were allowed to migrate for 16-20 h. Remaining cells in the upper 
chambers were removed with a cotton swab, then the inserts were fixed with 
100% methanol (20 min, -20°C), washed 3 times with PBS, and stained with 2-
(4-amidinophenyl)-1H -indole-6-carboxamidine (DAPI). The insert membranes 
were removed with a scalpel and mounted on a slide for examination using a 
Zeiss Axiovert 200M microscope. Two to three images at 10x magnification were 
taken for each membrane. FIJI was used to quantify the migrating cells 
(Schindelin et al. 2012). 
 
Histological Analysis 
Mammary glands #2-5 were harvested, fixed in 10% formalin, dehydrated, and 
embedded in paraffin. Hematoxylin and eosin-stained sections (5 µm) were 
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reviewed by a board-certified veterinary pathologist to identify and classify 
proliferative lesions (Cardiff et al. 2000). To detect proliferation, sections were 
treated with the endogenous biotin blocking kit (Thermo Fisher Scientific 
E21390), prior to incubation with a biotin-conjugated antibody to PCNA (Thermo 
Fisher Scientific Cat# 13-3940 RRID:AB_2533; dilution 1:50), and an AlexaFluor 
633-conjugated streptavidin (Thermo Fisher Scientific Cat# S-21375 
RRID:AB_2313500). For PCNA quantification 49-50 fields were examined across 
JNKWT (n=4) and JNKKO (n=5) mice. PCNA positive duct cells were normalized to 
the total number of duct cells in the field examined. Additional sections were 
stained with cleaved-caspase-3 (Cell Signaling Technology Cat# 9662 
RRID:AB_331439; 1:100), keratin 5 (BioLegend Cat# 905501 
RRID:AB_2565050; 1:50), keratin 8 (DSHB Cat# TROMA-I RRID:AB_531826; 
1:100), GFP (Thermo Fisher Scientific Cat# A21311 RRID:AB_221477; 1:100), 
estrogen receptor (Santa Cruz Biotechnology Cat# sc-542 RRID:AB_631470; 
1:500), and progesterone receptor (Santa Cruz Biotechnology Cat# sc-538 
RRID:AB_632263; 1:300). For immunohistochemistry, a biotinylated rabbit 
antibody (Biogenex Cat# HK340-5K) in conjunction with streptavidin-conjugated 
horseradish peroxidase (Vector Laboratories Cat# PK-6100) and 3,3’-
diaminobenzidene (Vector Laboratories Cat# SK-4100) was used to detect the 
primary antibody. Sections were then counterstained with hematoxylin (Fisher 
Scientific) and pictures were taken using a Zeiss Axiovert. AlexaFluor 546 
conjugated-goat anti-rabbit IgG (H+L) antibody (Thermo Fisher Scientific Cat# 
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A11035 RRID:AB_143051) and AlexaFluor 488 conjugated-goat anti-rat IgG 
(H+L) antibody (Thermo Fisher Scientific Cat# A11006 RRID:AB_141373) were 
used to detect immune complexes in co-staining experiments. These sections 
were counterstained with DAPI and immunofluorescence was examined using a 
Leica SP2 confocal microscope. 
 
Immunoblot Analysis 
Cell lysates were prepared using Triton lysis buffer (20 mM Tris [pH 7.4], 1% 
Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM β-
glycerophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl 
fluoride, and 10μg/mL of aprotinin and leupeptin). Extracts (30 µg) were 
examined by immunoblot analysis by probing with antibodies to phospho-ERK 
(Cell Signaling Technology Cat# 9101 RRID:AB_2315114), ERK2 (Santa Cruz 
Biotechnology Cat# sc-1647 RRID:AB_627547), phospho-JNK (Cell Signaling 
Technology Cat# 9255 RRID:AB_2307321), JNK (R & D Systems Cat# AF1387 
RRID:AB_2140743R&D), p38 (Cell Signaling Technology Cat# 9212 
RRID:AB_330713), phospho-p38 (Cell Signaling Technology Cat# 9211 also 
9211L, 9211S RRID:AB_331641), phospho-JUN (S63) (Cell Signaling 
Technology Cat# 9261L RRID:AB_2130159), JUN (Santa Cruz Biotechnology 
Cat# sc-1694 RRID:AB_631263), p-AKT (T308) (Cell Signaling Technology Cat# 
5106S RRID:AB_836861), p-AKT (S473) (Cell Signaling Technology Cat# 9271 
RRID:AB_329825), AKT (Cell Signaling Technology Cat# 9272 
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RRID:AB_329827), and α-Tubulin (Millipore-Sigma Cat# T5168 
RRID:AB_477579). IRDye 680LT conjugated-donkey anti-mouse IgG antibody 
(LI-COR Biosciences Cat# 926-68022 RRID:AB_10715072) and IRDye 800CW 
conjugated-goat anti-rabbit IgG (LI-COR Biosciences Cat# 926-32211 
RRID:AB_621843) were used to detect and quantitate immune complexes with 
the Odyssey infrared imaging system (LI-COR Biosciences). 
 
Exome Sequencing 
Genomic DNA was isolated from cancer cell lines using the DNEasy kit, including 
RNase treatment (Qiagen). For each genotype, a control sample was generated 
by isolating genomic DNA from mammary glands of a virgin mouse of the same 
genotype. Whole exome sequencing libraries were prepared using the Agilent 
SureSelect XT library preparation kit. DNA (OD260/280 1.7-2.0 and 
OD260/230>2.0) was sheared using a Covaris LE220. End-repaired, adenylated 
DNA fragments were ligated to Illumina sequencing adapters and amplified by 
PCR. Exome capture was performed using the Agilent SureSelect Mouse All 
Exon (50 mb) capture probe set; captured exome libraries were enriched by 
PCR. Final libraries were quantified using the KAPA Library Quantification Kit 
(KAPA Biosystems), Qubit Fluorometer (Life Technologies) and Agilent 2100 
BioAnalyzer, and were sequenced on an Illumina HiSeq2500 machine using 
2x125 bp cycles. Single nucleotide variants were reported as the union of SNVs 
called by muTect (Cibulskis et al. 2013), Strelka (Saunders et al. 2012), and 
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LoFreq (Wilm et al. 2012) and indels were reported as the union of indels called 
by Strelka, somatic versions of Pindel (Ye et al. 2009) and Scalpel (Narzisi et al. 
2014). ExomeCNV was run with default settings using mm10 reference to 
generate copy-number calls (Sathirapongsasuti et al. 2011). The segmentation 
and log2 ratios from ExomeCNV output were used to identify amplified, deleted 
and copy-neutral regions. Log2 thresholds of >0.2 and <-0.2 were used to label a 
segment as amplified or deleted, respectively, and the segments were visualized 
(Krzywinski et al. 2009). Bedtools (Quinlan and Hall 2010) was run to identify 
genes overlapping copy-number segments. 
 
Analysis of mRNA Expression 
Cellular RNA was isolated using the RNeasy kit with DNase treatment (Qiagen) 
and RNA quality (RIN>9) was confirmed using the Bioanalyzer 2100 system 
(Agilent Technologies). Libraries were constructed according to the 
manufacturer’s instructions (Illumina). Two to three libraries were analyzed for 
each condition. Single-end sequencing with reads of 40 bp reads (for JNKWT and 
JNKKO) was performed on a HiSeq 2000 platform and paired-end sequencing 
with 150 bp reads (for MEC and MEKO) was performed on a NextSeq500 platform 
(Figure IV.4) (Illumina). Poor quality reads, adapter sequences, and reads less 
than 40 bp were removed using Trimmomatic (version 0.36) (Bolger et al. 2014). 
First, the MEC and MEKO biological groups were analyzed (Figure IV.4). Second, 
to adequately compare the four biological groups (MEC, MEKO, JNKWT, and 
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JNKKO), seqtk was used to sample sequences averaging 40 million single-end 
reads per sample (Figure IV.9A) (Li 2017). Reads were aligned to the mouse 
genome mm10 using Bowtie2 (v 2-2.1.0) (Langmead and Salzberg 2012) and 
Tophat2 (v 2.0.14) (Kim et al. 2013). Samtools (version 0.0.19) (Li et al. 2009) 
and IGV (version 2.3.60) (Thorvaldsdottir et al. 2013) were used for indexing the 
alignment files and viewing the aligned reads respectively. Cufflinks (v 2.2.1) 
(Trapnell et al. 2010; Trapnell et al. 2012) was used to quantitate gene 
expression as fragments per kilobase of exon model per million mapped 
fragments (FPKM); differential expression was identified using the Cufflinks tools, 
Cuffmerge and Cuffdiff. Cummerbund version 2.4.1 (Trapnell et al. 2012) was 
used to assess replicate concordance. The complex heatmap package version 
1.12.0 (Gu et al. 2016) was used to generate heatmaps of differentially 
expressed (q<0.05, |log2Fold Change|>0.75) genes. Gene set enrichment 
analysis was performed on differentially expressed genes using the WEB-based 
GEne SeT AnaLysis Toolkit (Webgestalt) (Wang et al. 2013) with the KEGG 
database. Ingenuity Pathway Analysis (Qiagen) was used to predict pathway 
activation based on differentially expressed genes. The top 100 pathways ranked 
by score (the sum across tumor genotypes of -log10 p-value calculated by 
Fisher’s exact test) were identified. Treeview (Java) (Saldanha 2004) was used 
to make heatmaps showing pathway activation z-scores. 
The expression of mRNA was also determined by RT-PCR using a 
Quantstudio 12K Flex machine (Thermo Fisher Scientific). TaqMan® assays were 
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used to quantify the expression of Bmi1 (Mm03053308_g1), Pou5f1 
(Mm03053917_g1), and Nanog (Mm02019550_s1). Relative expression was 
normalized to the expression of 18S RNA in each sample using Taqman© assays 
(catalog number 4308329; Thermo Fisher Scientific). 
 
Quantification and Statistical Analysis 
Data are presented as the mean and standard error. Statistical analysis was 
performed using GraphPad Prism version 7 (GraphPad Software). ANOVA with 
Bonferroni’s test was used to determine significance with an assumed confidence 
interval of 95%. Two-tailed, unpaired t-test with Welch’s correction was used for 
pairwise comparisons. Chi-squared was used to determine differences in litter 
survival and Fisher’s exact test was used to determine differences in tumor or 
MIN incidence. Kaplan-Meier analysis of mammary tumor-free survival was 
performed using the log-rank test. Statistical significance was defined as p<0.05. 
 
Data Availability 
The raw data has been deposited in the Mendeley repository 
(https://data.mendeley.com/datasets/fzygb8drwc/draft?a=136fb1fa-23b4-4272-
adc4-76800ee14b4c ) . The RNA-seq raw data files have been deposited with 
NCBI; GEO accession numbers GSE100581 and GSE92560. The exome 
sequence data were deposited with NCBI; SRA accession number 
PRJNA401332.  
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CHAPTER V 
DISCUSSION AND FUTURE DIRECTIONS 
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Discussion 
The JNK pathway is required during developmental morphogenesis and its de-
regulation can promote disease (Davis 2000; Manning and Davis 2003).  The 
context-specific responses of this pathway require systematic characterization of 
its roles in different cell types under varied conditions.  To this end, I sought to 
study the importance of JNK in epithelial cells.  In particular, I focused on aspects 
of mammary gland biology to elucidate how JNK signaling may participate in 
breast carcinogenesis.  I found that suspended epithelial cells require JNK for 
efficient anoikis (Chapter II).  Also, JNK in the mammary epithelium promotes cell 
death during post-lactational involution, and its absence results in substantial 
disruption of the involution gene expression program (Chapter III).  Finally, JNK 
loss is sufficient for mammary carcinogenesis and accelerates transformation in 
a model of breast cancer (Chapter IV).  Collectively, this work furthers our 
understanding of how JNK promotes cell death and it establishes the JNK 
pathway as a regulator of mammary epithelial cells at several stages of 
mammary gland development (Figure V.1). 
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Figure V.1.  JNK participates in several aspects of mammary gland biology. 
Prior to these studies, the requirement of JNK for branching morphogenesis and luminal 
clearance had been established.  In the current body of work, I show that JNK in the 
mammary epithelium suppresses carcinogenesis and promotes involution after lactation.  
Additional work will be needed to determine if JNK contributes to the development of the 
gland during pregnancy and lactation. 
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Anoikis – suspension-induced cell death – is important in the mammary 
gland for ductal clearance during pubertal development (Humphreys et al. 1996).  
It is also a barrier that transformed cells must overcome during disease initiation 
to expand into luminal spaces (Taraseviciute et al. 2010; Leung and Brugge 
2012; Pradeep et al. 2012) and during metastasis to travel to distant sites 
(Douma et al. 2004).   Among the proteins involved in anoikis are the pro-
apoptotic BH3-only proteins BIM and BMF (Reginato et al. 2003; Mailleux et al. 
2007; Schmelzle et al. 2007) that can initiate cell death by promoting BAK/BAX-
mediated cytochrome c release from mitochondria (Huang and Strasser 2000; 
Pinon et al. 2008; Czabotar et al. 2014). 
The ability of the JNK pathway to mediate cell death and survival 
decisions make it an appealing candidate for regulating anoikis.  However, JNK 
responses to stress stimuli are selective, as JNK is required for UV-induced 
apoptosis, but does not contribute to cell death mediated by the FAS and TNFR1 
cell surface receptors (Tournier et al. 2000; Lamb et al. 2003; Das et al. 2009).  
Early studies testing the importance of JNK in anoikis used dominant-negative 
mutants and arrived at contradicting conclusions (Frisch et al. 1996; Khwaja and 
Downward 1997).  In later studies, in vitro acinar formation assays (Zhan et al. 
2008; McNally et al. 2011) as well as observations from mammary gland 
development (Cellurale et al. 2012) showed that JNK pathway inactivation results 
in luminal infilling, supporting a role for JNK in anoikis.  Using chemical inhibition 
and genetic ablation of JNK, I demonstrate that JNK indeed promotes anoikis 
197 
 
 
(Figures II.1 & II.2).  Furthermore, JNK regulation of anoikis occurs in both 
human and murine cells, indicating a conserved function for JNK during this 
process. 
JNK-mediated anoikis relies on activating the BIM/BMF-BAK/BAX 
pathway (Figures II.5 & II.10).  Previous work showed that JNK activates BIM 
and BMF by phosphorylating dynein light chain binding motifs to promote their 
translocation to mitochondria where they activate BAK/BAX (Lei et al. 2002; Lei 
and Davis 2003; Hubner et al. 2008; Hubner et al. 2010).  Mutation of this site on 
BMF (Ser74 to Ala) increases cell survival during suspension (Figure II.15).  
However, mutating the analogous site on BIM (Thr112 to Ala) did not result in 
increased survival during cell suspension (Figure II.15), indicating that JNK 
phosphorylation of BIM at Thr112 is not required for anoikis. 
Altering gene expression through AP1 transcription factors such as cJUN 
constitutes another mechanism by which JNK could promote anoikis (Davis 
2000).  Indeed, Bcl2l11 (encoding BIM) is a cJUN target gene (Whitfield et al. 
2001).  In the absence of JNK activity, suspended cells expressed lower levels of 
Bcl2l11 mRNA (Figure II.1E & II.8) and BIM protein (Figure II.7), while Bmf 
mRNA levels were independent of JNK (Figure II.1E & II.8).  Suspension culture 
also did not alter BMF protein levels (Figure II.7), suggesting that BMF 
participation in anoikis is regulated by its cellular localization.  Collectively, these 
data show that JNK promotes anoikis at the level of transcription (Bcl2l11) and 
protein phosphorylation (BMF) (Figure V.2). 
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Figure V.2.  JNK promotes anoikis through transcriptional regulation of BIM and 
phosphorylation of BMF. 
When epithelial cells become detached, activated JNK can increase expression of BIM 
and phosphorylate BMF to induce anoikis.  Thus, transcription factor and non-
transcription factor targets of JNK contribute to its regulation of suspension-induced 
death. 
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The JNK-dependent expression of Bcl2l11 appears to be a general 
phenomenon.  Both human mammary epithelial cells (Figure II.1E) and mouse 
kidney epithelial cells (Figure II.8A & II.9B) require JNK to induce Bcl2l11 during 
anoikis.  JNK was also needed for Bcl2l11 induction during mammary gland 
involution (Figure III.15A, C).  Furthermore, the similar phenotypes observed in 
developing JNK-deficient (Cellurale et al. 2012) and BIM-deficient (Figure II.12A 
& Mailleux et al. 2007) mammary glands suggests that these proteins may 
participate in the same pathway during lumen formation in terminal end buds 
(TEB).  However, elimination of the JNK phosphorylation site on BIM (Thr112 
replacement with Ala) did not result in occluded TEBs (Figure II.16), indicating 
that phosphorylation of this site is not needed for luminal clearance.  Together, 
these observations suggest that JNK-mediated BIM expression also constitutes 
part of the TEB clearance program.  
The transcription factor responsible for JNK-mediated Bcl2l11 induction 
during anoikis and involution was not identified.  However, cJUN, a major target 
of JNK (Davis 2000) and a positive regulator of Bcl2l11 expression in neurons 
(Whitfield et al. 2001), is an appealing candidate.  In the context of involution, two 
additional pieces of evidence implicate cJUN: (1) cessation of suckling increases 
phosphorylation cJUN and AP1 DNA binding activity (Jaggi et al. 1996), and (2) 
the differentially expressed genes in involuting JNKKO glands show significant 
enrichment for cJUN/JUND binding sites (Figure III.12). 
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The JNK-dependent expression of Bcl2l11 in the involuting mammary 
gland may partially account for the promotion of involution by JNK (Figure III.2 & 
III.3).  However, the involution defect in JNKKO mice (Figure III.2) is more severe 
than the defect observed in Bcl2l11-/- mice (Sakamoto et al. 2016; Schuler et al. 
2016), indicating that JNK loss affects additional proteins.  Indeed, of the more 
than 10,000 genes that are differentially expressed during involution, 26% rely on 
an active JNK pathway (Figure III.10A).   
Among the groups of genes that exhibit JNK-dependent expression 
(Figure III.10C) and cJUN/JUND binding (Figure III.12) are matrix 
metalloproteases (Figure III.13) and cathepsins (Figure III.14), both of which 
promote involution (Lund et al. 1996; Kreuzaler et al. 2011).  JNK deficiency 
during involution also resulted in decreased expression of the AP1 members 
ATF3 and FOSL2 (Figure III.9).  Thus, these transcription factors may contribute 
to the delayed gland remodeling observed in JNKKO glands (Figure III.2 & III.3).  
These observations indicate that JNK is a major regulator of the gene expression 
program that enables mammary gland remodeling after lactation.   
In addition to elucidating developmental processes, studying the pathways 
that lead to cell death advances our understanding of carcinogenesis.  
Overcoming anoikis is considered an early step in tumor development 
(Taraseviciute et al. 2010; Leung and Brugge 2012; Pradeep et al. 2012).  
Inhibition of anoikis is also necessary for tumor cell metastasis (Douma et al. 
2004).  Thus, the ability of JNK to promote anoikis suggests that it may suppress 
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cancer.  Indeed, in my breast cancer model, JNK loss on a sensitized 
background accelerates disease initiation (Figure IV.4A).  These JNK-deficient 
tumor cells are largely similar to cells isolated from control tumors (Figure IV.14).  
However, JNK-deficient tumor cells have increased survival in suspension and 
they form more colonies in soft agar (Figure IV.14E-G).  These observations 
indicate that loss of JNK in tumor cells reduces their sensitivity to anoikis.  
Furthermore, JNK-deficient mice exhibit mammary epithelial cell proliferation into 
the lumens earlier than Controls (Figure IV.15B, C).  Considering that members 
of the JNK pathway are frequently mutated in human breast cancer (Nik-Zainal et 
al. 2016a), these observations have important implications for understanding 
disease initiation and progression.   
The roles of the JNK pathway during puberty (Cellurale et al. 2012), 
involution (Chapter III), and mammary carcinogenesis (Chapter IV) illustrate its 
importance in mammary gland biology.  However, the role of JNK in the gland 
during pregnancy and lactation has yet to be established (Figure V.1).  My 
observation that female mice lacking JNK in their mammary epithelium have 
difficulty supporting litters after the first litter (Figure IV.5) suggests there may be 
a defect in the mammary glands of these mice.  Whereas JNK deficiency does 
not impair mammary epithelial cell proliferation during pubertal development 
(Cellurale et al. 2012), it may be involved in the expansion of the epithelial 
compartment that occurs during pregnancy.  The role that JNK plays in cell 
survival (Lamb et al. 2003) may also be important during pregnancy and 
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lactation, when the epithelial cells must resist premature involution.  Alternatively, 
JNK pathway loss may affect the differentiation state of the epithelial cells, 
resulting in lactation defects.  Indeed, the JNK pathway is involved in lineage-
specific differentiation of embryonic stem cells (Xu and Davis 2010).  It also has 
been shown to restrict stem cell populations (Hubner et al. 2012) and regulate 
differentiation (Davies et al. 2014) in adult tissues.  In the mammary glands of 
Mapk9-/- mice, the luminal epithelial cell population is expanded (Cantrell et al. 
2015).  My data showing transdifferentiation of mammary epithelial cells that 
have lost JNK (Figure IV.2A) provides additional evidence that this pathway may 
influence mammary epithelial cell fate.  In addition to affecting the cycle of 
lactation and involution, this role for JNK could have implications for mammary 
carcinogenesis.   
The studies described herein have focused exclusively on the importance 
of JNK in epithelial cells.  However, the intricate crosstalk of epithelial and 
stromal cells regulates all stages of mammary biology and disease.  Disruption of 
JNK signaling in these stromal cells might also impact involution and mammary 
carcinogenesis.  For example, interleukin 6, a factor that promotes mammary 
gland involution (Zhao et al. 2002), has been shown to exhibit JNK-dependent 
expression in both macrophages and adipocytes (Sabio et al. 2008; Han et al. 
2013).  Similarly, JNK in macrophages induces the expression of inflammatory 
cytokines that are required for carcinogenesis in a model of hepatocellular 
carcinoma (Das et al. 2011; Han et al. 2016).  Since breast carcinogenesis also 
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exploits macrophages to promote disease progression (Lin et al. 2002; Qian and 
Pollard 2010), this role for JNK in macrophages may apply to this disease.  
Studies of JNK in the mammary stroma will likely reveal additional contributions 
of JNK to mammary gland biology, extending beyond its function in mammary 
epithelial cells.  
This work has resolved the controversy surrounding the role of JNK in 
anoikis, uncovered an unappreciated role for JNK in involution, and established 
JNK as a tumor suppressor in the mammary epithelium.  These types of studies 
are important for our understanding of when and how the JNK pathway functions.  
Since JNK inhibitors are being tested in the clinic, new insights into this pathway 
are crucial to develop better and safer therapies.  
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Future Directions 
The work described herein has established a role for JNK in anoikis and 
demonstrated that JNK is involved in several aspects of mammary gland biology.  
While these studies have advanced our understanding of this pathway and 
mammary gland biology, they have also provided additional questions that form 
the basis of future work in these fields. 
 
Future studies of JNK in anoikis: 
(1)  Hypothesis: Additional BH3-only proteins compensate for BIM and BMF in 
suspended, constitutive JNK-expressing BIM/BMFKO cells. 
In suspension culture, cell death increases in BIM/BMFKO cells expressing the 
constitutively active JNK compared to vector controls (Figure II.10).  This finding 
suggests that other BH3-only proteins compensate for BIM and BMF.  To identify 
these compensating proteins, CRISPR/Cas9 gene editing could be used in 
BIM/BMFKO cells to delete additional BH3-only proteins before inducing 
expression of the constitutively active JNK. 
(2)  Hypothesis: JNK-dependent expression of Bcl2l11 through cJUN is a major 
contributor to anoikis. 
Both chemical inhibition (Figure II.1E) and genetic ablation of JNK (Figure II.8A & 
II.9B) results in decreased Bcl2l11 expression.  Future studies could clarify the 
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importance of transcriptional regulation by JNK during anoikis and confirm that 
this regulation occurs through cJUN.  Treatment of Control and JNKKO cells with 
actinomycin D to inhibit transcription and cyclohexamide to inhibit translation 
would establish the importance of gene expression during anoikis.  To 
specifically address the question of whether Bcl2l11 expression is important for 
anoikis, a lentiviral vector expressing an inducible Bcl2l11 could be introduced 
into JNKKO kidney epithelial cells and the expression of Bcl2l11 could be titrated 
to achieve levels present in suspended Control cells.  Suspension culture 
experiments using the JUN point mutant (JUNAA) that lacks the JNK 
phosphorylation sites (Behrens 1999) would determine the importance of JNK-
mediated JUN activation in survival and gene induction during anoikis.  Finally, 
ChIP assays examining cJUN binding of Bcl2l11 would demonstrate that cJUN 
indeed regulates Bcl2l11 expression in suspended kidney epithelial cells. 
(3)  Hypothesis: Cell death during suspension requires MAP2K4 and MAP2K7. 
JNK is activated by MAP2K4 and MAP2K7 (Davis 2000).  While both kinases are 
required for full activation of JNK, they do exhibit selectivity for certain stimuli 
(Tournier et al. 2001).  Subjecting Rosa-CreERT Map2k4LoxP/LoxP, Rosa-CreERT 
Map2k7LoxP/LoxP, and Rosa-CreERT Map2k4LoxP/LoxP Map2k7LoxP/LoxP cells to 
suspension culture and monitoring JNK activation, cell death, and gene 
expression would determine the relative contributions of these kinases to anoikis. 
(4)  Hypothesis: MAP3K1 is required for JNK activation and JNK-induced anoikis. 
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The upstream signals that activate JNK in response to anoikis remain unknown.  
Using a genetic approach, I determined that the MAP3Ks MLK2 and MLK3 are 
dispensable for epithelial cell anoikis (Figure II.3) indicating some other MAP3K 
is responsible for JNK pathway activation.  MEKK1, another MAP3K, is a 
member of the JNK pathway that has been implicated in anoikis (Cardone et al. 
1997).  Using MEKK1-null cells (Yujiri et al. 1998), the role of this MAP3K in 
anoikis could be confirmed.  To determine if MEKK1 signals through JNK during 
suspension, JNK activation in MEKK1-null and control cells could be examined.  
Assuming the MEKK1-deficient cells exhibit delayed anoikis, the constitutively 
active JNK could be used to rescue anoikis in these cells.  This approach should 
be employed to assay the involvement of additional MAP3K, including MEKK2 
(Kesavan et al. 2004), TAK1 (Shim et al. 2005), and ASK1 (Tobiume et al. 2001).  
It may be necessary to examine compound deficiencies of different combinations 
of the MAP3K because they can be partially redundant (Kant et al. 2011).  
 
Future studies of JNK in mammary gland development: 
(1)  Hypothesis: JNK-mediated expression of Bcl2l11 through cJUN contributes 
to TEB clearance. 
Whole-mammary gland JNK loss leads to increased ductal branching and inhibits 
luminal cell clearance during pubertal mammary gland development (Cellurale et 
al. 2012).  Gene expression analysis performed on a selection of genes in 
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Control and JNK-deficient mammary epithelial cells revealed changes in 
expression; however these expression changes could not explain the observed 
phenotype (Cellurale et al. 2012).  It is known that loss of Bcl2l11 leads to filled 
TEB (Figure II.12 & II.13) (Mailleux et al. 2007).  Also, Bcl2l11 is down-regulated 
in JNK-deficient cells (Figure II.8A, II.9B, & III.15A, B).   Collectively, these 
observations suggest that decreased Bcl2l11 expression in JNK-deficient TEB 
epithelial cells contributes to luminal infilling.  Gene expression analysis of 
Control and JNK-deficient pubertal mammary glands would reveal if Bcl2l11 
expression is also decreased in this context.  Rescuing the occluded lumen 
phenotype in transplanted JNK-deficient mammary glands using a doxycycline-
inducible Bcl2l11 could confirm the importance of JNK-mediated BIM expression.  
Furthermore, examining mammary gland development in JUNAA (Behrens et al. 
1999) mutant females would determine if a JNK/c-JUN pathway is involved in 
TEB luminal clearance. 
(2)  Hypothesis: The JNK pathway contributes to embryonic development of the 
mammary epithelium. 
The JNK pathway is required for embryonic development (Kuan et al. 1999; 
Sabapathy et al. 1999).  It also promotes developmental processes, including 
closure of the eyelids and the optic fissure (Weston et al. 2003; Weston et al. 
2004).  The role of JNK at this stage of mammary gland development is 
unknown.  Because JNK-deficiency is embryonic lethal (Kuan et al. 1999; 
Sabapathy et al. 1999), a conditional deletion strategy must be applied.  CRE 
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recombinase expression driven by the Krt14 promoter has been used to assess 
the importance of other proteins in embryonic mammary gland development 
(Watson and Khaled 2008). Thus, Krt14-Cre+ Mapk8LoxP Mapk9LoxP mice could 
be generated to target JNK deletion to the developing mammary epithelium.  
Previous studies of JNK in development suggest that the JNK-deficient epithelial 
cells may exhibit a migration defect (Kuan et al. 1999; Sabapathy et al. 1999; 
Weston et al. 2003; Weston et al. 2004).  However, JNK is dispensable for the 
migration of kidney epithelial cells in vitro (Appendix A) and of gut and mammary 
epithelial cells in vivo (Cellurale et al. 2012).  Furthermore, unlike previously 
reported (Huang et al. 2003), JNK is not required for paxillin phosphorylation to 
promote migration (Appendix A).  An understanding of JNK during mammary 
gland development at this stage would advance our understanding of the role of 
JNK in various cellular processes.  These studies could also provide insight into 
the role of JNK during the development of branched epithelia. 
(3)  Hypothesis: The JNK pathway contributes to mammary gland development 
and function during pregnancy and lactation.   
I observed that the percentage of surviving litters decreases with each 
subsequent pregnancy for females lacking JNK in their mammary epithelium 
(Figure IV.5).  This observation suggests a defect in epithelial cell expansion and 
alveolar differentiation during pregnancy, or a lactation defect.  Gland 
morphology should be examined in late pregnancy and at parturition to determine 
whether JNK loss has prevented the elaboration and expansion of the ductal 
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network.  Furthermore, the differentiation of luminal cells to alveolar cells should 
be confirmed.  Gene expression analysis could determine if any genes involved 
in milk production or secretion have been impacted by JNK loss. 
 
Future studies of JNK in involution 
(1) Hypothesis: JNK phosphorylation of cJUN rather than BIM and BMF regulates 
involution.  
Which JNK targets are key for the progression of involution is unknown.  Since 
BIM and BMF are JNK targets that have been implicated in involution (Sakamoto 
et al. 2016; Schuler et al. 2016), they are appealing candidates.  Subjecting the 
BIMT112A and BMFS74A mutant mice to involution studies would determine if JNK 
phosphorylation of either of these effectors is important for cell death during the 
remodeling process.  These experiments could also provide evidence of the 
physiological relevance of these phosphorylation sites in vivo.  However, the 
Bcl2l11-/- and Bmf-/- involution phenotypes (Schuler et al. 2016) are not as 
dramatic as the phenotype observed in JNKKO animals (Figure III.2), suggesting 
that JNK regulation of these proteins will not account for the involution defect in 
JNKKO animals.  Instead, JNK phosphorylation of transcription factors is the more 
likely means of regulating gland remodeling.  This activation of transcription 
factors by JNK would account for the de-regulated gene expression program in 
JNKKO glands during involution (Figure III.10).  The finding that the JNK-
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dependent genes are highly enriched for cJUN binding sites implicates this AP1 
member (Figure III.12).  Involution studies together with gene expression 
analysis using the JUNAA mutant could assess the importance of JNK-mediated 
JUN phosphorylation in involution. 
(2)  Hypothesis: The AP1 members Jun, Jund, Atf3, and Fosl2 are responsible 
for the JNK-dependent gene expression program during involution.    
The expression of Jun, Jund, Atf3, and Fosl2 was significantly decreased in 
JNKKO glands during involution (Figure III.9).  To determine the relevance of this 
down-regulation and establish the relative contributions of these transcription 
factors to the involution response, mice expressing conditional Jun (Behrens et 
al. 2002), Atf3 (Taketani et al. 2012), and Fosl2 (Karreth et al. 2004) genes could 
be used. Similarly, mice expressing conditional Jund should be generated to 
study the role of JUND in involution. 
(3)  Hypothesis: Loss of JNK in mammary epithelial cells affects gene expression 
in the epithelium and stroma. 
In my approach, I used whole tissue lysates for RNA isolation and sequencing.  
The next step is to systematically dissect gene expression in different cell 
populations of the involuting gland.  This goal can be achieved by crossing 
reporter mice, for example RosamTmG mice (Muzumdar et al. 2007), to the JNKKO 
and Control animals and purifying epithelial cells before RNA isolation in order to 
determine which genes are directly affected by JNK loss.  Similarly, the 
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RosaNuTRAP (Roh et al. 2017) allele could be used to isolate epithelial cell mRNA 
and nuclei.  Comparing the gene expression changes in epithelial cells to 
changes in the whole tissue lysate could suggest which changes occur indirectly 
in other cell types as a consequences of JNK loss in epithelial cells.  Examples of 
non-epithelial changes could include different rates of repopulation by 
adipocytes, changes in immune cell infiltrates, or altered gene expression in 
stromal cells due to aberrant signals from epithelial cells as a result of JNK loss.  
Further sorting of cells for RNA isolation could be done based on cell surface 
markers. 
(4)  Hypothesis: JNK ablation in stromal cells of the mammary gland will disrupt 
involution.  
Adipocytes and macrophages participate in mammary gland remodeling after 
lactation by secreting factors that can promote involution (O'Brien et al. 2010; 
O'Brien et al. 2012; Martinson et al. 2015).  An example of a secreted factor 
implicated in promoting involution is IL6, although the source of IL6 has not been 
determined (Zhao et al. 2002; O'Brien et al. 2012).  Interestingly, Il6 exhibits JNK-
dependent expression in adipocytes and macrophages (Sabio et al. 2008; Han et 
al. 2013).  Studies of mice with JNK-deficient adipocytes and myeloid cells could 
determine the importance of JNK in these cell types during involution.  
Additionally, these studies could provide more insight into the source of IL6 and 
determine if it is expressed in a JNK-dependent manner during involution.   
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(5)  Hypothesis: The ERK and p38 MAPK pathways are regulators of involution. 
The importance of JNK during involution suggests that the other MAPK pathways 
may also participate in this process.  For example, the p38 MAPK pathway 
induces BIM expression during anoikis and is required for luminal clearance 
during pubertal mammary gland development (Wen et al. 2011).  Furthermore, it 
plays a role in luminal epithelial cell fate (Del Barco Barrantes et al. 2018).  The 
ERK pathway is also likely to contribute to involution.  It is activated during early 
involution (Zhao et al. 2002) and it can phosphorylate STAT3 (Chung et al. 
1997).  These observations together with my data regarding JNK in involution 
suggest that similar studies should be performed to establish the roles of ERK 
and p38 MAPK during involution. 
  
Future studies of JNK in breast cancer: 
(1)  Hypothesis: The early lesions in Control and JNK-deficient mammary glands 
exhibit gene expression and mutational load differences.   
Despite the dramatic acceleration of tumor onset in the absence of JNK (Figure 
IV.4A), JNK-deficient tumors closely resemble Control tumors.  This observation 
suggests that the early stages of carcinogenesis account for the different 
phenotypes.  Thus, analysis of these early lesions could be performed to gain 
insight into the mechanism of JNK tumor suppression.  These studies could 
include RNA sequencing to examine gene expression changes and pathway 
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deregulation, and DNA sequencing to determine genomic stability.  The 
RosamTmG (Muzumdar et al. 2007) allele could be used to label the mammary 
epithelial cells for isolation.  Alternatively, the RosaNuTRAP (Roh et al. 2017) allele 
could be introduced into the mice to directly isolate the mRNA and nuclei. 
(2)  Hypothesis: Map2k4 loss in the mammary epithelium accelerates 
carcinogenesis on a sensitized background. 
Mutations in MAP2K4 and MAP3K1 are frequently found in human breast cancer 
(Cancer Genome Atlas 2012; Stephens et al. 2012; Nik-Zainal et al. 2016a).  
However, JNK mutations are not.  The reason for this may be that the 
ubiquitously expressed JNK1 and JNK2 proteins have largely redundant 
functions.  It is likely that deletion of Map2k4 in this model would result in 
accelerated tumor formation.  However, MAP2K4 has additional targets.  Studies 
of Map2k4-deficient mammary epithelial cells and conditional mice will further 
uncover the role of this mutation in human disease.  Such studies considered in 
the context of my data from JNK-deficient tumors could inform the contributions 
of additional pathways (e.g., p38 MAPK) to mammary carcinogenesis. 
(3)  Hypothesis: The role of JNK in carcinogenesis depends on the genetic 
context.   
My studies demonstrate that epithelial cell JNK suppresses breast cancer.  This 
finding is somewhat surprising given that JNK activates an oncogene (cJUN) and 
that other oncogenes, such as ERBB2, may rely on JNK activity (Guo et al. 
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2006).  Furthermore, unpublished data from our lab suggest that mammary 
epithelial cells expressing activated ERBB2 require JNK for acinus formation in 
Matrigel.  To test if JNK is a tumor suppressor in other genetic backgrounds, the 
conditional JNK alleles can be crossed to a mouse expressing Erbb2-IRES-Cre 
under the control of the MMTV promoter (Ursini-Siegel et al. 2008).  In this 
mouse, JNK loss would be targeted to Erbb2-expressing mammary epithelial 
cells, and breast tumor formation could be compared to the Erbb2-IRES-Cre 
animals. 
(4)  Hypothesis: JNK loss promotes tumor cell metastasis. 
The ability of JNK to promote anoikis in epithelial cells and tumor cells suggests 
that loss of JNK may promote metastasis.  By crossing the JNK conditional 
alleles into a breast cancer model with reported metastasis, I could assay its 
importance in this process.  E-cadherin loss has been shown to increase 
metastasis of breast tumors in mice (Derksen et al. 2006).  Thus, cohorts of 
Wap-Cre-/+ Trp53LoxP/LoxP and Wap-Cre-/+ Trp53LoxP/LoxP Mapk8LoxP/LoxP 
Mapk9LoxP/LoxP mice with additional E-cadherin loss could be examined.  To 
determine if JNK loss in human breast cancer increases metastasis, a study 
could be performed examining the correlation between metastasis and MAP2K4 
or MAP3K1 mutations.   
 
215 
 
 
(5)  Hypothesis: JNK loss in tumor cells will increase cell sensitivity to certain 
treatments.  
Cancer therapies are becoming personalized, with tumor mutations informing 
treatment strategies.   One example of this type of approach is the administration 
of PARP inhibitors to patients with BRCA1/2 mutations (Sonnenblick et al. 2015).  
The loss of BRCA1/2 inactivates homologous recombination in tumor cells and 
the addition of PARP inhibitors renders them incapable of resolving DNA 
damage, leading to tumor cell death.  The JNK pathway has also been implicated 
in genome maintenance (Chen et al. 2010; Van Meter et al. 2016; Calses et al. 
2017) and in the expression of DNA damage response proteins following 
cisplatin treatment (Hayakawa et al. 2004).  Thus, tumors that have lost JNK 
pathway activity through mutations may be more susceptible to certain genotoxic 
drugs.  I have initiated studies examining this possibility (Appendix B).  
(6)  Hypothesis: JNK inhibitors can improve the response of cells to therapies 
currently used in the clinic. 
Co-treatment with a JNK inhibitor may sensitize tumor cells to drugs already 
used in the clinic, either by inactivating DNA damage repair (previous hypothesis) 
or by an alternative mechanism.  Indeed, combined JNK and RAF inhibitor 
treatment in melanoma cells that express the mutant BRAFV600E protein results in 
a substantial increase in cell death relative to RAF inhibitors alone (Fallahi-
Sichani et al. 2015).  Similarly, in triple negative breast cancer cells, co-treatment 
of lapatinib and JNK inhibitors results in enhanced cell death (Ebelt et al. 2017).  
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While promising, these findings are restricted to a small subset of tumor types.  
Exploring additional drug combinations with JNK inhibitors in more tumor cell 
lines is therefore warranted.  I have initiated these studies (Appendix B).  
(7)  Hypothesis: JNK expression in myeloid cells is required for carcinogenesis.  
JNK loss in macrophages can prevent hepatocellular carcinoma due to 
decreased inflammation (Das et al. 2011; Han et al. 2016).  Macrophages and 
the associated inflammation are implicated in breast cancer (Lin et al. 2002; Qian 
and Pollard 2010).  It is unknown if JNK deficiency in macrophages would 
similarly suppress breast cancer.  Myeloid cell-specific JNK loss in breast cancer 
models could assay the impact of myeloid JNK on mammary carcinogenesis. 
 
Final Conclusion 
In conclusion, I have established that JNK promotes anoikis and is a key player 
in mammary gland biology.  In addition to regulating normal mammary gland 
development, JNK suppresses carcinogenesis in the breast epithelium. These 
studies have answered several questions in the field and uncovered exciting new 
avenues of research.  Confirming these observations in humans will be an 
important next step.  
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APPENDIX A 
 
JNK IS DISPENSABLE FOR EPITHELIAL CELL MIGRATION 
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Abstract 
Developmental morphogenesis, maintenance of tissue architecture, healing, 
invasion, and metastasis all require cell movement.  The cJUN NH2-terminal 
kinase (JNK) pathway is required for the proper execution of several 
developmental processes that rely on cell migration.  This observation led to 
mechanistic studies that implicated JNK as a positive regulator of focal adhesion 
turnover through phosphorylation of paxillin.  However, JNK is dispensable 
during mammary epithelial cell migration through the fat pad and for gut epithelial 
cell migration along villi.  These conflicting results indicate that the role of JNK in 
cell migration may be more nuanced than previously appreciated.  Using a 
genetic ablation strategy in epithelial cells, I assayed the importance of JNK in 
migration.  I found that JNK is dispensable for both cell migration and paxillin 
phosphorylation in kidney epithelial cells.  Additionally, conditioned media from 
JNK-deficient cells did not promote Control cell migration.  These observations 
indicate that the role of JNK in migration has been over-simplified and warrants 
additional study. 
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Introduction 
Cell migration is critical during developmental morphogenesis and tissue 
homeostasis.  Dorsal closure in Drosophila requires migration of epithelial cells to 
join at the dorsal midline (Ring and Martinez Arias 1993).  Analogous processes 
occur during mammalian developmental morphogenesis to close the neural tube 
and optic fissure (Morriss-Kay 1981; Weston et al. 2003).  In the pubertal 
mammary gland, branching morphogenesis involves luminal and myoepithelial 
cell migration to elaborate the ductal network (Ewald et al. 2008).  Defects in cell 
motility would prevent the proper execution of these processes. 
Cell motility depends on dynamic assembly and disassembly of cell 
adhesions (Webb et al. 2002).  These adhesions contain many proteins, 
including paxillin, which coordinates signaling through its numerous binding sites 
and docking motifs (Schaller 2001).  Phosphorylation of paxillin at serine 178 
prevents focal adhesions from forming, keeping cells poised to migrate (Huang et 
al. 2003).  The cJUN NH2-terminal kinase (JNK) has been shown to 
phosphorylate this site, and JNK inhibition results in decreased paxillin 
phosphorylation and consequent reduced cell motility (Huang et al. 2003). 
There are 2 ubiquitously expressed JNK proteins, JNK1 and JNK2 
(encoded by Mapk8 and Mapk9), as well as the neuronally-restricted JNK3 
(encoded by Mapk10) (Davis 2000).  JNK1 and JNK2 are largely redundant 
(Tournier et al. 2000), although there is evidence for differences between their 
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function or expression (Weston et al. 2004).  JNK activation requires 
phosphorylation by both MAP kinase kinase 4 (MAP2K4) and MAP kinase kinase 
7 (MAP2K7) (Tournier et al. 2001).  These MAP2K are activated by a number of 
MAP kinase kinase kinases, or MAP3K (Davis 2000).   
Developmental defects observed in JNK pathway-deficient animals 
support a role for this pathway in cell migration.  Mice that lack MAP3K1, one of 
the MAP3K in the JNK pathway, are born with their eyes open (Yujiri et al. 2000; 
Zhang et al. 2003).  Similarly, reduced JNK protein levels (Weston et al. 2004) or 
deletion of the JNK target cJUN (Zenz et al. 2003) prevents eyelid closure in 
mice due to decreased EGFR pathway activity.  During embryonic development, 
the JNK pathway is required for neural tube closure in mice and dorsal closure in 
Drosophila (Riesgo-Escovar et al. 1996; Sluss et al. 1996; Riesgo-Escovar and 
Hafen 1997; Kuan et al. 1999; Sabapathy et al. 1999).   
These observations together with the mechanistic studies demonstrating 
paxillin phosphorylation by JNK (Huang et al. 2003) and in vitro experiments 
employing JNK inhibitors and dominant-negative mutants (Huang et al. 2004) 
have led to the conclusion that the JNK pathway is required for cell migration (Xia 
and Karin 2004).  However, in several cell types JNK is dispensable for 
migration, including intestinal and mammary epithelial cells (Cellurale et al. 
2012), mouse embryonic fibroblasts (MEFs) (Ventura et al. 2004b), and 
endothelial cells (Ramo et al. 2016).  Furthermore, in neurons JNK activity 
impedes, rather than promotes, cell migration through MARCKSL1-mediated 
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actin stabilization (Bjorkblom et al. 2012).  These data refute the notion that JNK 
is required for migration. 
To determine the importance of JNK in epithelial cell migration, I used 
kidney epithelial cells in which JNK was genetically ablated.  A comparison of 
paxillin phosphorylation in Control and JNK-deficient cells revealed no defects in 
the mutant cells, suggesting that another protein may compensate for JNK.  
Additionally, loss of JNK in these cells did not result in a migration defect and 
instead enhanced cell migration under certain conditions.  These findings 
indicate that the role of JNK in epithelial cell migration is not as simple as 
previously concluded (Xia and Karin 2004). 
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Results 
Paxillin phosphorylation at serine 178 is present in JNK-deficient cells  
To study the role of JNK in cell migration, I used the previously described Rosa-
CreERT-/+ Mapk8LoxP/LoxP Mapk9-/- kidney epithelial cells (Girnius and Davis 2017a).  
Treatment with 4-hydroxy tamoxifen ablates Mapk8, resulting in JNK-deficient 
cells (JNKKO).  Because JNK deficiency can induce cellular senescence (Das et 
al. 2007) or increased proliferation (Cellurale et al. 2012), I monitored Control 
(Rosa-CreERT-/+) and JNKKO cell growth.  Cell proliferation was comparable 
between genotypes whether cells were cultured in the presence or absence of 
serum (Figure A.1A).  Likewise, bromodeoxyuridine (BrdU) incorporation at the 
leading edge of a wound was no different between JNKKO and Control cells 
(Figure A.1B). 
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Figure A.1.  JNK-deficient cells proliferate comparably to Control cells. 
A) Rosa-CreERT-/+ (Control) and RosaCreERT-/+ Mapk8LoxP/LoxP Mapk9-/- (JNKKO) kidney 
epithelial cells were cultured in growth media and serum-free media.  Cell proliferation 
was monitored by crystal violet stain at 0, 3, 5, 6, and 7 days, and the growth relative to 
day 0 was calculated (mean ± SEM; n=2-3).  Similar data was obtained from 2 additional 
experiments. 
B)  Confluent monolayers of Control and JNKKO cells on coverslips were wounded, 
incubated with bromodeoxyuridine (BrdU, 10 µM) for 4 h, then stained with an antibody 
for BrdU and counterstained with DAPI. Scale bar = 75µm. 
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A proposed mechanism for JNK promotion of migration involves 
phosphorylation of serine 178 on paxillin by JNK, allowing turnover of focal 
adhesions (Huang et al. 2003).  To examine paxillin phosphorylation in the 
kidney epithelial cells, I irradiated Control and JNKKO cells with ultraviolet (UV) 
light to activate the JNK pathway and performed immunoblot analysis for Paxillin 
phosphorylated on serine 178.  Paxillin phosphorylation was dramatically induced 
in Control cells 60 minutes after UV exposure (Figure A.2A).  Interestingly, JNKKO 
cells also had substantially elevated levels of phospho-Ser178 Paxillin at 60 
minutes after UV exposure (Figure A.2A).  Furthermore, phosphorylated Paxillin 
was also evident in Control and JNKKO cells 30 minutes post-UV exposure 
(Figure A.2B), indicating that JNK is not necessary for this phosphorylation event. 
To determine whether the JNK pathway was necessary for paxillin 
phosphorylation in another cell type, I exposed JNK pathway-inactivated Map2k4-
/- Map2k7-/- immortalized MEFs to UV.  Phosphorylation of serine 178 on paxillin 
was evident in the Control cells following UV exposure (Figure A.2C).  Map2k4-/- 
Map2k7-/- MEFs also exhibited paxillin phosphorylation, albeit at lower levels than 
the Control cells indicating less phosphorylation or increased de-phosphorylation 
(Figure A.2C).  These results indicate that another kinase (or kinases) is able to 
phosphorylate paxillin on Ser178.  Thus, JNK is not required for phosphorylation of 
Paxillin at Ser178. 
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Figure A.2  Paxillin is phosphorylated at serine 178 in cells despite JNK pathway 
inactivation. 
A)  Control and JNKKO kidney epithelial cells were exposed to 60 J/m2 of ultraviolet light 
(UV) and cultured for the indicated times before cell lysates were prepared.  Immunoblot 
analysis was performed using antibodies for Paxillin phosphorylated at serine 178 (p-
Paxillin), Paxillin, and JNK.  α-Tubulin served as a loading control. 
B)  Cell lysates were made from Control and JNKKO kidney epithelial cells 30 minutes 
after UV (60 J/m2) exposure.  Immunoblot analysis for Paxillin and p-Paxillin.  α-Tubulin 
served as a loading control. 
C)  Immortalized Control and Map2k4-/- Map2k7-/- mouse embryonic fibroblasts were 
cultured post-UV exposure for the indicated times.  Immunoblot analysis was performed 
on cell lysates using antibodies for Paxillin and p-Paxillin.  α-Tubulin served as a loading 
control. 
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JNK is not required for cell migration 
The observation that JNK is not required for Paxillin phosphorylation suggested 
that the JNKKO kidney epithelial cells would not exhibit a migration defect.  To test 
this hypothesis, confluent monolayers of Control and JNKKO cells growing on 
collagen I, collagen IV, fibronectin, or laminin were scratched with a pipet tip and 
monitored for infilling of the scratched area.  In these “wound healing assays”, 
the epithelial cells moved as sheets to “heal” the wound made by scratching.  
The Control cells had closed approximately 20-30% of the original wound 24 h 
after assay initiation, regardless of the surface coating (Figure A.3A).  While the 
JNKKO cells migrating on collagen I and laminin coated surfaces had healed 
similarly to Control cells after 24 h, the JNKKO cells migrating on collagen IV, 
fibronectin, or tissue culture dishes healed wounds faster than Control cells 
(Figure A.3A).  Analysis of wound healing after 48 h of migration showed that 
JNKKO cells migrating on any of the tested substrates healed more of the original 
wound area than Control cells (Figure A.3B).  Continuous monitoring of wound 
closure (4 h intervals) similarly showed that JNK-deficient cells migrated more 
rapidly than Control cells (Figure A.3C). 
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Figure A.3.  Compound JNK-deficiency does not inhibit migration of kidney 
epithelial cells. 
A, B)  Confluent monolayers of Control and JNKKO kidney epithelial cells were wounded 
and given low serum media.  After 24 (A) or 48 (B) h the wound area was quantified and 
the percent healed was calculated based on the wound width at 0 h (mean ± SEM; 
**p<0.01, ***p<0.001, n=9-14).  Similar data were obtained from 2 additional 
experiments.  
C, D)  Migration of confluent monolayers of Control and JNKKO kidney epithelial cells 
(n=24) (C), or Control, JNKKO, and JNKΔ/Δ (Mapk8f/f Mapk9f/f Rosa-CreERT) cells (n=7-8) 
(D) was monitored continuously every 4 h for 48 h using an IncuCyte ZOOM.  The 
wound density was quantified (mean ± SEM; ***p<0.001).  Similar data were obtained 
from 2 (C) or 1 (D) additional experiment.  
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E)  Control and JNKKO kidney epithelial cells were plated in transwells coated with the 
indicated matrix proteins.  Migration was induced with a serum gradient (0 to 10%).  
After 20 h, migrating cells were quantified (mean ± SEM of migrating cells/40x field).  
Similar data were obtained in 2 additional experiments. No significant differences were 
observed (p>0.05, n=3). 
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Throughout their life, the JNKKO cells never expressed JNK2.  Thus, the 
observed migration phenotype could be the result of compensation that occurred 
as a result of the absence of JNK2.  To eliminate this possibility and confirm that 
JNK ablation promotes wound closure, I assayed the migration of Rosa-CreERT-/+ 
Mapk8LoxP/LoxP Mapk9LoxP/LoxP (JNKΔ/Δ) kidney epithelial cells.  In contrast to the 
JNKKO cells, these cells expressed both JNK proteins throughout development 
and had only experienced JNK loss after 4-hydroxy tamoxifen administration.  
Like the JNKKO cells, the JNKΔ/Δ cells migrate comparably to Control cells.  
However, the JNKΔ/Δ cells do not exhibit the significantly increased rate of wound 
closure observed in the JNKKO cells (Figure A.3D). 
To examine individual cell migration instead of epithelial sheet migration, I 
performed Boyden chamber assays with collagen I, collagen IV, fibronectin, 
laminin, matrigel, or uncoated transwells.  Regardless of transwell coating, there 
were no significant differences (p>0.05) between Control and JNKKO cell 
migration (Figure A.3E).  Taken together, these data show that JNK is not 
essential for kidney epithelial cell migration. 
 
JNK inhibitors produce different migration phenotypes 
The evidence for JNK pathway promotion of migration comes largely from JNK 
inhibitor-based approaches (Huang et al. 2003; Huang et al. 2004).  To test how 
drugs targeting the JNK pathway would impact kidney epithelial cell migration, 
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wound healing assays were performed in the presence of the commonly used 
JNK inhibitor SP600125.  Surprisingly, SP600125 significantly increased Control 
and JNKKO cell migration relative to their respective vehicle treated controls 
(Figure A.4A).  This finding suggests that the previously observed changes in cell 
migration during JNK pathway inhibition may be the result of off-target effects of 
SP600125 (Bain et al. 2007). 
A more specific JNK inhibitor (JNK-IN-8) has been developed (Zhang et 
al. 2012).  Treatment of Control and JNKKO cells with JNK-IN-8 had no effect on 
wound closure (Figure A.4B).  Unlike treatment with SP600125 (Figure A.4A), 
JNK-IN-8 treatment did not enhance cell migration in either genotype (Figure 
A.4B).  In the context of the JNK-deficient cells, this observation supports the 
conclusion that JNK-IN-8 is a highly specific JNK inhibitor.  The inability of JNK-
IN-8 treatment of Control cells to phenocopy genetic ablation of JNK may be 
evidence of off-target effects of the inhibitor or compensation in the JNK-deleted 
cells.  Nevertheless, JNK-IN-8 treatment of Control cells also did not inhibit cell 
migration (Figure A.4B). 
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Figure A.4.  Motility of Control cells is not repressed by JNK inhibitor treatment. 
A, B)  Confluent monolayers of Control and JNKKO kidney epithelial cells were wounded 
and given low serum media with or without different JNK inhibitors (40 µM SP600125 in 
A (n=6-18) or 5 µM JNK-IN-8 in B (n=3-10)).  Wound density was quantified every 4 h for 
48 h using an IncuCyte ZOOM (mean ± SEM; *p<0.05, ***p<0.01).  Similar data were 
obtained in an additional experiment. 
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  The enhanced migration in cells with genetic JNK inactivation may be the 
result of time course effects of JNK loss.  Thus, acute loss of JNK activity through 
inhibitor treatment would produce a different migratory phenotype than JNK loss 
through gene deletion.  As an alternative means to examine acute JNK pathway 
inhibition, I tested the effects of the drug 1-naphthylmethyl-4-amino-1-tert-butyl-3-
[p-methylphenyl]pyrazolo(3,4-d)pyrimidine (NMPP1) on cells isolated from 
Mapk8-/- Mapk9MG/MG mice (Jaeschke et al. 2006).  These mice express a JNK2 
protein with an enlarged ATP binding pocket (Ventura et al. 2006) that allows 
targeted protein inhibition by treatment with NMPP1.  Treatment of Mapk8-/- 
Mapk9MG/MG with NMPP1 cells did not affect transwell migration in response to a 
serum gradient (Figure A.5A).  In wound healing assays, NMPP1 treatment of 
Mapk8-/- Mapk9MG/MG cells resulted in significantly delayed wound closure relative 
to vehicle-treated Mapk8-/- Mapk9MG/MG cells (Figure A.5B).  However, WT cells 
treated with NMPP1 also healed wounds significantly slower than the vehicle-
treated cells (Figure A.5B).  This decreased cell motility is likely the result of 
inhibition of additional kinases by NMPP1 (Bain et al. 2007).  Previous studies in 
MEFs had not observed NMPP1-mediated inhibition of cell migration in Control 
cells (Jaeschke et al. 2006).  The use of different cell types in these studies likely 
accounts for this discrepancy.  Thus, studies of the JNK pathway using drug-
based approaches must be executed with caution. 
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Figure A.5.  Treatment of kidney epithelial cells with NMPP1 decreases wound 
healing regardless of genotype. 
A)  Mapk8-/- Mapk9MG/MG cells were plated in transwells and treated with vehicle (DMSO) 
or NMPP1.  Cell migration was induced with a serum gradient (0 to 10%).  Migrating 
cells were quantified (mean ± SEM of migrating cells/40x field; n=3).  Similar data were 
obtained from 2 additional experiments. 
B)  Confluent monolayers of WT and Mapk8-/- Mapk9MG/MG cells were wounded and 
given low serum media with DMSO or NMPP1.  Wound density was monitored every 4 h 
for 48 h using an IncuCyte ZOOM (mean ± SEM; n=2-5; ***p<0.01).  Similar data were 
obtained in an additional experiment. 
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Relative contribution of JNK1 and JNK2 to migration 
JNK1 and JNK2 serve partially redundant functions (Davis 2000; Tournier et al. 
2000).  However, there are distinct roles for JNK1 and JNK2 as evidenced by the 
eyes-open-at-birth phenotype observed in Mapk8-/- Mapk9+/- mice in contrast to 
the healthy Mapk8+/- Mapk9-/- mice (Weston et al. 2004).  To assess the relative 
contributions of JNK1 and JNK2 to kidney epithelial cell migration, wound healing 
assays were performed with Mapk8-/-, Mapk9-/-, and WT cells.  Neither Mapk8-/- 
nor Mapk9-/- cells exhibited reduced cell migration (Figure A.6).  Indeed, Mapk8-/- 
cells closed wounds faster than Mapk9-/- or control cells, indicating that JNK1 
may be the major isoform inhibiting cell migration in kidney epithelial cells (Figure 
A.6). 
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Figure A.6.  Loss of JNK1 promotes wound healing. 
Migration of confluent monolayers of C57Bl6/J (WT), Mapk8-/-, and Mapk9-/- kidney 
epithelial cells was monitored every 4 h for 48 h using an IncuCyte ZOOM and wound 
density was quantitated. Data (mean ± SEM) from 1 of 2 representative experiments is 
presented (***p<0.001, n=4-5). 
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Secreted factors from JNK-deficient cells do not enhance Control cell 
migration 
The increased motility of JNK-deleted cells may be the result of a secreted factor 
that enhances migration.  Indeed, JNK deficiency in MEFs causes increased 
TGFβ expression, resulting in more motile cells (Ventura et al. 2004b).  Gene 
expression analysis demonstrated that JNKKO kidney epithelial cells expressed 
significantly increased TGFβ message compared to control cells (Figure A.7A). 
If JNK deficiency results in the production of migration-promoting secreted 
factors, then conditioned media from JNKKO cells should enhance Control cell 
migration.  To test this hypothesis, I applied conditioned media from migrating 
Control and JNKKO cells on Control cells as well as JNKKO cells.  Regardless of 
which conditioned media the cells received, monolayers of JNKKO cells healed 
wounds faster than Control monlayers (Figure A.7B,C).  Furthermore, wound 
closure by Control cells was unaffected by the media they received (Figure 
A.7B,C).  Thus, I found no evidence that the increased motility of JNKKO cells is 
the result of a secreted factor stimulating migration. 
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Figure A.7.  Cell migration in response to conditioned media. 
A)  RNA sequencing was performed on Control and JNKKO kidney epithelial cells.  The 
expression of Tgfβ1 is presented as the mean fragments per kilobase of exon model per 
million mapped fragments (FPKM) ± SEM (n=3; ***q<0.01). 
B, C)  Wound healing of confluent monolayers of Control and JNKKO kidney epithelial 
cells was monitored (48 h).  During the assay, cells were treated with media from plates 
of migrating Control or JNKKO cells.  Wound area was measured at 0, 24 and 48 h.  The 
percentage healed was calculated and expressed as mean ± SEM at 24 h (B) and 48 h 
(C). Data from 1 of 3 experiments are presented (n=6; ***p<0.001, **p<0.01, *p<0.05).  
 
  
238 
 
 
Discussion 
It is widely accepted that JNK is a key promoter of cell migration (Huang et al. 
2004).  While observations based on experiments using JNK inhibitors may 
produce misleading results, observations from developmental studies of JNK-
deficient animals support this conclusion (Riesgo-Escovar et al. 1996; Sluss et al. 
1996; Riesgo-Escovar and Hafen 1997; Kuan et al. 1999; Sabapathy et al. 1999; 
Weston et al. 2003; Weston et al. 2004).   
However, JNK-deficient adult colonic and intestinal epithelial cells show no 
defects in migration, and mammary epithelial cells devoid of JNK are also 
capable of migrating efficiently through the fat pad to elaborate ductal trees 
(Cellurale et al. 2012).  Furthermore, observations made in vitro using mammary 
epithelial cells (Cellurale et al. 2012) in conjunction with my findings (Figure A.3) 
demonstrate that JNK in several epithelial cell types is dispensable for migration.  
These conflicting results indicate that the role of JNK in cell migration is more 
complicated than was previously thought. 
How JNK regulates motility is not clear and may depend on cell type.  
Through AP1 transcription factors such as cJUN, JNK can regulate the 
expression of secreted factors that promote migration.  Examples of such 
secreted proteins include TGFβ in MEFs (Ventura et al. 2004b) or EGF in 
epidermal cells (Weston et al. 2004).  However, I found no evidence that the 
expression of secreted factors promotes JNKKO kidney epithelial cell migration 
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(Figure A.7B,C).  Whereas JNK loss may not result in the production of secreted 
factors that promote migration, it may alter the cell surface receptor repertoire of 
JNKKO cells.  The differences in receptor expression could result in different 
sensitivities to these factors.  Thus, examining candidate receptor expression 
and activation as well as downstream signaling in these two genotypes may 
reveal differences that would account for the increased motility of JNKKO cells. 
Another method for JNK to regulate migration could be through 
phosphorylation of proteins involved in migration, such as paxillin (Huang et al. 
2003).  The presence of phosphorylated paxillin in JNK-deficient cells (Figure 
A.2) indicates that another kinase (or kinases) compensates for JNK, allowing 
the kidney epithelial cells to migrate.  Alternatively, JNK phosphorylation of 
paxillin may not be required for kidney epithelial cell migration.  In neurons, JNK 
phosphorylation of MARCKSL1 results in actin stabilization and increased 
filopodia, leading to reduced migration (Bjorkblom et al. 2012).  This function of 
MARCKSL1 is dominant to paxillin: MARCKSL1 expression in MEFs reverses 
the SP600125-mediated inhibition of migration in these cells, restoring cell 
motility to normal levels (Bjorkblom et al. 2012).  The relevance of the 
JNK/MARCKSL1 pathway in kidney epithelial cell migration remains to be 
studied. 
In conclusion, my study demonstrates that the role of JNK signaling in cell 
migration is more nuanced than previously appreciated (Xia and Karin 2004).  
Based on the data presented, it is clear that kidney epithelial cells do not require 
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JNK for their motility.  Future mechanistic studies will not only clarify how JNK 
regulates kidney epithelial cell migration, but may also elucidate the reasons for 
the different migratory phenotypes observed across various cell types.  
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Materials and Methods 
Mice 
RosaCreERT-/+ Mapk8LoxP/LoxP Mapk9-/- mice (Das et al. 2007), Mapk8-/- 
Mapk9MG/MG mice (Jaeschke et al. 2006), Mapk8-/- (Dong et al. 1998), Mapk9-/- 
(Yang et al. 1998) mice, and Mapk8LoxP/LoxP Mapk9LoxP/LoxP mice (Han et al. 2013) 
have been previously described.  C57BL/6J mice (Stock # 000664; 
RRID:IMSR_JAX:000664) and B6;129-Gt(ROSA)26Sortm1(cre/ERT)Nat/J mice (Stock 
# 004847; RRID:IMSR_JAX:004847) (Badea et al. 2003) were purchased from 
Jackson Laboratories.  The mice were housed in a specific pathogen-free facility 
accredited by the American Association of Laboratory Animal Care.  Both male 
and female mice (age 8 wks) were used to establish kidney epithelial cells.  All 
animal studies were approved by the Institutional Animal Care and Use 
Committee at the University of Massachusetts Medical School. 
 
Cell culture 
Murine kidney epithelial cells were prepared (Follit et al. 2008) from kidneys of 8-
week-old mice by digestion (37°C, <2 h, shaking) with 0.1% collagenase, 0.1% 
trypsin, and 150 mM NaCl in Dulbecco’s modified Eagle’s medium (DMEM) (Life 
Technologies).  These cells were maintained in DMEM/F12 media containing 
10% fetal bovine serum (FBS) and supplemented with 150 mM urea plus 150 
mM NaCl.  Kidney epithelial cells expressing conditional alleles as well as their 
controls were treated for 24 h with 1 µM 4-hydroxytamoxifen (Millipore Sigma) to 
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induce CREERT-mediated LoxP site recombination.  C57Bl/6J and Map2k4-/- 
Map2k7-/- MEFs (Tournier et al. 2001) were immortalized using the 3T3 protocol.  
These cells were maintained in DMEM media containing 10% FBS. 
 
Proliferation Assays 
Cells were plated in 24-well plates, grown in 10% or 0.1% media, and fixed 
(100% methanol, -20°C) at different time points.  Crystal violet dissolved in 20% 
methanol / 80% PBS at 0.1% was used to stain the cells.  Proliferation was 
quantitated by extracting the crystal violet dye with 10% acetic acid and 
measuring the absorbance at 590 nm (Tecan Instruments).  To observe 
proliferation during wound healing, confluent monolayers of cells grown on glass 
coverslips were scratched with a pipet tip and incubated with 1mM 
bromodeoxyuridine (BrdU) in 0.1% serum media for 4 hrs to label proliferating 
cells.  Cells were stained according to the manufacturer’s instructions (BD), 
counterstained with 2-(4-amidinophenyl)-1H -indole-6-carboxamidine (DAPI), and 
examined using a Leica SP2 confocal microscope. 
  
Wound healing 
Confluent monolayers of cells were scratched with a pipet tip, washed, and given 
DMEM/F12 media containing 0.1% FBS.  Images were taken at 0, 24, and 48 h 
using a Zeiss Axiovert 200M microscope.  The bottom of the plates was marked 
in order to image the same area at each time point.  Wound area was quantified 
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using ImageJ (Schneider et al. 2012).  The 24 and 48 h time points were 
compared to the 0 h time point to calculate the percentage healed.  Where 
indicated, tissue culture dishes were coated with fibronectin (10µg/cm2), laminin 
(5µg/cm2), collagen I (15µg/cm2), and collagen IV (2.5µg/cm2) for 16h (37 °C), 
washed, and blocked with bovine serum albumin.  To test the involvement of 
secreted factors, media was collected from migrating monolayers, centrifuged to 
remove debris, and applied to migrating cells.  This procedure was performed at 
the start and 24 h into the wound healing assay. 
For wound healing assays using the IncuCyte ZOOM (Essen Bioscience), 
cells were plated in 96-well ImageLock plates (Essen Bioscience) to achieve 
confluent monolayers.  These were wounded using the WoundMaker (Essen 
Bioscience), washed, and given media containing 0.1% FBS.  Images were 
acquired every 4 h for 48 h and the relative wound density (cell density within the 
wound area relative to cell density outside of the wound area) was calculated. 
 
Transwell assays 
Kidney epithelial cells (6x104/well) in serum-free media were plated in the upper 
chamber of 8 µm transwells (Corning) and allowed to adhere overnight.  A serum 
gradient was applied by adding media containing 10% FBS to the lower chamber 
and allowing cells to migrate (20 h).  Following migration, cells remaining in the 
upper chambers were removed with a cotton swab.  The migrating cells were 
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fixed (100% methanol, -20°C) and stained with DAPI.  A Zeiss Axiovert 200M 
microscope was used to image 6 40x-fields per membrane for quantitation of cell 
migration.  Where indicated, both sides of transwell inserts were coated with 
fibronectin (10 µg/cm2), laminin (5 µg/cm2), collagen I (15 µg/cm2), and collagen 
IV (2.5 µg/cm2) for 16 h (37°C), washed, and blocked with bovine serum albumin. 
 
Immunoblot analysis 
Cell lysates were prepared using Triton lysis buffer (20 mM Tris [pH 7.4], 1% 
Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM β-
glycerophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl 
fluoride, and 10 μg/mL of aprotinin plus leupeptin).  Extracts (30 µg) were 
subjected to immunoblot analysis with antibodies to αTubulin (Sigma-Aldrich 
Cat# T5168; RRID:AB_477579), phospho-Paxillin (serine 178) (Bethyl 
Laboratories Cat# A300-100A), and Paxillin (Millipore Cat# 05-417, Clone 5H11).  
Immune complexes were detected with IRDye 680LT conjugated-donkey anti-
mouse IgG antibody (LI-COR Biosciences Cat# 926-68022 RRID:AB_10715072) 
and IRDye 800CW conjugated-goat anti-rabbit IgG (LI-COR Biosciences Cat# 
926-32211 RRID:AB_621843), and quantitated using the Odyssey infrared 
imaging system (LI-COR Biosciences).   
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RNA Sequencing 
RNA was isolated using the RNeasy kit (Qiagen).  RNA quality (RIN > 9) was 
verified using a Bioanalyzer 2100 System (Agilent Technologies).  Total RNA 
was used to prepare each RNA-seq library by following the manufacturer’s 
instructions (Illumina).  Three independent libraries per genotype were examined.  
The cDNA libraries were sequenced by Illumina Hi-Seq with a paired-end 40-bp 
format.  These RNA-seq data have been deposited in the Gene Expression 
Omnibus (GEO) database with accession number GSE88856.  Reads from each 
sample were aligned to the mouse genome (UCSC genome browser mm10 
build) using TopHat2 (Kim et al. 2013).  The average number of aligned reads 
per library was > 30,000,000.  Gene expression was quantitated as fragments 
per kilobase of exon model per million mapped fragments (FPKM) using Cufflinks 
(Trapnell et al. 2010).  Differentially expressed genes were identified using the 
Cufflinks tools Cuffmerge and Cuffdiff.   
    
Statistical Analysis 
Data are presented as the mean and standard error.  Statistical analysis was 
performed using GraphPad Prism version 6 (GraphPad Software).  Pair-wise 
comparisons of data were performed using a t-test to determine significance 
(p<0.05).  When more than two populations were compared, ANOVA with 
Bonferroni’s test was used to determine significance with an assumed confidence 
interval of 95%.  Similarly, time courses were compared using repeated 
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measures two-way ANOVA with Bonferroni’s multiple comparisons test and an 
assumed confidence interval of 95%. 
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APPENDIX B  
BREAST CANCER CELL SENSITIVITY TO GENOTOXIC DRUGS IN THE 
CONTEXT OF JNK INACTIVATION 
 
  
248 
 
 
Abstract 
Triple negative breast cancer cells lack specific targets for therapy.  As a result, 
they are treated with DNA damaging agents, which are less specific than drugs 
that target particular pathways and thus produce more side effects.  Sensitizing 
tumor cells to these agents could allow clinicians to administer lower doses with 
less toxicity.  Inhibition of the cJUN NH2-terminal kinase (JNK), a protein 
activated by several genotoxic agents, may provide a means for this 
sensitization.  Here, I tested if JNK inhibition in a breast cancer cell line could 
enhance the toxicity of various chemotherapeutic agents.  I also compared the 
genotoxic drug sensitivity of JNK-proficient and JNK-deficient mouse tumor cell 
lines.  In these studies, I established a lack of cooperation between several 
chemotherapeutic agents and JNK inhibition.  Furthermore, the data presented 
demonstrate that drugs that interact with JNK inhibitors may not produce the 
same effect in JNK-deficient tumor cells.  These results have important 
implications in the development of new therapeutic approaches. 
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Introduction 
Breast tumors that express the estrogen receptor (ER) or have amplified ERBB2 
(encoding HER2) respond to therapies that inactivate these two important 
pathways (Bange et al. 2001).  This intrinsic tumor cell weakness can be 
exploited to combat the disease.  In contrast, tumors that have not amplified 
ERBB2 and that lack ER –called triple negative breast cancers (TNBC) – are not 
sensitive to ER antagonists or anti-HER2 monoclonal antibodies.  Thus patients 
with these tumors receive chemotherapy or radiation therapy (Perou 2011).  
Frequently used genotoxic drugs in breast cancer include cisplatin, doxorubicin, 
and etoposide (Wahba and El-Hadaad 2015; Castrellon et al. 2017).  Because 
these tumors are characterized by high rates of proliferation, they are sensitive to 
DNA damaging agents and respond to treatment (Perou 2011).  However, 
chemotherapy causes toxicity in healthy cells, leading to side effects.  Improved 
treatment, either through entirely new approaches or through sensitization to 
chemotherapeutic drugs, is needed for this group of patients. 
Among the TNBC group are tumors bearing BRCA1 mutations (Perou 
2011).  Cells that have lost BRCA1 function are unable to perform homologous 
recombination, making them sensitive to inhibition of an alternative DNA repair 
pathway through poly(ADP-ribose), or PARP (Sonnenblick et al. 2015).  This 
synergistic effect of inhibiting two DNA repair pathways to induce cancer cell 
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death is termed synthetic lethality, and discovering more such combinations for 
treatment is a major research goal (Helleday et al. 2008).  Accomplishing this will 
require understanding the pathways that sense and repair DNA damage. 
A potential pathway for this type of research is the stress-activated cJUN 
NH2-terminal kinase (JNK) pathway (Davis 2000).  JNK phosphorylates SIRT6 in 
the presence of oxidative stress to promote double strand break (DSB) repair 
(Van Meter et al. 2016).  JNK also phosphorylates DGCR8 to initiate 
transcriptionally-coupled nucleotide exchange repair (Calses et al. 2017).  In 
mouse embryonic fibroblasts (MEFs) JNK deficiency results in a rapid 
progression to aneuploidy (N. Kennedy, unpublished data).  Also, JNK2-deficient 
tumors exhibit evidence of replicative stress and increased genomic instability 
compared to control tumors (Chen et al. 2010).  These data indicate that JNK 
may be involved in genome maintenance.  Indeed, the DNA damaging agents 
cisplatin, doxorubicin, and etoposide all activate JNK (Sanchez-Perez et al. 1998; 
Brantley-Finley et al. 2003; Helbig et al. 2011).  Cisplatin-induced DNA adducts 
are sufficient for JNK activation (Helbig et al. 2011), and sustained activation 
during cisplatin treatment leads to increased cell death (Sanchez-Perez et al. 
1998).  Treatment with cisplatin also induces expression of several DNA repair 
proteins through JNK and its targets cJUN and ATF2 (Hayakawa et al. 2004).  
Finally, inhibition of JNK or loss of its activator Map2k7 results in dampened DNA 
damage repair signaling and TP53 phosphorylation, respectively, during 
doxorubicin treatment (Schramek et al. 2011; Boege et al. 2017).  Thus, not only 
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is JNK activated by DNA damage, its activation may impact how the cell 
responds to that damage.  
Considering the treatment options for TNBC patients and the JNK 
pathway’s relationship with DNA damage, I sought to identify a drug that would 
synergize with JNK inhibition to more efficiently kill tumor cells.  I found that JNK 
inhibition with a small molecule did not sensitize MDA-MB-231 cells to cisplatin, 
doxorubicin, etoposide, or methyl methanesulfonate.  Also, tumor cells 
responded similarly to these drugs, regardless of JNK pathway status.  These 
studies eliminate these agents as candidates for combined therapies with JNK 
inhibitors or in treating JNK-deficient tumors.  They also provide insight for 
designing therapeutic approaches in the context of JNK inhibition or JNK 
pathway loss. 
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Results and Discussion 
JNK Inhibition in MDA-MB-231 Cells 
JNK-IN-8 is a highly specific covalent inhibitor of JNK that binds in the activation 
loop of the kinase (Zhang et al. 2012).  To test JNK pathway signaling and JNK-
IN-8 potency in the TNBC cell line MDA-MB-231, I exposed the cells to ultraviolet 
light (UV) in the presence or absence of the inhibitor.  Both JNK and cJUN were 
phosphorylated after UV exposure, indicating that the JNK pathway is functional 
in these cells (Figure B.1).  Inhibition of JNK with JNK-IN-8 (2 µM) following UV-
stimulation resulted in decreased cJUN phosphorylation relative to DMSO treated 
controls (Figure B.1).  In contrast, a 4 hour pretreatment with the drug nearly 
abolished cJUN phosphorylation (Figure B.1).  Thus, all subsequent experiments 
were performed with a 4 hour pretreatment of JNK-IN-8. 
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Figure B.1.  JNK pathway inhibition in MDA-MB-231 by JNK-IN-8. 
MDA-MB-231 cells were left unirradiated or were exposed to 60 J/m2 ultraviolet (UV) 
light.  Following UV exposure, cells received 2 µM JNK-IN-8 or vehicle (DMSO).  For the 
pre-treated condition, cells were incubated with JNK-IN-8 or DMSO for 4 h prior to UV 
exposure and treatment was continued until cells were harvested.  Immunoblot analysis 
of p-JNK and p-cJUN (S63) was performed on the lysates.  GAPDH served as a loading 
control. 
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Because cisplatin, doxorubicin, and etoposide are among the 
chemotherapeutic drugs used to treat TNBC, I chose to test if concomitant JNK 
inhibition would impact cell survival (Wahba and El-Hadaad 2015; Castrellon et 
al. 2017).  Treatment of MDA-MB-231 cells with JNK-IN-8 alone had no effect on 
cell growth (Figure B.2).  This finding suggests that any changes in sensitivity 
observed in JNK-inhibited cells would not be the result of changes in 
proliferation.  It also demonstrates that JNK inhibition by itself does not negatively 
impact tumor cells.  In contrast, MDA-MB-231 cell growth was significantly 
reduced by all three of the tested drugs (Figure B.2A-C).  The addition of JNK-IN-
8 to cisplatin or doxorubicin treated cells had no significant effect on cell 
proliferation (Figure B.2A & B), regardless of the drug concentration (Figure B.3).  
However, co-treatment of etoposide and JNK-IN-8 increased cell proliferation 
relative to etoposide-only treated cells (Figure B.2C), indicating that JNK is 
necessary for inhibiting tumor cell growth following etoposide treatment.   
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Figure B.2.  JNK-IN-8 treatment does not sensitize MDA-MB-231 cells to cisplatin, 
doxorubicin, etoposide, or methyl methanesulfonate. 
A-D)  MDA-MB-231 cells were cultured with DMSO or JNK-IN-8 (2 µM) for 4 h (starting 
at time 0 h) before addition of (A) cisplatin (n=24), (B) doxorubicin (n=8), (C) etoposide 
(n=8), or (D) methyl methanesulfonate (MMS; n=24).  Cell confluence was monitored 
regularly for 48 h and plotted as relative growth, with each well normalized to its time 0 
confluence.  After 20 h of drug treatment, cells were washed and received fresh media 
containing the appropriate treatment (arrow).  Graphs show mean ± SEM of 1 of 2 
(doxorubicin, etoposide), 3 (MMS), or 4 (cisplatin) experiments (*p<0.05, ***p<0.001, N. 
S. p>0.05). 
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Figure B.3.  Titration of cisplatin and doxorubicin concentrations results in similar 
growth of MDA-MB-231 cells, regardless of JNK-IN-8 treatment.   
A, B)  MDA-MB-231 cells were cultured with DMSO or JNK-IN-8 (2 µM) for 4 h before 
addition of varying concentrations of (A) cisplatin or (B) doxorubicin.  Cell confluence 
was monitored every 3 h for 48 h and plotted as relative growth, with each well 
normalized to its time 0 confluence.  After 20 h of drug treatment, cells were washed and 
received fresh media containing the appropriate treatment (arrow).  Graphs show mean 
± SEM (n=8; N. S. p>0.05) 
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The finding that JNK inhibition does not sensitize cells to cisplatin was 
surprising.  Presumably, the ability of JNK to promote the expression of proteins 
that repair cisplatin-induced DNA adducts would promote cell survival (Hayakawa 
et al. 2004).  Furthermore, higher concentrations of cisplatin in the context of JNK 
inhibition should result in more unrepaired lesions, causing additional cell death.  
However, increasing cisplatin doses had no significant effect on cell survival 
(Figure B.3A).  Thus, alternative mechanisms must exist that compensate for 
JNK-mediated expression of repair proteins in cisplatin-treated cells.   
Both etoposide and doxorubicin induce DNA damage by inhibiting 
topoisomerase; however doxorubicin can also cause the formation of reactive 
oxygen species (ROS) in treated cells (Thorn et al. 2011; Montecucco et al. 
2015).  The exact stimulus that activates JNK in response to doxorubicin is 
therefore unclear and may account for the different response of cells treated with 
these two agents.  Metabolites of doxorubicin can also disrupt mitochondria and 
cause the release of cytochrome c (Thorn et al. 2011).  Thus, JNK may be 
necessary for executing apoptosis during etoposide treatment, but dispensable 
for apoptosis induced by doxorubicin. 
As a positive control for JNK inhibition affecting cellular response to a 
genotoxic drug, I treated cells with methyl methanesulfonate (MMS).  MMS is 
known to activate JNK (Wilhelm et al. 1997), and JNK-deficient MEFs are 
protected from its cytotoxic effects (Tournier et al. 2000).  Thus, treatment of 
MDA-MB-231 cells with MMS and JNK-IN-8 should result in increased tumor cell 
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survival.  Indeed, JNK inhibition rendered cells more resistant to MMS than MMS 
treatment alone (Figure B.2D).   
Collectively, these data show that JNK inhibition does not sensitize MDA-
MB-231 cells to any of the tested drugs (Figure B.2 & B.3).  In fact, JNK activity is 
required for the deleterious effects of etoposide and MMS treatment (Figure B.2C 
& D).  These findings should be validated in additional TNBC cell lines.  Studies 
determining which DNA lesions activate JNK and the consequences of JNK 
activation in response to these different types of DNA damage could inform 
which cytotoxic agents may synergize with JNK inhibitors.     
While my studies did not reveal synergy between JNK-IN-8 and the tested 
agents, others have determined that JNK-IN-8 sensitizes MDA-MB-231 cells to 
the EGFR inhibitor lapatinib by increasing ROS production and subsequent 
tumor cell death (Ebelt et al. 2017).  In BRAFV600E-mutant melanoma, JNK 
inhibition prevents cells from becoming quiescent during RAF inhibitor treatment, 
thereby maximizing cell killing and reducing adaptation (Fallahi-Sichani et al. 
2015).  These results indicate that further studies of combinatorial therapies 
including JNK-IN8 are warranted. 
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Variable Sensitivity of JNK-Deficient Tumor Cells to Select Genotoxic 
Agents 
I have previously described mouse tumor cell lines isolated from Wap-Cre-/+ 
Trp53LoxP/LoxP (JNKWT) and Wap-Cre-/+ Trp53LoxP/LoxP Mapk8LoxP/LoxP Mapk9LoxP/LoxP 
(JNKKO) tumors (Chapter IV).  Overall, JNKWT and JNKKO cells proliferate 
similarly (Figure B.4). 
 To determine if JNK status in tumor cells affects sensitivity to different 
genotoxic drugs, I treated these cell lines with cisplatin, doxorubicin, etoposide 
and MMS.  The presence of JNK in tumor cells did not predict their response to 
any of the tested drugs (Figure B.5).  Instead, proliferation rate correlated with 
sensitivity to cisplatin and doxorubicin, as the two most proliferative cell lines 
exhibited significantly decreased growth relative to more moderately proliferating 
cells (Figures B.4, B.5A, & B).  JNKWT cells treated with etoposide also showed a 
pattern of increased proliferation leading to increased sensitivity (Figure B.5C).  
In contrast, the moderately proliferating JNKKO lines had widely varying 
responses to etoposide (Figure B.5C).  Interestingly, the slowest-growing JNKWT 
cell line was the most resistant to cisplatin and etoposide, and this resistance 
was significantly greater than that observed in JNKKO cells (Figure B.5A & C).  
This observation may indicate a tendency for JNK-deficient tumor cells to be 
more sensitive to these two agents.  However this sensitivity is not strictly 
associated with JNK-deficiency since the JNKKO lines respond similarly to the 
sensitive JNKWT line. 
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Figure B.4.  Proliferation of tumor cells is similar regardless of JNK status. 
A, B)  Confluence of cell lines isolated from mouse tumors was monitored every 4 h for 
48 h.  The relative growth was calculated by normalizing each well to its confluence at 
time 0.  The composite of JNKWT (2 independent cell lines, n=2) and JNKKO (4 
independent cell lines, n=4) was plotted (A).  Individual cell growth curves (B) are also 
presented (n=16). Graphs show mean ± SEM of 1 of 3 experiments (*p<0.05, 
***p<0.001, N. S. p>0.05). 
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Figure B.5.  Murine tumor-derived cells respond variably to drug treatments. 
A-D)  JNKWT and JNKKO cells were treated with (A) 31 µM cisplatin, (B) 25 µM 
doxorubicin, (C) 100 µM etoposide, and (D) 1 mM MMS beginning at time 0.  Cell 
confluence was monitored every 4 h for 48 h and plotted as relative growth, with each 
well normalized to its time 0 confluence.  After 24 h, cells were washed and given fresh 
media with the appropriate treatment (arrow), then monitored for an additional 24 h.  
Graphs show mean ± SEM (n=16; *p<0.05, ***p<0.001, N. S. p>0.05). 
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Neither proliferation nor genotype predicted the response to MMS 
treatment (Figure B.5D).  There was no statistically significant difference between 
the growth rates of the JNKWT cells (Figure B.5D).  Furthermore, the most 
sensitive and the most resistant cell lines to MMS were both JNK-deficient cells 
with moderate rates of proliferation (Figure B.5D).  This finding contrasts with 
observations made studying JNK-deficient MEFs (Tournier et al. 2000) and JNK-
IN-8 treated MDA-MB-231 cells (Figure B.2D).  This analysis highlights how 
different cell types (MEFs vs. tumor) and different time courses of JNK loss 
(acute inhibition with a small molecule vs. long-term deletion) can result in 
variable responses from the JNK pathway.  Thus, treatments that synergize with 
JNK inhibitors cannot be assumed to benefit tumors with JNK mutations. 
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Conclusions 
These data show that JNK pathway inhibition in TNBC cells does not render 
them selectively sensitive to cisplatin, doxorubicin, etoposide, or MMS.  
Furthermore, tumors with genetic inactivation of the JNK pathway are not 
sensitive to these agents.  However, studies testing additional chemotherapeutic 
and cytotoxic agents in the presence of either chemical or genetic JNK 
inactivation may reveal synthetic lethalities that could be exploited in the clinic. 
Human tumor sequencing studies (Teng et al. 1997; Parsons et al. 2005; 
Greenman et al. 2007) and in vivo models (Cellurale et al. 2011; Das et al. 2011; 
Davies et al. 2014; Gozdecka et al. 2014) have demonstrated that the JNK 
pathway contributes to other malignancies.  Thus, performing these types of 
studies using cell lines from different tumor types may uncover JNK-dependent 
tumor cell sensitivities.  Continuing studies like the ones described here will 
provide a better appreciation of the role of JNK in DNA damage signaling and 
could inform new therapeutic approaches. 
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Materials and Methods 
Cell Culture 
MDA-MB-231 cells were acquired from American Type Culture Collection 
(ATCC).  The murine tumor cell lines have been previously described (Chapter 
IV, submitted).  All cells were maintained in DMEM/F12 (Thermo Fisher 
Scientific) containing 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (Thermo Fisher Scientific). 
 
JNK-IN-8 Inhibition 
JNK inhibition by JNK-IN-8 was assayed by monitoring cJUN phosphorylation at 
serine 63 following pathway activation.  Cells were left untreated or pre-treated 
with 2 µM JNK-IN-8 (Millipore Sigma) for 4 hours prior to stimulation (60J/m2 
ultraviolet (UV) light).  They were cultured for an additional 30 mins with or 
without the inhibitor before protein isolation. 
 
Immunoblot Analysis 
Protein lysates were prepared using Triton lysis buffer (20 mM Tris [pH 7.4], 1% 
Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM β-
glycerophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl 
fluoride, and 10 μg/mL of aprotinin plus leupeptin).  Extracts (50 µg) were 
subjected to immunoblot analysis with antibodies to phospho-JNK (Cell Signaling 
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Technology Cat# 9255 RRID:AB_2307321), phospho-cJUN (S63) (Cell Signaling 
Technology Cat# 9261L RRID:AB_2130159), and GAPDH (Santa Cruz 
Biotechnology Cat# sc-25778; RRID:AB_10167668; dilution 1:1000).  Immune 
complexes were detected using IRDye 680LT conjugated-donkey anti-mouse 
IgG antibody (LI-COR Biosciences Cat# 926-68022 RRID:AB_10715072) and 
IRDye 800CW conjugated-goat anti-rabbit IgG (LI-COR Biosciences Cat# 926-
32211 RRID:AB_621843).  Quantitation was performed using the Odyssey 
infrared imaging system (LI-COR Biosciences). 
 
Drug Treatment 
Cells were plated in 96-well plates at 30,000 cells/well.  Before drug 
administration, MDA-MB-231 cells were pretreated with DMSO or 2 µM of JNK-
IN-8 for 4 h (time 0 h).  After pretreatment, cells were given etoposide (Millipore 
Sigma), methyl methanesulfonate (MMS; Millipore Sigma), doxorubicin (Millipore 
Sigma), or cisplatin (Millipore Sigma) in addition to JNK-IN-8 or DMSO (time 4 h). 
Dead cells were washed from the well and fresh media with the appropriate 
compounds was given to the remaining cells 20 h after drug administration.  Cell 
confluence was monitored at regular intervals for 48 h using an IncuCyte Zoom 
(Essen BioScience). 
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Statistical Analysis 
Data are presented as the mean and standard error.  Statistical analysis was 
performed using GraphPad Prism version 7 (GraphPad Software).  Repeated 
measures two-way ANOVA using Bonferroni’s multiple comparisons test with an 
assumed confidence interval of 95% was performed to compare cell confluence 
over time. 
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